<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for asymptomatic carotid stenosis - Clezar, CNB - 2023 | Cochrane Library</title> <meta content="Pharmacological interventions for asymptomatic carotid stenosis - Clezar, CNB - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013573.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for asymptomatic carotid stenosis - Clezar, CNB - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013573.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013573.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for asymptomatic carotid stenosis" name="citation_title"/> <meta content="Caroline NB Clezar" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="caroline.bessa@gmail.com" name="citation_author_email"/> <meta content="Carolina DQ Flumignan" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Nicolle Cassola" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Luis CU Nakano" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Virginia FM Trevisani" name="citation_author"/> <meta content="Escola Paulista de Medicina, Universidade Federal de São Paulo and Universidade de Santo Amaro" name="citation_author_institution"/> <meta content="Ronald LG Flumignan" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD013573.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/08/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013573.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013573.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013573.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aspirin [adverse effects]; *Atherosclerosis [complications]; Atorvastatin; *Carotid Stenosis [complications, drug therapy]; Chlorthalidone; Fluvastatin; Hemorrhage; *Ischemic Stroke [complications]; Metoprolol; Pravastatin; Probucol; Rosuvastatin Calcium; *Stroke [etiology, prevention &amp; control]; Warfarin" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013573.pub2&amp;doi=10.1002/14651858.CD013573.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013573\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013573\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","ms","hr","fa","pl","fr","hu","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013573.pub2",title:"Pharmacological interventions for asymptomatic carotid stenosis",firstPublishedDate:"Aug 4, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013573.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013573.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013573.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013573.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013573.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013573.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013573.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013573.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013573.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013573.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3294 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013573.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-sec-0133"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-sec-0019"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-sec-0020"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-sec-0116"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/appendices#CD013573-sec-0138"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/supinfo/CD013573-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/supinfo/CD013573-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for asymptomatic carotid stenosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information#CD013573-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Caroline NB Clezar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information#CD013573-cr-0005">Carolina DQ Flumignan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information#CD013573-cr-0006">Nicolle Cassola</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information#CD013573-cr-0007">Luis CU Nakano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information#CD013573-cr-0008">Virginia FM Trevisani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information#CD013573-cr-0009">Ronald LG Flumignan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information/en#CD013573-sec-0152">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 August 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013573.pub2">https://doi.org/10.1002/14651858.CD013573.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013573-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013573-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013573-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013573-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013573-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013573-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013573-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013573-abs-0001" lang="en"> <section id="CD013573-sec-0001"> <h3 class="title" id="CD013573-sec-0001">Background</h3> <p>Carotid artery stenosis is narrowing of the carotid arteries. Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease. It is caused by atherosclerosis; that is, the build‐up of fats, cholesterol, and other substances in and on the artery walls. Atherosclerosis is more likely to occur in people with several risk factors, such as diabetes, hypertension, hyperlipidaemia, and smoking. As this damage can develop without symptoms, the first symptom can be a fatal or disabling stroke, known as ischaemic stroke. Carotid stenosis leading to ischaemic stroke is most common in men older than 70 years. Ischaemic stroke is a worldwide public health problem. </p> </section> <section id="CD013573-sec-0002"> <h3 class="title" id="CD013573-sec-0002">Objectives</h3> <p>To assess the effects of pharmacological interventions for the treatment of asymptomatic carotid stenosis in preventing neurological impairment, ipsilateral major or disabling stroke, death, major bleeding, and other outcomes. </p> </section> <section id="CD013573-sec-0003"> <h3 class="title" id="CD013573-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group trials register, CENTRAL, MEDLINE, Embase, two other databases, and three trials registers from their inception to 9 August 2022. We also checked the reference lists of any relevant systematic reviews identified and contacted specialists in the field for additional references to trials. </p> </section> <section id="CD013573-sec-0004"> <h3 class="title" id="CD013573-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs), irrespective of publication status and language, comparing a pharmacological intervention to placebo, no treatment, or another pharmacological intervention for asymptomatic carotid stenosis. </p> </section> <section id="CD013573-sec-0005"> <h3 class="title" id="CD013573-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodological procedures. Two review authors independently extracted the data and assessed the risk of bias of the trials. A third author resolved disagreements when necessary. We assessed the evidence certainty for key outcomes using GRADE. </p> </section> <section id="CD013573-sec-0006"> <h3 class="title" id="CD013573-sec-0006">Main results</h3> <p>We included 34 RCTs with 11,571 participants. Data for meta‐analysis were available from only 22 studies with 6887 participants. The mean follow‐up period was 2.5 years. None of the 34 included studies assessed neurological impairment and quality of life. </p> <p><b>Antiplatelet agent (acetylsalicylic acid) versus placebo</b> </p> <p>Acetylsalicylic acid (1 study, 372 participants) may result in little to no difference in ipsilateral major or disabling stroke (risk ratio (RR) 1.08, 95% confidence interval (CI) 0.47 to 2.47), stroke‐related mortality (RR 1.40, 95% CI 0.54 to 3.59), progression of carotid stenosis (RR 1.16, 95% CI 0.79 to 1.71), and adverse events (RR 0.81, 95% CI 0.41 to 1.59), compared to placebo (all low‐certainty evidence). The effect of acetylsalicylic acid on major bleeding is very uncertain (RR 0.98, 95% CI 0.06 to 15.53; very low‐certainty evidence). The study did not measure neurological impairment or quality of life. </p> <p><b>Antihypertensive agents (metoprolol and chlorthalidone) versus placebo</b> </p> <p>The antihypertensive agent, metoprolol, may result in no difference in ipsilateral major or disabling stroke (RR 0.14, 95% CI 0.02 to1.16; 1 study, 793 participants) and stroke‐related mortality (RR 0.57, 95% CI 0.17 to 1.94; 1 study, 793 participants) compared to placebo (both low‐certainty evidence). However, chlorthalidone may slow the progression of carotid stenosis (RR 0.45, 95% CI 0.23 to 0.91; 1 study, 129 participants; low‐certainty evidence) compared to placebo. Neither study measured neurological impairment, major bleeding, adverse events, or quality of life. </p> <p><b>Anticoagulant agent (warfarin) versus placebo</b> </p> <p>The evidence is very uncertain about the effects of warfarin (1 study, 919 participants) on major bleeding (RR 1.19, 95% CI 0.97 to 1.46; very low‐certainty evidence), but it may reduce adverse events (RR 0.89, 95% CI 0.81 to 0.99; low‐certainty evidence) compared to placebo. The study did not measure neurological impairment, ipsilateral major or disabling stroke, stroke‐related mortality, progression of carotid stenosis, or quality of life. </p> <p><b>Lipid‐lowering agents (atorvastatin, fluvastatin, lovastatin, pravastatin, probucol, and rosuvastatin) versus placebo or no treatment</b> </p> <p>Lipid‐lowering agents may result in little to no difference in ipsilateral major or disabling stroke (atorvastatin, lovastatin, pravastatin, and rosuvastatin; RR 0.36, 95% CI 0.09 to 1.53; 5 studies, 2235 participants) stroke‐related mortality (lovastatin and pravastatin; RR 0.25, 95% CI 0.03 to 2.29; 2 studies, 1366 participants), and adverse events (fluvastatin, lovastatin, pravastatin, probucol, and rosuvastatin; RR 0.76, 95% CI 0.53 to1.10; 7 studies, 3726 participants) compared to placebo or no treatment (all low‐certainty evidence). The studies did not measure neurological impairment, major bleeding, progression of carotid stenosis, or quality of life. </p> </section> <section id="CD013573-sec-0007"> <h3 class="title" id="CD013573-sec-0007">Authors' conclusions</h3> <p>Although there is no high‐certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality. High‐quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis. In the interim, clinicians will have to use other sources of information. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013573-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013573-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013573-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013573-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013573-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013573-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013573-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD013573-abs-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013573-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013573-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD013573-abs-0016">Română</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013573-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013573-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013573-abs-0002" lang="en"> <h3>What medicines are best for people with narrowing of the carotid arteries (blood vessels that deliver oxygen‐rich blood from the heart to the brain)? </h3> <p><b>Key messages</b> </p> <p>Compared to placebo (an inactive medicine):<br/>‐ warfarin, an anticoagulant (blood‐thinning medicine), may reduce the risk of side effects by 11%;<br/>‐ chlorthalidone, an antihypertensive (medicine for lowering high blood pressure), may slow the progression of carotid stenosis (narrowing of the carotid arteries) by 55%. </p> <p>Studies with more participants and with long‐term follow‐up are needed to define the best medical treatment for modifiable risk factors in people with no symptoms of carotid narrowing. </p> <p><b>What is asymptomatic carotid stenosis?</b> </p> <p>Carotid artery stenosis is narrowing of the carotid arteries, the major blood vessels that provide the brain's blood supply. 'Asymptomatic carotid stenosis' is when this narrowing occurs in people without symptoms of this disease. It is caused by atherosclerosis: the buildup of fats, cholesterol (high blood fats), and other substances in and on the blood vessel walls. Narrowing of the carotid arteries can develop without symptoms, so the first symptom can be a fatal or disabling stroke. </p> <p><b>How is asymptomatic carotid stenosis treated?</b> </p> <p>The risk of having a stroke might be reduced by controlling modifiable, atherosclerosis risk factors, such as high blood pressure, smoking, cholesterol, and diabetes. There are a range of medicines used for these purposes, including: </p> <p>‐ antihypertensive medicines (which lower high blood pressure);<br/>‐ cholesterol‐ or lipid‐lowering medicines (drugs that lower high cholesterol levels);<br/>‐ anticoagulants (also called 'blood thinners'); or<br/>‐ antiplatelet medicines (drugs that prevent blood clots from forming). </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out which medicines for asymptomatic carotid stenosis are best for preventing: damage to the brain, stroke, death, major bleeding, and progression of the carotid arteries' narrowing. </p> <p>We also wanted to find out if these medicines make any difference to people's quality of life and whether they are associated with any unwanted or harmful effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared one type of medicine with another type of medicine, placebo (an inactive medicine), or no treatment, in people of any age with asymptomatic carotid narrowing. </p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 34 studies that examined the medicines we were interested in. The studies involved a total of 11,571 people with asymptomatic carotid stenosis. The participants' average age was 61 years (range = 18 to 100 years old), and nearly two‐thirds of participants were male. The studies were carried out in outpatient medical settings around the world. The average follow‐up period was under three years. </p> <p>Of these 34 studies, only 22 assessed our outcomes of interest and were included in our analyses. These 22 studies involved a total of 6887 people with asymptomatic carotid stenosis. </p> <p>None of the studies assessed participants for neurological (i.e. brain) damage, and none measured changes in people's quality of life. </p> <p><b>Main results</b> </p> <p><b><i>Antiplatelets (aspirin) compared to placebo</i> </b> </p> <p>Aspirin (1 study; 372 participants) may not prevent stroke, stroke‐related death, progression of carotid narrowing, or increase side effects compared to placebo. We are very uncertain about the effect of aspirin on large bleeding events. </p> <p><b><i>Antihypertensive drugs (metoprolol and chlorthalidone) compared to placebo</i> </b> </p> <p>It is uncertain if metoprolol (1 study, 793 participants) may prevent stroke or stroke‐related death. However, chlorthalidone (1 study, 129 participants) may slow the progression of carotid narrowing compared to placebo. Neither study measured large bleeding events or side effects. </p> <p><b><i>Anticoagulant drug (warfarin) compared to placebo</i> </b> </p> <p>It is uncertain whether warfarin (1 study, 919 participants) increases large bleeding events compared to placebo. However, it may lead to side effects compared to placebo. The study did not measure stroke, stroke‐related death, or progression of carotid stenosis. </p> <p><b><i>Cholesterol‐lowering drugs (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and probucol) compared to placebo or no treatment</i> </b> </p> <p>It is unclear if cholesterol‐lowering drugs prevent stroke (5 studies, 2235 participants), stroke‐related death (2 studies, 1366 participants), or increase side effects (7 studies, 3726 participants) compared to placebo or no treatment. The studies did not measure large bleeding events or progression of carotid stenosis. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We have limited confidence in the evidence for prevention of stroke, death, progression of carotid narrowing, side effects, and major bleeding events. Some studies had methodological problems or study designs that were not well reported. Overall, there is limited evidence to inform decision‐making about the use of medicines for asymptomatic carotid artery stenosis. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to August 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013573-sec-0133" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013573-sec-0133"></div> <h3 class="title" id="CD013573-sec-0134">Implications for practice</h3> <section id="CD013573-sec-0134"> <p>There is limited evidence to inform decision‐making about the use of pharmacological interventions in asymptomatic carotid artery stenosis. There is no evidence currently available from randomised controlled trials about the effects of pharmacological interventions on neurological impairment and quality of life. </p> <p>Antiplatelets, lipid‐lowering drugs, and the antihypertensive drug, metoprolol, may have little to no effect on stroke and stroke‐related death. </p> <p>Antiplatelets and lipid‐lowering medications may have little to no effect on side effects, and antiplatelets may have little to no effect on the progression of carotid narrowing. </p> <p>Anticoagulants in people with asymptomatic carotid stenosis may decrease the risk of adverse events by 11% compared to placebo. </p> <p>Chlorthalidone – an antihypertensive drug – may decrease the risk of progression of carotid stenosis by 55% compared to placebo. </p> <p>The evidence of the effects of antiplatelets and anticoagulants on major bleeding is very uncertain. </p> <p>Therefore, this restricted evidence should not be interpreted as demonstrating the ineffectiveness of pharmacological treatment for asymptomatic carotid stenosis, but rather highlights a need for more trials. In the interim, clinicians will have to use information from other prevention trials to help guide decision‐making. </p> </section> <h3 class="title" id="CD013573-sec-0135">Implications for research</h3> <section id="CD013573-sec-0135"> <p>There is no high‐quality evidence on pharmacological interventions to prevent stroke and its sequelae. </p> <p>Given the lack of evidence, randomised controlled trials involving more participants (at least 4000 in total) and with a minimum follow‐up of two years are needed to assess cardiovascular changes and events over the long term in people with atherosclerosis. Studies should focus on the following outcomes: neurological impairment, mortality, and changes in quality of life. </p> <p>Adherence to pharmacological interventions remains an issue, even in high‐income countries and even when people are participating in randomised controlled trials (<a href="./references#CD013573-bbs2-0095" title="HaleyW , ShawlF , SternberghWC , TuranTN , BarrettK , Voeks J et al. Non-adherence to antihypertensive guidelines in patients with asymptomatic carotid stenosis. Journal of Stroke and Cerebrovascular Diseases2021;30(8):105918. [PMID: 10.1016/j.jstrokecerebrovasdis.2021.105918]">Haley 2021</a>). Researchers should thus anticipate and try to address this problem when developing new trial protocols. </p> <p>Most data in our review come from high‐income countries. Data from under‐represented continents, particularly Africa, and from participants with different social and economic characteristics are warranted, to enhance external validity and translate evidence into practice. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013573-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013573-sec-0008"></div> <div class="table" id="CD013573-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet agent versus placebo for asymptomatic carotid stenosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antiplatelet agent compared to placebo<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> antiplatelet agent<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№</b> of participants<br/>(studies) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with antiplatelet agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ipsilateral major or disabling stroke (CT scan or MRI)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.47 to 2.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(29 fewer to 80 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke‐related mortality (CT scan or MRI)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(0.54 to 3.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 more per 1000<br/>(17 fewer to 99 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding (not reported)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.06 to 15.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(5 fewer to 79 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression of carotid stenosis (DUS/every 6 months)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/>(0.79 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 more per 1000<br/>(42 fewer to 143 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (not reported)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/>(0.41 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 fewer per 1000<br/>(52 fewer to 47 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CT scan</b> : computerised tomography scan; <b>DUS</b> : duplex ultrasonography; <b>MRI</b> : magnetic resonance imaging; <b>№:</b> number; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>One study included in this comparison<br/><sup>b</sup>Acetylsalicylic acid<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, one study, and 95% CI consistent with possible benefit and possible harm<br/><sup>d</sup>Downgraded one level due to indirectness: unexplained major bleeding definition </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013573-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antihypertensive agent versus placebo for asymptomatic carotid stenosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antihypertensive agent compared to placebo<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> antihypertensive agent<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement/time point)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№</b> of participants<br/>(studies) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with antihypertensive agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ipsilateral major or disabling stroke (not reported)</p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>793<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.14<br/>(0.02 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1000<br/>(17 fewer to 3 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke‐related mortality (not reported)</p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>793<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/>(0.17 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/>(15 fewer to 17 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression of carotid stenosis (DUS/at beginning and end)</p> <p>Follow‐up: 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>129<br/>(1 RCT)<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.45<br/>(0.23 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 fewer per 1000<br/>(239 fewer to 28 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CT scan</b> : computerised tomography scan; <b>DUS</b> : duplex ultrasonography; <b>MRI</b> : magnetic resonance imaging; <b>№:</b> number; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Two studies included in this comparison<br/><sup>b</sup>Metoprolol<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, few studies, and 95% CI consistent with possible benefit and possible harm<br/><sup>d</sup>Chlorthalidone </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013573-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anticoagulant agent versus placebo for asymptomatic carotid stenosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Anticoagulant agent compared to placebo<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> anticoagulant agent<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement/time point)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of</b> participants<br/>(studies) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with anticoagulant agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding (hospital records/every 6 weeks)</p> <p>Follow‐up: 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>919<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/>(0.97 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 more per 1000<br/>(8 fewer to 120 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (hospital records/every 6 weeks)</p> <p>Follow‐up: 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>919<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.81 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>644 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 fewer per 1000<br/>(122 fewer to 6 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>One study included in this comparison<br/><sup>b</sup> Warfarin<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, one study, and 95% CI consistent with possible benefit and possible harm<br/><sup>c</sup>Downgraded one level due to indirectness: unexplained major bleeding definition </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013573-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Lipid‐lowering agent compared to placebo or no treatment for asymptomatic carotid stenosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Lipid‐lowering agent compared to placebo<sup>a</sup> or no treatment for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> lipid‐lowering agent<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p>Outcomes <b>(measurement/time point)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lipid‐lowering agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ipsilateral major or disabling stroke (only reported for two studies: one used CT scan, MRI and hospital records/every 6 weeks<sup>b</sup>; the other used physical examination/at beginning and 10 days after the end<sup>c</sup>) </p> <p>Follow‐up: 3.1 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2235<br/>(5 RCTs)<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.36<br/>(0.09 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 fewer per 1000<br/>(16 fewer to 10 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke‐related mortality (only reported for one study: CT scan, MRI and hospital records/every 6 weeks<sup>b</sup>) </p> <p>Follow‐up: 4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1366<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.25<br/>(0.03 to 2.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/>(4 fewer to 6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (only reported for two studies: one study used CT scan, MRI and hospital records/every 6 weeks<sup>b</sup>; the other used physical examination/at beginning and 10 days after the end<sup>c</sup>) </p> <p>Follow‐up: 3.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3726<br/>(7 RCTs)<sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76<br/>(0.53 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 fewer per 1000<br/>(41 fewer to 9 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CT scan</b> : computerised tomography scan; <b>MRI</b> : magnetic resonance imaging; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Nine studies included in this comparison<br/><sup>b</sup><a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a><br/><sup>c</sup><a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a><br/><sup>d</sup>Lovastatin, pravastatin, rosuvastatin, and atorvastatin<br/><sup>e</sup>Downgraded two levels due to imprecision: few events, one study, and 95% CI consistent with possible benefit and possible harm<br/><sup>f</sup>Lovastatin and pravastatin<br/><sup>g</sup>Fluvastatin, rosuvastatin, lovastatin, pravastatin, and probucol </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013573-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013573-sec-0009"></div> <p>See <a href="#CD013573-tbl-0005">Table 1</a> for a glossary of terms. </p> <div class="table" id="CD013573-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amaurosis fugax</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient monocular visual loss associated with vascular thromboembolic events arising from the internal carotid arterial system </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticoagulants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drugs that suppress, delay, or prevent blood clots</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antiplatelet agents</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drugs which prevent blood clots by inhibiting platelet function</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atherosclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A disease characterised by a build‐up of abnormal fat, cholesterol and platelet deposits on the inner wall of the arteries </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atheromatous plaques</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A fatty deposit in the inner lining (intima) of an artery, resulting from atherosclerosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atherosclerotic debris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pieces of atheromatous plaque that can break off and be carried by the bloodstream</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body mass index (BMI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body mass divided by the square of the body height, universally expressed in units of kg/m<sup>2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computed tomography angiography (CTA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computed tomography scanning that uses an injection of contrast material into the blood vessels to help diagnose and evaluate blood vessel disease or related conditions </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digital subtraction angiography (DSA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoroscopy technique used in interventional radiology to clearly visualise blood vessels in a bony or dense soft tissue environment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Direct thrombin inhibitors</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug that acts as an anticoagulant by directly inhibiting the enzyme thrombin (factor IIa) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive evaluation of blood flow through the arteries and veins by ultrasound devices </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyslipidaemia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal concentration of fats (lipids or lipoproteins) in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Embolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obstruction of an artery or vein, typically by a clot of blood or an air bubble</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fator Xa inhibitors</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of anticoagulant that works by selectively and reversibly blocking the activity of clotting factor Xa, preventing clot formation </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug which is used to prevent blood clotting (anticoagulant, blood thinner)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ipsilateral encephalic territories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The same side of the brain</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low molecular weight heparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug which is used to prevent blood clotting (anticoagulant)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnetic resonance angiography (MRA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A group of techniques based on magnetic resonance imaging (MRI) to image blood vessels</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obesity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A condition where the amount of body fat is beyond healthy conditions (BMI greater than 30 kg/m<sup>2</sup>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oedema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excess watery fluid which collects in tissues of the body, causing swelling when fluid leaks out of the body's vessels </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overweight</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where body fat is over that of the average population, but less than unhealthy conditions (BMI between 25 kg/m<sup>2</sup> and 30 kg/m<sup>2</sup>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substance or treatment with no active effect, like a sugar pill</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised controlled trial (RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A study in which the participants are divided randomly into separate groups to compare different treatments </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological deficit attributed to an acute focal injury of the central nervous system by a vascular cause, persisting ≥ 24 hours or until death </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local coagulation of blood (clot) in a part of the circulatory system</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient ischaemic attack (TIA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A transient episode (less than 24 hours) of neurological dysfunction caused by focal brain, spinal cord, or retinal ischaemia without acute infarction </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfractionated heparin (UFH)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A mixture of heparins obtained from animals which is used to prevent blood coagulation. Used to prevent and treat clotting disorders </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relating to blood vessels (arteries and veins)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K antagonists (VKAs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substances that reduce blood clotting by reducing the action of vitamin K</p> </td> </tr> </tbody> </table> </div> <section id="CD013573-sec-0010"> <h3 class="title" id="CD013573-sec-0010">Description of the condition</h3> <p>Strokes, characterised by brain tissue injury due to stenosis or arterial occlusion, can cause death or permanent neurological disability, and approximately 90% of strokes are ischaemic. This largely occurs as a result of carotid stenosis, hypertension, or cardiac arrhythmia (<a href="./references#CD013573-bbs2-0072" title="BrottTG , HalperinJL , AbbaraS , BacharachJM , BarrJD , BushRL , et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Developed in collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography. Catheterization and Cardiovascular Interventions2013;81(1):E76-123. [PMID: 23281092]">Brott 2013</a>; <a href="./references#CD013573-bbs2-0088" title="FlumignanCD , FlumignanRL , NavarroTP . Extracranial carotid stenosis: evidence based review [Estenose de carotida extracraniana: revisao baseada em evidencias]. Revista do Colegio Brasileiro de Cirurgioes2017;44(3):293-301. [PMID: 28767806]">Flumignan 2017</a>; <a href="./references#CD013573-bbs2-0106" title="MozaffarianD , BenjaminEJ , GoAS , ArnettDK , BlahaMJ , CushmanM , et al. Heart disease and stroke statistics - 2016 update: a report from the American Heart Association. Circulation2016;133(4):e38-360. [PMID: 26673558]">Mozaffarian 2016</a>). Carotid artery stenosis (narrowing of the carotid arteries) is an important cause of cerebrovascular disease and transient ischaemic attack (TIA), underlying almost 15% of strokes (<a href="./references#CD013573-bbs2-0083" title="EastonJD , SaverJL , AlbersGW , AlbertsMJ , ChaturvediS , FeldmannE , et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke2009;40(6):2276-93. [PMID: 19423857]">Easton 2009</a>). The cumulative risk of stroke related to severe carotid stenosis is nearly 12% in the first year (approximately 15% to 18% in one year and 26% over two years (<a href="./references#CD013573-bbs2-0070" title="BarnettHJ , TaylorDW , HaynesRB , SackettDL , PeerlessSJ , FergusonGG , et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New England Journal of Medicine1991;325(7):445-53. [PMID: 1852179]">Barnett 1991</a>)), and approximately 30% over five years (<a href="./references#CD013573-bbs2-0070" title="BarnettHJ , TaylorDW , HaynesRB , SackettDL , PeerlessSJ , FergusonGG , et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New England Journal of Medicine1991;325(7):445-53. [PMID: 1852179]">Barnett 1991</a>; <a href="./references#CD013573-bbs2-0105" title="MooreWS , BarnettHJ , BeebeHG , BernsteinEF , BrenerBJ , BrottT , et al. Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the Ad Hoc Committee, American Heart Association. Circulation1995;91(2):566-79. [PMID: 7805271]">Moore 1995</a>). Significant stenosis (of more than 50% of vessel diameter) is usually responsible for 8% of all strokes, and increases the risk of recurrence after the first episode to 16% over five years (<a href="./references#CD013573-bbs2-0099" title="HillenT , CoshallC , TillingK , RuddAG , McGovernR , WolfeCD . Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke2003;34(6):1457-63. [PMID: 12750544]">Hillen 2003</a>), mostly due to cerebral embolisms caused by biological changes to the atherosclerotic plaque (<a href="./references#CD013573-bbs2-0087" title="FlahertyML , KisselaB , KhouryJC , AlwellK , MoomawCJ , WooD , et al. Carotid artery stenosis as a cause of stroke. Neuroepidemiology2013;40(1):36-41. [PMID: 23075828]">Flaherty 2013</a>). </p> <p>Ischaemic stroke is the second most common cause of death and a major global public health problem (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>; <a href="./references#CD013573-bbs2-0086" title="FeiginVL , StarkBA , JohnsonCO , RothGA , BisignanoC , Abady GG et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 . The Lancet Neurology2021;20(10):795-820. [DOI: 10.1016/s1474-4422(21)00252-0]">Feigin 2021</a>). Each year, more than 7.6 million new strokes are recorded and about 3.3 million people die from ischaemic stroke (<a href="./references#CD013573-bbs2-0086" title="FeiginVL , StarkBA , JohnsonCO , RothGA , BisignanoC , Abady GG et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 . The Lancet Neurology2021;20(10):795-820. [DOI: 10.1016/s1474-4422(21)00252-0]">Feigin 2021</a>). </p> <p>Furthermore, stroke is a significant cause of permanent neurological disability in Europe: out of approximately 1.2 million stroke survivors in the UK (<a href="./references#CD013573-bbs2-0078" title="De WaardDD , MorrisD , De BorstGJ , BulbuliaR , HallidayA . Asymptomatic carotid artery stenosis: who should be screened, who should be treated and how should we treat them?Journal of Cardiovascular Surgery2017;58(1):3-12. [DOI: 10.23736/S0021-9509.16.09770-6] [PMID: 27901325]">De Waard 2017</a>), 60% are discharged with some impairment (<a href="./references#CD013573-bbs2-0075" title="Centers for Disease Control and Prevention (CDC). Prevalence of disabilities and associated health conditions among adults - United States, 1999. Morbidity and Mortality Weekly Report2001;50(7):120-5. [PMID: 11393491]">CDC 2001</a>; <a href="./references#CD013573-bbs2-0110" title="National Institute for Health and Clinical Excellence (NICE). Impact stroke. NICE practice guidelines 2019. Available from www.nice.org.uk/Media/Default/About/what-we-do/Into-practice/measuring-uptake/NICE-Impact-stroke.pdf (accessed 09 July 2019).">NICE 2019</a>; <a href="./references#CD013573-bbs2-0120" title="StrongK , MathersC , BonitaR . Preventing stroke: saving lives around the world. Lancet Neurology2007;6(2):182-7. [PMID: 17239805]">Strong 2007</a>). </p> <p>The direct costs of stroke alone amounted to approximately USD 28 billion (USD 28,000 million) between the years 2014 and 2015 in the USA, and this cost is expected to more than double in the next 20 years (<a href="./references#CD013573-bbs2-0071" title="BenjaminEJ , MuntnerP , AlonsoA , BittencourtMS , CallawayCW , CarsonAP , et al. Heart disease and stroke statistics - 2019 update: a report from the American Heart Association. Circulation2019;139(10):e56-e528. [PMID: 30700139]">Benjamin 2019</a>; <a href="./references#CD013573-bbs2-0085" title="FeiginVL , RothGA , NaghaviM , ParmarP , KrishnamurthiR , ChughS , et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurology2016;15(9):913-24. [PMID: 27291521]">Feigin 2016</a>; <a href="./references#CD013573-bbs2-0090" title="GorelickPB , SaccoRL , SmithDB , AlbertsM , Mustone-AlexanderL , RaderD , et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA1999;281(12):1112-20. [PMID: 10188663]">Gorelick 1999</a>). By 2020, it was expected that there would be 80 million strokes worldwide, with 12 million deaths (an increase of 50% compared with 2012), and 200 million disability‐adjusted life years lost worldwide (<a href="./references#CD013573-bbs2-0071" title="BenjaminEJ , MuntnerP , AlonsoA , BittencourtMS , CallawayCW , CarsonAP , et al. Heart disease and stroke statistics - 2019 update: a report from the American Heart Association. Circulation2019;139(10):e56-e528. [PMID: 30700139]">Benjamin 2019</a>; <a href="./references#CD013573-bbs2-0086" title="FeiginVL , StarkBA , JohnsonCO , RothGA , BisignanoC , Abady GG et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 . The Lancet Neurology2021;20(10):795-820. [DOI: 10.1016/s1474-4422(21)00252-0]">Feigin 2021</a>). </p> <p>Extracranial carotid stenosis may be asymptomatic or symptomatic. The embolisation of atherosclerotic debris or thrombotic material from plaques of arterial stenoses are most frequently associated with cerebrovascular symptoms such as stroke, TIA in the ipsilateral encephalic territories, and amaurosis fugax. People with asymptomatic carotid stenosis (ACS) are at risk not only of stroke and related symptoms, but also of other cardiovascular episodes, such as myocardial infarction (heart attack) and peripheral artery disease (<a href="./references#CD013573-bbs2-0082" title="DivyaKP , SandeepN , SarmaS , SylajaPN . Risk of stroke and cardiac events in medically treated asymptomatic carotid stenosis. Journal of Stroke and Cerebrovascular Diseases2015;24(9):2149-53. [PMID: 26142257]">Divya 2015</a>; <a href="./references#CD013573-bbs2-0088" title="FlumignanCD , FlumignanRL , NavarroTP . Extracranial carotid stenosis: evidence based review [Estenose de carotida extracraniana: revisao baseada em evidencias]. Revista do Colegio Brasileiro de Cirurgioes2017;44(3):293-301. [PMID: 28767806]">Flumignan 2017</a>). </p> <p>Asymptomatic carotid stenosis is a common condition in clinical practice, affecting about 3% to 7% of the general population. It is more prevalent in older people (over 60 years of age), and can evolve into a stroke in 0.3% to 2% of patients each year (<a href="./references#CD013573-bbs2-0079" title="De WeerdM , GrevingJP , HedbladB , LorenzMW , MathiesenEB , O'LearyDH , et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke2010;41(6):1294-7. [PMID: 20431077]">De Weerd 2010</a>; <a href="./references#CD013573-bbs2-0113" title="ParkMS , KwonS , LeeMJ , KimKH , JeonP , ParkYJ , et al. Identification of high risk carotid artery stenosis: a multimodal vascular and perfusion imaging study. Frontiers in Neurology2019;10:765. [PMID: 31379719]">Park 2019</a>). An atherosclerotic lesion, a diffuse and degenerative disease of the arteries, usually provokes ACS, which narrows the vessel wall. A sudden rupture of atheromatous plaques from significant asymptomatic stenosis of the carotid artery can lead to thromboembolism, which causes 10% to 15% of all strokes (<a href="./references#CD013573-bbs2-0073" title="BulbuliaR , HallidayA . The Asymptomatic Carotid Surgery Trial-2 (ACST-2): an ongoing randomised controlled trial comparing carotid endarterectomy with carotid artery stenting to prevent stroke. Health Technology Assessment2017;21(57):1-40. [PMID: 29019319]">Bulbulia 2017</a>). Thus, for people with extracranial carotid disease, it is important to identify risk factors, the degree of stenosis of the artery, and the characteristics of the plaque, such as ulcerations, intra‐plaque haemorrhage, and lipid content, that may increase the likelihood of a cerebrovascular event (<a href="./references#CD013573-bbs2-0078" title="De WaardDD , MorrisD , De BorstGJ , BulbuliaR , HallidayA . Asymptomatic carotid artery stenosis: who should be screened, who should be treated and how should we treat them?Journal of Cardiovascular Surgery2017;58(1):3-12. [DOI: 10.23736/S0021-9509.16.09770-6] [PMID: 27901325]">De Waard 2017</a>; <a href="./references#CD013573-bbs2-0081" title="DerdeynCP . Carotid stenting for asymptomatic carotid stenosis: trial it. Stroke2007;38(2 Suppl):715-20. [PMID: 17261723]">Derdeyn 2007</a>; <a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>; <a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). </p> <p>The modifiable risk factors associated with ACS — such as hypertension, smoking, dyslipidaemia, diabetes, obesity, a sedentary lifestyle, alcoholism, inadequate diet quality, and psychosocial factors — can vary in importance according to region, ethnic group, gender, age, and family history. However, together these factors consistently contribute towards increasing the risk of cerebrovascular disease, making them targets for general approaches to preventing cerebrovascular events worldwide (<a href="./references#CD013573-bbs2-0069" title="ArnettDK , BlumenthalRS , AlbertMA , BurokerAB , GoldbergerZD , HahnEJ , et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation2019;140(11):e596-646. [PMID: 30879355]">Arnett 2019</a>; <a href="./references#CD013573-bbs2-0094" title="GuzikA , BushnellC . Stroke epidemiology and risk factor management. Continuum2017;23(1):15-39. [PMID: 28157742]">Guzik 2017</a>; <a href="./references#CD013573-bbs2-0111" title="O'DonnellMJ , ChinSL , RangarajanS , XavierD , LiuL , ZhangX , et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet2016;20(388):761-75.">O'Donnel 2016</a>). </p> <p>In order to diagnose and classify ACS, there are some complementary imaging tests: duplex ultrasound (DUS) and angiography by magnetic resonance imaging (MRI), computed tomography angiography (CTA), or digital subtraction angiography (DSA) (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>). DSA was discontinued in practice at the end of the 20th century as a diagnostic method, especially in asymptomatic patients, as it is associated with a 1.2% risk of neurological events (<a href="./references#CD013573-bbs2-0124" title="WalkerMD , MarlerJR , GoldsteinM , GradyPA , TooleJF , BakerWH , et al. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA1995;273(18):1421-8. [PMID: 7723155]">Walker 1995</a>; <a href="./references#CD013573-bbs2-0125" title="WardlawJM , ChappellFM , StevensonM , De NigrisE , ThomasS , GillardJ , et al. Accurate, practical and cost-effective assessment of carotid stenosis in the UK. Health Technology Assessment2006;10(30):iii-iv, ix-x, 1-182. [PMID: 16904049]">Wardlaw 2006</a>). On the other hand, DUS is affordable and non‐invasive. It also does not bring the additional risks associated with DSA, magnetic resonance angiography (MRA), and CTA, such as the use of iodinated or paramagnetic contrast, X‐ray exposure, and embolisation risks (<a href="./references#CD013573-bbs2-0074" title="CassolaN , Baptista-SilvaJC , NakanoLC , FlumignanCD , SessoR , Vasconcelos V et al. Duplex ultrasound for diagnosing symptomatic carotid stenosis in the extracranial segments. Cochrane Database of Systematic Reviews2022, Issue 7. Art. No: CD013172. [DOI: 10.1002/14651858.CD013172.pub2]">Cassola 2022</a>). Thus, DUS is widely used as the first diagnostic method for detecting carotid stenosis in both symptomatic patients and those with risk factors for asymptomatic stenosis (<a href="./references#CD013573-bbs2-0077" title="DaolioRM , CassolaN , FlumignanC , NakanoL , GuedesH , AmorimJ , et al. PC126. Accuracy of vascular ultrasound compared with computed tomography angiography for extracranial carotid stenosis imaging. Journal of Vascular Surgery2019;69(6):e239-40. [DOI: 10.1016/j.jvs.2019.04.356]">Daolio 2019</a>; <a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). </p> <p>The European Carotid Surgery Trial (<a href="./references#CD013573-bbs2-0084" title="European Carotid Surgery Trialists' Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet1998;351(9113):1379-87. [PMID: 9593407]">ECST 1998</a>) and the North American Symptomatic Carotid Endarterectomy Trial (NASCET; <a href="./references#CD013573-bbs2-0070" title="BarnettHJ , TaylorDW , HaynesRB , SackettDL , PeerlessSJ , FergusonGG , et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New England Journal of Medicine1991;325(7):445-53. [PMID: 1852179]">Barnett 1991</a>) applied different techniques to measure the percentage of stenosis in DSA (<a href="#CD013573-fig-0001">Figure 1</a>), and identified those patients who would benefit from revascularisation. Whilst the ECST used residual lumen diameter as a denominator, the NASCET used disease‐free diameter in a segment of the carotid artery above the stenosis. Using NASCET measurement standards, other studies (namely, the Asymptomatic Carotid Atherosclerosis Study (ACAS; <a href="./references#CD013573-bbs2-0124" title="WalkerMD , MarlerJR , GoldsteinM , GradyPA , TooleJF , BakerWH , et al. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA1995;273(18):1421-8. [PMID: 7723155]">Walker 1995</a>) and the Asymptomatic Carotid Surgery Trial 1 (ACST‐1)) have shown that surgical intervention would also benefit some asymptomatic patients with carotid stenosis greater than 60% of diameter on DSA (<a href="./references#CD013573-bbs2-0096" title="HallidayA , MansfieldA , MarroJ , PetoC , PetoR , PotterJ , et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet2004;363(9420):1491-502. [DOI: 10.1016/S0140-6736(04)16146-1] [PMID: 15135594]">Halliday 2004</a>; <a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>; <a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). </p> <div class="figure" id="CD013573-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Longitudinal view of carotid bifurcation with methods of measuring carotid stenosis at angiographyA: narrowest ICA diameter B: normal distal cervical ICA diameter C: estimated original diameter at the site of the most stenosisCCA: common carotid artery ECA: external carotid artery ECST: European Carotid Surgery Trial ICA: internal carotid artery NASCET: North American Symptomatic Carotid Endarterectomy Trial" data-id="CD013573-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-01.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Longitudinal view of carotid bifurcation with methods of measuring carotid stenosis at angiography </p> <p>A: narrowest ICA diameter<br/>B: normal distal cervical ICA diameter<br/>C: estimated original diameter at the site of the most stenosis </p> <p>CCA: common carotid artery<br/>ECA: external carotid artery<br/>ECST: European Carotid Surgery Trial<br/>ICA: internal carotid artery<br/>NASCET: North American Symptomatic Carotid Endarterectomy Trial </p> </div> </div> </div> </section> <section id="CD013573-sec-0011"> <h3 class="title" id="CD013573-sec-0011">Description of the intervention</h3> <p>It is important to ensure that people with ACS receive the best therapeutic option to avoid cerebral ischaemias. These options include: the control of hypertension; the use of lipid‐lowering drugs to reduce cholesterol levels in order to regress plaque(s), decrease the risk of plaque accident, and for anti‐inflammatory purposes; the use of hypoglycaemic drugs; and the use of antiplatelet and anticoagulant agents. </p> <section id="CD013573-sec-0012"> <h4 class="title">Antihypertensive therapy</h4> <p>High blood pressure is one of the most powerful risk factors, and its decrease seems to be directly related to a lower incidence of stroke. A reduction of 5 mmHg to 10 mmHg blood pressure is associated with a 30% to 40% reduced risk of stroke compared with placebo (<a href="./references#CD013573-bbs2-0102" title="LawesCM , BennettDA , FeiginVL , RodgersA . Blood pressure and stroke: an overview of published reviews. Stroke2004;35(3):776-85. [PMID: 14976329]">Lawes 2004</a>). Despite a lack of randomised controlled trials (RCTs) assessing the effects of antihypertensives in people with ACS, the European Society for Vascular Surgery (ESVS) recommends a target blood pressure for people with ACS below 140/90 mmHg (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>; <a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). More radically, in two guidelines, the American Heart Association (AHA) lowered these ideal blood pressure levels to close to 130/80 mmHg, with diastolic blood pressure less than 85 mmHg for people with diabetes (<a href="./references#CD013573-bbs2-0069" title="ArnettDK , BlumenthalRS , AlbertMA , BurokerAB , GoldbergerZD , HahnEJ , et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation2019;140(11):e596-646. [PMID: 30879355]">Arnett 2019</a>; <a href="./references#CD013573-bbs2-0072" title="BrottTG , HalperinJL , AbbaraS , BacharachJM , BarrJD , BushRL , et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Developed in collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography. Catheterization and Cardiovascular Interventions2013;81(1):E76-123. [PMID: 23281092]">Brott 2013</a>). </p> <p>Maintaining blood pressure may reduce stenosis and prevent lesion progression. Calcium channel blockers and angiotensin‐converting enzyme inhibitors are associated with plaque reduction to a greater extent than diuretics and beta‐blockers (<a href="./references#CD013573-bbs2-0069" title="ArnettDK , BlumenthalRS , AlbertMA , BurokerAB , GoldbergerZD , HahnEJ , et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation2019;140(11):e596-646. [PMID: 30879355]">Arnett 2019</a>; <a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>; <a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). </p> </section> <section id="CD013573-sec-0013"> <h4 class="title">Lipid‐lowering drugs</h4> <p>At the start of the 21st century, there was an increase in statin use as studies showed a decrease in cardiovascular events in symptomatic patients by more than one‐third when low‐density lipoprotein (LDL) cholesterol levels were below 70 mg/dL (<a href="./references#CD013573-bbs2-0068" title="AmarencoP , BogousslavskyJ , Callahan A 3rd, GoldsteinLB , HennericiM , RudolphAE , et al. High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine2006;355(6):549-59. [PMID: 16899775]">Amarenco 2006</a>; <a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>; <a href="./references#CD013573-bbs2-0121" title="TaylorAJ , KentSM , FlahertyPJ , CoyleLC , MarkwoodTT , VernalisMN . ARBITER: ARterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation2002;106(16):2055-60. [PMID: 12379573]">Taylor 2002</a>). Systematic reviews observed a significant reduction in cardiovascular mortality (including stroke) when statins, mainly atorvastatin 80 mg daily, were used in primary prevention; for instance, in people with ACS (<a href="./references#CD013573-bbs2-0072" title="BrottTG , HalperinJL , AbbaraS , BacharachJM , BarrJD , BushRL , et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Developed in collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography. Catheterization and Cardiovascular Interventions2013;81(1):E76-123. [PMID: 23281092]">Brott 2013</a>; <a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>; <a href="./references#CD013573-bbs2-0122" title="TaylorF , HuffmanMD , MacedoAF , MooreTH , BurkeM , Davey SmithG , et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD004816. [DOI: 10.1002/14651858.CD004816.pub5]">Taylor 2013</a>). However, ezetimibe or proprotein convertase subtilisin/kexin type (9PCSK9) inhibitors may be an alternative treatment for high‐risk patients who cannot tolerate statins (<a href="./references#CD013573-bbs2-0127" title="WilsonPW , PolonskyTS , MiedemaMD , KheraA , KosinskiAS , KuvinJT . Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation2019;139(25):e1144-61. [PMID: 30586775]">Wilson 2019</a>; <a href="./references#CD013573-bbs2-0128" title="ZhanS , TangM , LiuF , XiaP , ShuM , WuX . Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD012502. [DOI: 10.1002/14651858.CD012502.pub2]">Zhan 2018</a>). </p> </section> <section id="CD013573-sec-0014"> <h4 class="title">Management of diabetes</h4> <p>Diabetes mellitus is an independent predictor of moderate and severe carotid stenosis, and can contribute to doubling the chances of stroke (<a href="./references#CD013573-bbs2-0100" title="HolmanRR , SourijH , CaliffRM . Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet2014;383(9933):2008-17. [PMID: 24910232]">Holman 2014</a>). Medications used for glycaemic control include oral hypoglycaemic agents (metformin or sulphonylureas, or both), insulin therapy, or the new glucose‐lowering medications, such as the analogue of human glucagon‐like peptide 1, dipeptidyl peptidase 4 inhibitors, sodium‐glucose cotransporter 2 inhibitors, and thiazolidine (<a href="./references#CD013573-bbs2-0100" title="HolmanRR , SourijH , CaliffRM . Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet2014;383(9933):2008-17. [PMID: 24910232]">Holman 2014</a>). Strong control of glycaemic levels is not directly related to a decreased risk of stroke, but glycosylated haemoglobin levels lower than 7% may contribute to a reduction in other related events, such as microangiopathy (<a href="./references#CD013573-bbs2-0129" title="ZhangC , ZhouYH , XuCL , ChiFL , JuHN . Efficacy of intensive control of glucose in stroke prevention: a meta-analysis of data from 59,197 participants in 9 randomized controlled trials. PLoS One2013;8(1):e54465. [PMID: 23372729]">Zhang 2013</a>). Meanwhile, systematic reviews indicated that strict control in people with a body mass index above 30 kg/m<sup>2</sup> was effective in reducing the risk of cerebrovascular disease (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>; <a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). </p> </section> <section id="CD013573-sec-0015"> <h4 class="title">Antiplatelet drugs</h4> <p>There is weak evidence for the use of antiplatelet drugs in people with ACS for reducing the risk of stroke, but there is more robust evidence for their use in secondary prevention (<a href="./references#CD013573-bbs2-0107" title="MurphySJ , NaylorAR , RiccoJB , SillesenH , KakkosS , HallidayA , et al. Optimal antiplatelet therapy in moderate to severe asymptomatic and symptomatic carotid stenosis: a comprehensive review of the literature. European Journal of Vascular and Endovascular Surgery2019;57(2):199-211. [DOI: 10.1016/j.ejvs.2018.09.018] [PMID: 30414802]">Murphy 2019</a>). However, the use of aspirin at doses between 75 mg and 325 mg (or clopidogrel 75 mg when aspirin is intolerable) is recommended in asymptomatic patients to prevent other cardiovascular events (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>; <a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). </p> </section> <section id="CD013573-sec-0016"> <h4 class="title">Anticoagulant agents</h4> <p>Anticoagulant therapy is known to prevent stroke in people with atrial fibrillation, but warfarin has not been shown to be more effective compared to antiplatelet therapy for secondary prevention in people without atrial fibrillation (<a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). However, recent studies have indicated that the use of low‐dose rivaroxaban together with aspirin may decrease the risk of stroke in both symptomatic and asymptomatic patients (<a href="./references#CD013573-bbs2-0119" title="SharmaM , HartRG , ConnollySJ , BoschJ , ShestakovskaO , NgKK , et al. Stroke outcomes in the COMPASS Trial. Circulation2019;139(9):1134-45. [PMID: 30667279]">Sharma 2019</a>). </p> </section> </section> <section id="CD013573-sec-0017"> <h3 class="title" id="CD013573-sec-0017">How the intervention might work</h3> <p>As carotid atherosclerosis is an important aspect in stroke pathophysiology, proper management of the diseases that lead to its increase may correspond to key targets for stroke prevention. The approaches discussed above work together to control the risk factors that increase atherosclerosis, avoiding irregular and ulcerated plaques and microembolic particles, and preventing carotid artery disease from progressing (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>). </p> <p>The ACAS and ACST‐1 studies used an initial pharmacological therapy which has significantly changed in recent decades. For instance, only around 10% to 20% of ACAS and ACST‐1 participants regularly used lipid‐lowering drugs (<a href="./references#CD013573-bbs2-0124" title="WalkerMD , MarlerJR , GoldsteinM , GradyPA , TooleJF , BakerWH , et al. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA1995;273(18):1421-8. [PMID: 7723155]">Walker 1995</a>). There was a decline in annual stroke rates of approximately 60% between 1995 and 2004, which strongly correlates with improved pharmacological treatment associated with the increased use of aspirin, antihypertensive drugs, and statins, in that decade (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>). Control of hypertension can reduce the risk of stroke by up to 30%, while control of cholesterol can reduce this risk by 15% (<a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). In addition, people with diabetes who, associated with glycaemic control, were taking statins, antiplatelet, and antihypertensive drugs, showed a 60% reduction in the risk of cardiovascular disease and death (<a href="./references#CD013573-bbs2-0096" title="HallidayA , MansfieldA , MarroJ , PetoC , PetoR , PotterJ , et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet2004;363(9420):1491-502. [DOI: 10.1016/S0140-6736(04)16146-1] [PMID: 15135594]">Halliday 2004</a>; <a href="./references#CD013573-bbs2-0116" title="RicottaJJ , AburahmaA , AscherE , EskandariM , FariesP , LalBK . Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery2011;54(3):e1-31. [DOI: 10.1016/j.jvs.2011.07.031] [PMID: 21889701]">Ricotta 2011</a>). </p> </section> <section id="CD013573-sec-0018"> <h3 class="title" id="CD013573-sec-0018">Why it is important to do this review</h3> <p>Some RCTs have evaluated the use of pharmacological interventions, and topical guidelines currently recommend triple medical therapy (e.g. antiplatelet agents, antihypertensive therapy, and statins) in addition to lifestyle interventions to reduce the risk of stroke (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>). Routine carotid endarterectomy or stenting is not reasonable in asymptomatic patients, except in particular high‐risk patients on medical therapy (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>). However, the optimal therapeutic management strategy remains unclear (<a href="./references#CD013573-bbs2-0114" title="RamanG , MoorthyD , HadarN , DahabrehIJ , O'DonnellTF , ThalerDE , et al. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Annals of Internal Medicine 2013 May 7;158(9):676-85. [DOI: 10.7326/0003-4819-158-9-201305070-00007] [PMID: 23648949]">Raman 2013</a>). Additionally, recent studies suggest that direct oral anticoagulants plus antiplatelet agents may be more effective than antiplatelet agents alone for decreasing the risk of major vascular events (<a href="./references#CD013573-bbs2-0066" title="AbbottAL , BladinCF , LeviCR , ChambersBR . What should we do with asymptomatic carotid stenosis?International Journal of Stroke2007;2(1):27-39. [PMID: 18705984]">Abbott 2007</a>; <a href="./references#CD013573-bbs2-0119" title="SharmaM , HartRG , ConnollySJ , BoschJ , ShestakovskaO , NgKK , et al. Stroke outcomes in the COMPASS Trial. Circulation2019;139(9):1134-45. [PMID: 30667279]">Sharma 2019</a>). </p> <p>Stroke continues to be the main cause of permanent disability and one of the most important causes of death in the world. Its impact leads to considerable socioeconomic impairment, not only to the individual and their family, but also to society as a whole. In this context, pursuing the best pharmacological strategies may be useful in decreasing ACS‐related mortality and permanent neurological disability (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013573-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013573-sec-0019"></div> <p>To assess the effects of pharmacological interventions for the treatment of asymptomatic carotid stenosis in preventing neurological impairment, ipsilateral major or disabling stroke, death, major bleeding, and other outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013573-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013573-sec-0020"></div> <section id="CD013573-sec-0021"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013573-sec-0022"> <h4 class="title">Types of studies</h4> <p>We included all RCTs with parallel (e.g. cluster or individual) or cross‐over design. We planned to only use data from the first phase of cross‐over studies to avoid the risk of carry‐over effects, as described in Section 23.2.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013573-bbs2-0098" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). We included studies reported in full texts, as abstracts only, and unpublished data. We did not include quasi‐randomised trials (i.e. studies in which participants are allocated to intervention groups based on methods that are not truly random, such as hospital number or date of birth). </p> </section> <section id="CD013573-sec-0023"> <h4 class="title">Types of participants</h4> <p>We considered for inclusion participants of any gender and any age with ACS. Carotid stenosis was defined as a narrowing of the internal or common carotid artery (or both), diagnosed by at least one valid objective test (e.g. DUS or angiography by tomography, magnetic resonance, or digital subtraction). We used the classification of carotid stenosis with the use of ultrasound, as defined by <a href="./references#CD013573-bbs2-0093" title="GrantEG , BensonCB , MonetaGL , AlexandrovAV , BakerJD , BluthEI , et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis - Society of Radiologists in Ultrasound Consensus Conference. Radiology2003;229(2):340-6. [PMID: 14500855]">Grant 2003</a>, for participant classification (<a href="#CD013573-tbl-0006">Table 2</a>). We used the Mannheim Consensus to distinguish between augmented intima‐media thickness (IMT) and carotid stenosis, as described by <a href="./references#CD013573-bbs2-0123" title="TouboulPJ , HennericiMG , MeairsS , AdamsH , AmarencoP , BornsteinN , et al. Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004–2006–2011): an update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovascular Diseases2012;34(4):290-6. [DOI: 10.1159/000343145]">Touboul 2012</a>, where the latter refers to plaque with an intima‐media thickness greater than 1.3 mm, from the media‐adventitia interface to the intima‐lumen interface. We considered participants as asymptomatic if they were without ipsilateral neurological symptoms (e.g. amaurosis fugax, TIA, or stroke) in the previous six months (<a href="./references#CD013573-bbs2-0109" title="NaylorR , RantnerB , AncettiS , BorstGJ , CarloM , HallidayA , et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery2023;65(1):7-111. [DOI: 10.1016/j.ejvs.2022.04.011]">Naylor 2023</a>). We considered all trials involving participants with ACS, irrespective of the degree of stenosis or the method of determining the degree of stenosis. </p> <div class="table" id="CD013573-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">DUS criteria for internal carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Consensus panel based on <a href="./references#CD013573-bbs2-0093" title="GrantEG , BensonCB , MonetaGL , AlexandrovAV , BakerJD , BluthEI , et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis - Society of Radiologists in Ultrasound Consensus Conference. Radiology2003;229(2):340-6. [PMID: 14500855]">Grant 2003</a> </p> </td> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Degree of stenosis (%)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Primary parameters</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Additional parameters</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ICA PSV (cm/sec)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Plaque estimate (%)*</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ICA/CCA PSV ratio</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ICA EDV (cm/sec)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% to 69%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125 to 230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0 to 4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 to 100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 70% but less than near occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Near occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High, low or undetectable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Undetectable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visible, no detectable lumen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*Plaque estimate (diameter reduction) based on DUS B‐mode and on additional colour mode ultrasound. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CCA: common carotid artery<br/>DUS: duplex ultrasound<br/>EDV: end diastolic velocity<br/>ICA: internal carotid artery<br/>PSV: peak systolic velocity </p> </div> </div> <p>If we found studies with mixed populations, and only a subset of the participants met our inclusion criteria, we attempted to obtain data for the subgroup of interest from the trialists in order to include the study. For studies with mixed populations where we could not obtain data on the subgroup of interest, but at least 50% of the study population was of interest, we included all participants in our analysis. We explored the effect of this decision in sensitivity analyses. We excluded studies in which less than 50% of the population were of interest and data on the subgroup of interest were not available. </p> </section> <section id="CD013573-sec-0024"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing one pharmacological intervention (agent or drug) with placebo, no treatment, or another pharmacological intervention. We included trials of any combination of interventions, providing co‐treatments were balanced between the treatment and control arms for the ACS treatment. We considered interventions such as fish oil and diet as no treatment. We also included studies that compared different doses of drugs. </p> <p>We considered the following interventions:</p> <p> <ul id="CD013573-list-0001"> <li> <p>anticoagulants (unfractionated heparin (UFH) and low molecular weight heparins (LMWHs); vitamin K antagonists (VKAs); direct oral anticoagulants (DOACs), factor Xa inhibitors and direct thrombin inhibitors; pentasaccharides); </p> </li> <li> <p>antiplatelet agents (e.g. aspirin, clopidogrel);</p> </li> <li> <p>antihypertensive drugs (e.g. angiotensin‐converting enzyme inhibitors, beta‐blockers);</p> </li> <li> <p>glycaemic‐lowering agents (e.g. biguanides, sulphonylureas); and</p> </li> <li> <p>lipid‐lowering agents (e.g. statins).</p> </li> </ul> </p> <p>The possible comparisons were:</p> <p> <ul id="CD013573-list-0002"> <li> <p>anticoagulants plus antiplatelet agents versus antiplatelet agents;</p> </li> <li> <p>one antiplatelet drug versus a combination of antiplatelets from two drugs;</p> </li> <li> <p>one antiplatelet drug versus another antiplatelet drug;</p> </li> <li> <p>anticoagulants versus antiplatelet drugs;</p> </li> <li> <p>one lipid‐lowering drug versus another lipid‐lowering drug;</p> </li> <li> <p>one antihypertensive drug versus another antihypertensive drug;</p> </li> <li> <p>one glycaemic‐lowering drug versus another glycaemic‐lowering drug; and</p> </li> <li> <p>any combination of the above treatments versus any combination, with or without placebo.</p> </li> </ul> </p> </section> <section id="CD013573-sec-0025"> <h4 class="title">Types of outcome measures</h4> <section id="CD013573-sec-0026"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013573-list-0003"> <li> <p>Neurological impairment, assessed using clinical outcome measures or any validated international scales (e.g. the National Institutes of Health Stroke Scale (NIHSS), the modified Rankin Scale (mRS), the Barthel Index (BI)). If we identified both dichotomous and continuous variables related to neurological impairment, we reported them separately as independent outcomes. </p> </li> <li> <p>Ipsilateral major or disabling stroke, related to the extracranial carotid stenosis and confirmed by any objective additional test (e.g. computerised tomography, angiography) other than clinical examination only. </p> </li> </ul> </p> </section> <section id="CD013573-sec-0027"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013573-list-0004"> <li> <p>Stroke‐related mortality</p> </li> <li> <p>Major bleeding: defined by a haemoglobin concentration decrease of 2 g/dL or more, a retroperitoneal or intracranial bleed, a transfusion of two or more units of blood, or fatal haemorrhagic events, as defined by the International Society on Thrombosis and Haemostasis (<a href="./references#CD013573-bbs2-0117" title="SchulmanS , AngerasU , BergqvistD , ErikssonB , LassenMR , FisherW . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. Journal of Thrombosis and Haemostasis2010;8(1):202-4. [PMID: 19878532]">Schulman 2010</a>). We also considered the definition stipulated by the included study. </p> </li> <li> <p>Progression of carotid stenosis (any increase in extracranial carotid stenosis), evaluated by change in range of stenoses; that is, less than 50%, 50% to 69%, 70% or more, near occlusion or occlusion. We considered the carotid stenosis if it was evaluated by any valid objective method (e.g. duplex ultrasound (<a href="./references#CD013573-bbs2-0093" title="GrantEG , BensonCB , MonetaGL , AlexandrovAV , BakerJD , BluthEI , et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis - Society of Radiologists in Ultrasound Consensus Conference. Radiology2003;229(2):340-6. [PMID: 14500855]">Grant 2003</a>), or angiography by tomography, magnetic resonance, or digital subtraction (<a href="./references#CD013573-bbs2-0070" title="BarnettHJ , TaylorDW , HaynesRB , SackettDL , PeerlessSJ , FergusonGG , et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New England Journal of Medicine1991;325(7):445-53. [PMID: 1852179]">Barnett 1991</a>)). </p> </li> <li> <p>Adverse events, such as all‐cause mortality, gastrointestinal events, allergic reaction, renal failure, or minor bleeding. </p> </li> <li> <p>Quality of life, analysed by any validated questionnaire (e.g. SF‐36 (<a href="./references#CD013573-bbs2-0126" title="WareJE , SherbourneCD . The MOS 36-item Short-form Health Survey (SF-36). I. Conceptual framework and item selection. Medical Care1992;30(6):473-83. [PMID: 1593914]">Ware 1992</a>)) or participants' subjective perception of improvement (yes or no) as reported by the study authors. If we were unable to pool data on quality of life due to the use of different measurements, we planned to extract data on improvement. </p> </li> </ul> </p> <p>We presented the outcomes at the following two time points after the start of the intervention, if data were available: </p> <p> <ul id="CD013573-list-0005"> <li> <p>early outcomes (at six months or less after the start of the intervention); and</p> </li> <li> <p>long‐term outcomes (more than six months after the start of the intervention).</p> </li> </ul> </p> </section> </section> </section> <section id="CD013573-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for trials in all languages and arranged for the translation of relevant articles where necessary. </p> <section id="CD013573-sec-0029"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Stroke Group trials register and the following electronic databases: </p> <p> <ul id="CD013573-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, issue 8) in the Cochrane Library (searched 9 August 2022); </p> </li> <li> <p>MEDLINE Ovid (from 1946 to 9 August 2022);</p> </li> <li> <p>Embase Ovid (from 1974 to 9 August 2022);</p> </li> <li> <p>Literatura Latino‐Americana e do Caribe em Ciências da Saúde (LILACS) (from 1982 to 9 August 2022), via <a href="https://bvsalud.org/" target="_blank">Virtual Health Library</a>); and </p> </li> <li> <p>Indice Bibliográfico Español de Ciencias de la Salud (IBECS), via <a href="https://bvsalud.org/" target="_blank">Virtual Health Library</a> (searched 9 August 2022). </p> </li> </ul> </p> <p>We modelled the subject strategies for databases on the search strategy designed for MEDLINE by the Cochrane Stroke Group's Information Specialist. We opted to write a highly‐sensitive search strategy and eliminated the pharmacological interventions component of the search entirely. The reasons for this are as follows. The problem component 'asymptomatic carotid stenosis' is already well‐defined and, when combined with Cochrane's verified RCT filter, retrieved a low number of results during test searches in MEDLINE Ovid. Pharmacological interventions search blocks can help improve recall when included in search strategies. However, because the initial test search recall was relatively low, as suggested above, we elected not to include them in the enclosed search, but we selected the relevant interventions manually. We combined all search strategies deployed with subject strategy adaptations of the highly‐sensitive search strategy designed by Cochrane for identifying RCTs and controlled clinical trials, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013573-bbs2-0103" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Lefebvre 2022</a>). </p> <p>We searched the following ongoing trials registers:</p> <p> <ul id="CD013573-list-0007"> <li> <p>US National Institutes of Health Ongoing Trials Register, ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>; searched 9 August 2022); and </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://who.int/ictrp/en/" target="_blank">who.int/ictrp/en/</a>; searched 9 August 2022). </p> </li> </ul> </p> <p>The most recent searches were carried out on 9 August 2022. The search strategies are reported in <a href="./appendices#CD013573-sec-0139">Appendix 1</a>. </p> </section> <section id="CD013573-sec-0030"> <h4 class="title">Searching other resources</h4> <p>In an effort to identify further published, unpublished, and ongoing trials, we:</p> <p> <ul id="CD013573-list-0008"> <li> <p>checked the bibliographies of included studies and any relevant systematic reviews identified for further references to relevant trials, and searched Google Scholar to forward‐track relevant references (<a href="http://scholar.google.co.uk/" target="_blank">scholar.google.co.uk/</a>); </p> </li> <li> <p>contacted original trial authors for clarification and further data if trial reports were unclear; </p> </li> <li> <p>where necessary, contacted experts/trialists/organisations in the field to obtain additional information on relevant trials, using a standard letter template (<a href="./appendices#CD013573-sec-0149">Appendix 2</a>); and </p> </li> <li> <p>conducted a search of various grey literature sources, dissertation and theses databases, and databases of conference abstracts, including: </p> <ul id="CD013573-list-0009"> <li> <p><a href="http://www.repositorio.unifesp.br/" target="_blank">Repositório UNIFESP</a> (thesis repository of Universidade Federal de São Paulo, Brazil; searched 9 August 2022; <a href="./appendices#CD013573-sec-0139">Appendix 1</a>); </p> </li> <li> <p><a href="https://ethos.bl.uk/" target="_blank">British Library EThOS</a> (UK E‐Theses Online Service; searched 9 August 2022; <a href="./appendices#CD013573-sec-0139">Appendix 1</a>); </p> </li> <li> <p><a href="https://www.proquest.com/products-services/pqdtglobal.html" target="_blank">ProQuest Dissertation and Theses Global</a> (searched 9 August 2022; <a href="./appendices#CD013573-sec-0139">Appendix 1</a>). </p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD013573-sec-0031"> <h3 class="title" id="CD013573-sec-0031">Data collection and analysis</h3> <section id="CD013573-sec-0032"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CNBC, NC) independently screened titles and abstracts of the references obtained as a result of our searching activities, and excluded obviously irrelevant reports using the <a href="./references#CD013573-bbs2-0076" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 25 March 2020. Available at www.covidence.org.">Covidence</a> tool. We retrieved the full‐text articles for the remaining references and two review authors (CNBC, NC) independently screened these, to identify studies for inclusion and to record reasons for exclusion of the ineligible studies. We resolved any disagreements through discussion or, when required, we consulted a third review author (RLGF). We collated multiple reports of the same study so that each study, not each reference, was the unit of interest in the review. We recorded the selection process and complete a PRISMA flow diagram (<a href="./references#CD013573-bbs2-0112" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372:n71. [DOI: 10.1136/bmj.n71]">Page 2021</a>). </p> </section> <section id="CD013573-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data, which we piloted on at least one study in the review. Two review authors (CNBC, NC) independently extracted data from the included studies. We extracted the following study characteristics. </p> <p> <ul id="CD013573-list-0010"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting and date of study. </p> </li> <li> <p>Participants: number randomised, number lost to follow‐up/withdrawn, number analysed, number of interest, mean age, age range, gender, severity of condition, diagnostic criteria, smoking history, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>We resolved disagreements by consensus or by involving a third review author (RLGF). One review author (CNBC) transferred data into Review Manager (<a href="./references#CD013573-bbs2-0115" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the data extraction form. A second review author (NC) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD013573-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CNBC, NC) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013573-bbs2-0097" title="HigginsJP , AltmanDG , SterneJA , (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We resolved any disagreements by discussion or by involving another review author (RLGF). We assessed the risk of bias according to the following domains: </p> <p> <ul id="CD013573-list-0011"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low, or unclear and provide a quote from the study report, together with a justification for our judgement in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the domains listed. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the risk of bias table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD013573-sec-0035"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD013573-bbs2-0130" title="ClezarCN , CassolaN , FlumignanCD , NakanoLC , TrevisaniVF , FlumignanRL . Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD013573. [DOI: 10.1002/14651858.CD013573]">Clezar 2020</a>), and reported any deviations from it in the <a href="#CD013573-sec-0156">Differences between protocol and review</a> section of the review. </p> </section> </section> <section id="CD013573-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs).</p> </section> <section id="CD013573-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>Individuals were our unit of analysis. If trials included multiple intervention arms, we considered only the arms relevant to the scope of our review. Where a study included multiple intervention groups, we combined groups to create a single pair‐wise comparison. Where a study included repeated observations, we followed recommendations in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013573-bbs2-0098" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD013573-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data (e.g. when we identified a study as an abstract only). Where possible, we used the Review Manager calculator to calculate missing standard deviations using other data from the trial, such as confidence intervals. Where this was not possible, and we thought the missing data introduced serious bias, we explored the impact of including such studies in the overall assessment of results by a sensitivity analysis. For all outcomes, we followed intention‐to‐treat (ITT) principles to the greatest degree possible: that is, we analysed participants in their randomised group regardless of what intervention they actually received. We used available‐case data for the denominator if ITT data were not available. </p> <p>We presented study‐level data so that missing and unclear data were clearly indicated and to make available any unpublished data acquired from investigators. </p> </section> <section id="CD013573-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>We inspected studies for clinical (variation in population, interventions, and outcomes) and methodological (variation in study design, outcome measurement, or risk of bias) heterogeneity. </p> <p>We inspected forest plots visually to consider the direction and magnitude of effects and the degree of overlap between confidence intervals. We used the I<sup>2</sup> statistic to measure heterogeneity amongst the trials in each analysis; we acknowledge that there is substantial uncertainty in the value of I<sup>2</sup> when there are few studies. If we identified substantial heterogeneity, we reported it and explored possible causes by prespecified subgroup analysis. </p> <p>As strict thresholds for interpretation of I<sup>2</sup> are not recommended, we followed the guide to interpretation in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013573-bbs2-0080" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>): </p> <p> <ul id="CD013573-list-0012"> <li> <p>0% to 40% might not be important;</p> </li> <li> <p>30% to 60% may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity; or</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When the I<sup>2</sup> value lies in an area of overlap between two categories (e.g. between 50% and 60%), we considered differences in participants and interventions amongst the trials contributing data to the analysis (<a href="./references#CD013573-bbs2-0080" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> </section> <section id="CD013573-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not use funnel plots to investigate reporting biases because we did not identify 10 or more studies in one comparison. </p> </section> <section id="CD013573-sec-0041"> <h4 class="title">Data synthesis</h4> <p>We synthesised the data using Review Manager 5.4 (<a href="./references#CD013573-bbs2-0115" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We undertook meta‐analysis only where this was meaningful; that is, if the treatments, participants, and the underlying clinical question were similar enough for pooling to be appropriate. </p> <p>If we were confident that trials were estimating the same underlying treatment effect — that is, the included studies were homogenous (considering population, interventions, comparators, and outcome characteristics) — we used a fixed‐effect meta‐analysis. If clinical differences were sufficient to expect that underlying treatment effects differed between trials or if we identified at least substantial heterogeneity, we used a random‐effects meta‐analysis. If there was substantial clinical, methodological, or statistical heterogeneity across trials that prevented the pooling of data, we used a narrative approach to data synthesis (<a href="./references#CD013573-bbs2-0080" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> <p>We addressed all outcomes listed in <a href="#CD013573-sec-0025">Types of outcome measures</a> in the <a href="#CD013573-sec-0063">Effects of interventions</a> section of the review, presenting the outcomes in the order in which they are shown in <a href="#CD013573-sec-0025">Types of outcome measures</a>. In addition, we presented one summary of findings table for each comparison, in which we summarised the main outcomes. We included the results of individual studies and any statistical summary of these in <a href="./references#CD013573-sec-0137" title="">Data and analyses</a> tables in the review. </p> </section> <section id="CD013573-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We were unable to conduct our preplanned subgroup analyses (<a href="./references#CD013573-bbs2-0130" title="ClezarCN , CassolaN , FlumignanCD , NakanoLC , TrevisaniVF , FlumignanRL . Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD013573. [DOI: 10.1002/14651858.CD013573]">Clezar 2020</a>), due to insufficient data. </p> </section> <section id="CD013573-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>We were only able to conduct one of our preplanned sensitivity analyses (<a href="./references#CD013573-bbs2-0130" title="ClezarCN , CassolaN , FlumignanCD , NakanoLC , TrevisaniVF , FlumignanRL . Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD013573. [DOI: 10.1002/14651858.CD013573]">Clezar 2020</a>), comparing a fixed‐effect versus random‐effects model for the 'ipsilateral major or disabling stroke' outcome. </p> </section> <section id="CD013573-sec-0044"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created tables for each of our 10 comparisons, and from these, selected the four most clinically relevant to present as our core summary of findings tables. We have presented the remaining comparisons as additional tables. </p> <p>We present the following outcomes in all tables:</p> <p> <ul id="CD013573-list-0013"> <li> <p>neurological impairment;</p> </li> <li> <p>ipsilateral major or disabling stroke;</p> </li> <li> <p>stroke‐related mortality;</p> </li> <li> <p>major bleeding;</p> </li> <li> <p>progression of carotid stenosis;</p> </li> <li> <p>adverse events; and</p> </li> <li> <p>quality of life.</p> </li> </ul> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence as it related to the studies that contributed data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD013573-bbs2-0091" title="GRADE Working Group, AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490-4.">GRADE 2004</a>). We used methods and recommendations described in Chapter 15 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013573-bbs2-0118" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>), and GRADEpro GDT software (<a href="./references#CD013573-bbs2-0092" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>). We justified all decisions to downgrade the quality of studies using footnotes, and we made comments to aid the reader's understanding of the review where necessary. </p> <p>Two review authors (CNBC, NC), working independently, made judgements about the certainty of the evidence, with disagreements resolved by discussion or involving a third review author (RLGF). We justified, documented, and incorporated judgements into the reporting of results for each outcome. </p> <p>We extracted study data, formatted our comparisons in data tables, and prepared our summary of findings tables before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013573-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013573-sec-0045"></div> <section id="CD013573-sec-0046"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD013573-sec-0166" title="">Characteristics of included studies</a> and <a href="./references#CD013573-sec-0167" title="">Characteristics of excluded studies</a>. </p> <section id="CD013573-sec-0047"> <h4 class="title">Results of the search</h4> <p>We identified 10,368 records through the database searches and removed 1959 duplicate records. Two review authors (CNBC and NC) screened 8409 records and eliminated 8344 irrelevant records. We screened the remaining records against our inclusion criteria and analysed the full texts of 65 studies. We included 34 studies in qualitative analysis; 22 of these studies contributed to the quantitative analysis. Three included studies were multi‐armed (<a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>). We excluded 30 studies (see <a href="#CD013573-sec-0053">Excluded studies</a>). We identified one ongoing trial (<a href="./references#CD013573-bbs2-0065" title="AranzullaTC , PiazzaS , RicottiA , MusumeciG , GaggianoA . Carotid plaque stabilization and regression with evolocumab: rationale and design of the CARUSO study. Catheter Cardiovascular Intervention2021;98(1):E115-21. [DOI: 10.1002/ccd.29743]">Aranzulla 2021</a>). See <a href="#CD013573-fig-0002">Figure 2</a> for the study flow diagram (<a href="./references#CD013573-bbs2-0104" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [PMID: 19621070]">Liberati 2009</a>). </p> <div class="figure" id="CD013573-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013573-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD013573-sec-0048"> <h4 class="title">Included studies</h4> <p>We included 34 studies that met our prespecified inclusion criteria (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>; <a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0003" title="Blanco-ColioLM , Martin-VenturaJL , SolJM , DiazC , HernandezG , EgidoJ . Decreased circulating fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology2004;43(7):1188-94. [DOI: 10.1016/j.jacc.2003.10.046]Gómez-GeriqueJA , RosE , OlivánJ , MostazaJM , VilardellM , PintóX , et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis2002;162(2):245–51. [DOI: 10.1016/s0021-9150(01)00708-0]">Blanco‐Colio 2004</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>; <a href="./references#CD013573-bbs2-0005" title="CortiR , FusterV , FayadZA , WorthleySG , HelftG , ChaplinWF , et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. Journal of the American College of Cardiology2005;46(1):106-12. [DOI: 10.1016/j.jacc.2005.03.054]">Corti 2005</a>; <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0011" title="HuY , TongG , XuW , PanJ , RyanK , YangR , et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diabetes and Vascular Disease Research2009;6(4):262-8. [DOI: 10.1177/1479164109339966]">Hu 2009</a>; <a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>; <a href="./references#CD013573-bbs2-0013" title="KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouA , GerasimidisT , LiapisCD . Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2010;51:114-21. [DOI: 10.1016/j.jvs.2009.07.119]KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouAT , FotiadisG , VittaI , et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2009;49(5 suppl 1):4S-5S. ">Kadoglou 2010</a>; <a href="./references#CD013573-bbs2-0028" title="MagnaniB , Dal PaluC , ZanchettiA . Preliminary clinical experience with calcium antagonists in atherosclerosis. Drugs1992;44 Suppl 1:128-33. RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA , VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension 1997 Nov;15(11):1337-44. [DOI: 10.1097/00004872-199715110-00019]ZanchettiA , MagnaniB , Dal PaluC , on behalf of the VHAS Investigators. Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonography evaluations. Journal of Hypertension1997;15 Suppl 4:S91. ZanchettiA , MagnaniB , Dal PaluC , on behalf of the Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. Atherosclerosis and calcium antagonists: the VHAS. Journal of Human Hypertension1992;6 Suppl 2:S45-8. ZanchettiA , RoseiEA , Dal PaluC , LeonettiG , MagnaniB , PessinaA , et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16:1667-76. ZanchettiA . VHAS: Verapamil in Hypertension and Atherosclerosis Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. ">VHAS 1998</a>; <a href="./references#CD013573-bbs2-0014" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49:838-47. [DOI: 10.1177/0091270009337011]">Meaney 2009</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>; <a href="./references#CD013573-bbs2-0018" title="ReidJA , WolsleyC , LauLL , HannonRJ , LeeB , YoungIS , et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. European Journal of Vascular and Endovascular Surgery2005;30:464-8. [DOI: 10.1016/j.ejvs.2005.05.007]">Reid 2005</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0021" title="SempliciniA , MarescaA , SimonellaC , ChierichettiF , PaulettoP , MeneghettiG , et al. Cerebral perfusion in hypertensives with carotid artery stenosis: a comparative study of lacidipine and hydrochlorothiazide. Blood Pressure2000;9:34-9. [DOI: 10.1080/080370500439407 · S]SempliciniA , SimonellaC , MeneghettiG , ChierichettiF , SantipoloN , PaulettoP , et al. Lacidipine and cerebral perfusion in uncomplicated essential hypertensives with mild to moderate carotid artery stenosis. Journal of Hypertension1998;16 Suppl 2:S243. ">Semplicini 2000</a>; <a href="./references#CD013573-bbs2-0022" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45(2):188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>; <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>; <a href="./references#CD013573-bbs2-0027" title="DuR , CaiJ , PingY , WangQ , LiuD , WuH . Effect of low dose rosuvastatin therapy on regression of carotid plaque and vasa vasorums in Chinese population: a prospective clinical trial by MRI. Journal of the American College of Cardiology2013;61(10 Suppl 1):E938. HatsukamiTS , ZhaoXQ , YuanC , TessierJJ , MillerE , PearsJS . Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis. Atherosclerosis. Supplements2001;2:47-8. [DOI: 10.1016/s1567-5688(01)80057-x]NCT00654394. Progression of carotid artery atheroma in moderately hypercholesterolemic subjects. clinicaltrials.gov/ct2/show/NCT00654394 (first received 3 April 2008). [CLINICAL TRIALS REGISTER: NCT00654394]UnderhillHR , YuanC , ZhaoXQ , KraissLW , ParkerDL , SaamT , et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. American Heart Journal2008;155(3):584.e1–584.e8. [DOI: 10.1016/j.ahj.2007.11.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00654394]">Underhill 2008</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0030" title="C000000319. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. upload.umin.ac.jp (first received 01 February 2006). [UMIN-CTR CLINICAL TRIAL REGISTER:: C000000319]HoriM . The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. Circulation Journal2006;70(1):124-8. [DOI: 10.1253/circj.70.124]The J-ELAN Investigators. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. Circulation Journal2006;70:124-8. [DOI: 10.1253/circj.70.124]YamamotoK , OzakiH , TakayasuK , AkehiN , FukuiS , SakaiA , et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertension Research2011;34:325-30. [DOI: 10.1038/hr.2010.237] [UMIN CLINICAL TRIALS REGISTRY: C000000319]">Yamamoto 2011</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>). All 34 included studies were individually randomised, parallel RCTS. We identified no eligible cluster‐RCTs or cross‐over studies. </p> <p>Three of the included studies were multi‐armed (<a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>). Participants in <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a> and <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a> were randomly assigned to four groups; participants in <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a> were randomly assigned to three groups. </p> <p>Of these included studies, 14 were conducted in Europe (Italy, Finland, England, Ireland, Poland, the Netherlands, Czech Republic, Germany, Austria, Greece, Spain, Norway, Sweden, and France), 10 in Asia (four in China and six in Japan), seven in North America (five in the USA, one in Canada, and one in Mexico), and three were conducted in different continents at the same time (two in North America and Europe ‐ including Belgium ‐ and one in North America, Europe, and Oceania ‐ Australia). </p> <p>Only one study was performed in the last decade (<a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>). Twenty‐one studies were conducted in the 2000s, 10 were conducted in the 1990s (<a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0028" title="MagnaniB , Dal PaluC , ZanchettiA . Preliminary clinical experience with calcium antagonists in atherosclerosis. Drugs1992;44 Suppl 1:128-33. RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA , VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension 1997 Nov;15(11):1337-44. [DOI: 10.1097/00004872-199715110-00019]ZanchettiA , MagnaniB , Dal PaluC , on behalf of the VHAS Investigators. Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonography evaluations. Journal of Hypertension1997;15 Suppl 4:S91. ZanchettiA , MagnaniB , Dal PaluC , on behalf of the Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. Atherosclerosis and calcium antagonists: the VHAS. Journal of Human Hypertension1992;6 Suppl 2:S45-8. ZanchettiA , RoseiEA , Dal PaluC , LeonettiG , MagnaniB , PessinaA , et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16:1667-76. ZanchettiA . VHAS: Verapamil in Hypertension and Atherosclerosis Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. ">VHAS 1998</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>), and two were performed in the 1980s (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>) </p> <p>The length of follow‐up for these participants ranged from 30 days to six years, with more than half of the studies lasting between two and three years. The run‐in phase was only mentioned in 17 of the included studies, lasting between two and eight weeks, with placebo washouts generally being performed. </p> <p>Twenty‐one studies mentioned their sponsor. Of these, 15 were sponsored exclusively by pharmaceutical companies, five studies received government funds, and seven obtained sponsorship from both. Two studies were self‐sponsored. The funding resources were not mentioned in five studies. Only 13 studies mentioned conflicts of interest of the authors. </p> <p>Amongst the included studies, only 22 had the outcomes prespecified in our protocol (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>; <a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>; <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>; <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>; <a href="./references#CD013573-bbs2-0034" title="ZhuS , SuG , MengQH . Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clinical Chemistry2006;52(11):2036-42. [DOI: 10.1373/clinchem.2006.074724]">Zhu 2006</a>). In the remaining 12 studies, despite meeting the inclusion criteria proposed in our protocol, none assessed any of our prespecified outcomes of interest (<a href="./references#CD013573-bbs2-0003" title="Blanco-ColioLM , Martin-VenturaJL , SolJM , DiazC , HernandezG , EgidoJ . Decreased circulating fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology2004;43(7):1188-94. [DOI: 10.1016/j.jacc.2003.10.046]Gómez-GeriqueJA , RosE , OlivánJ , MostazaJM , VilardellM , PintóX , et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis2002;162(2):245–51. [DOI: 10.1016/s0021-9150(01)00708-0]">Blanco‐Colio 2004</a>; <a href="./references#CD013573-bbs2-0005" title="CortiR , FusterV , FayadZA , WorthleySG , HelftG , ChaplinWF , et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. Journal of the American College of Cardiology2005;46(1):106-12. [DOI: 10.1016/j.jacc.2005.03.054]">Corti 2005</a>; <a href="./references#CD013573-bbs2-0011" title="HuY , TongG , XuW , PanJ , RyanK , YangR , et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diabetes and Vascular Disease Research2009;6(4):262-8. [DOI: 10.1177/1479164109339966]">Hu 2009</a>; <a href="./references#CD013573-bbs2-0013" title="KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouA , GerasimidisT , LiapisCD . Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2010;51:114-21. [DOI: 10.1016/j.jvs.2009.07.119]KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouAT , FotiadisG , VittaI , et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2009;49(5 suppl 1):4S-5S. ">Kadoglou 2010</a>; <a href="./references#CD013573-bbs2-0028" title="MagnaniB , Dal PaluC , ZanchettiA . Preliminary clinical experience with calcium antagonists in atherosclerosis. Drugs1992;44 Suppl 1:128-33. RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA , VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension 1997 Nov;15(11):1337-44. [DOI: 10.1097/00004872-199715110-00019]ZanchettiA , MagnaniB , Dal PaluC , on behalf of the VHAS Investigators. Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonography evaluations. Journal of Hypertension1997;15 Suppl 4:S91. ZanchettiA , MagnaniB , Dal PaluC , on behalf of the Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. Atherosclerosis and calcium antagonists: the VHAS. Journal of Human Hypertension1992;6 Suppl 2:S45-8. ZanchettiA , RoseiEA , Dal PaluC , LeonettiG , MagnaniB , PessinaA , et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16:1667-76. ZanchettiA . VHAS: Verapamil in Hypertension and Atherosclerosis Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. ">VHAS 1998</a>; <a href="./references#CD013573-bbs2-0014" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49:838-47. [DOI: 10.1177/0091270009337011]">Meaney 2009</a>; <a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>; <a href="./references#CD013573-bbs2-0018" title="ReidJA , WolsleyC , LauLL , HannonRJ , LeeB , YoungIS , et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. European Journal of Vascular and Endovascular Surgery2005;30:464-8. [DOI: 10.1016/j.ejvs.2005.05.007]">Reid 2005</a>; <a href="./references#CD013573-bbs2-0021" title="SempliciniA , MarescaA , SimonellaC , ChierichettiF , PaulettoP , MeneghettiG , et al. Cerebral perfusion in hypertensives with carotid artery stenosis: a comparative study of lacidipine and hydrochlorothiazide. Blood Pressure2000;9:34-9. [DOI: 10.1080/080370500439407 · S]SempliciniA , SimonellaC , MeneghettiG , ChierichettiF , SantipoloN , PaulettoP , et al. Lacidipine and cerebral perfusion in uncomplicated essential hypertensives with mild to moderate carotid artery stenosis. Journal of Hypertension1998;16 Suppl 2:S243. ">Semplicini 2000</a>; <a href="./references#CD013573-bbs2-0022" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45(2):188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>; <a href="./references#CD013573-bbs2-0027" title="DuR , CaiJ , PingY , WangQ , LiuD , WuH . Effect of low dose rosuvastatin therapy on regression of carotid plaque and vasa vasorums in Chinese population: a prospective clinical trial by MRI. Journal of the American College of Cardiology2013;61(10 Suppl 1):E938. HatsukamiTS , ZhaoXQ , YuanC , TessierJJ , MillerE , PearsJS . Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis. Atherosclerosis. Supplements2001;2:47-8. [DOI: 10.1016/s1567-5688(01)80057-x]NCT00654394. Progression of carotid artery atheroma in moderately hypercholesterolemic subjects. clinicaltrials.gov/ct2/show/NCT00654394 (first received 3 April 2008). [CLINICAL TRIALS REGISTER: NCT00654394]UnderhillHR , YuanC , ZhaoXQ , KraissLW , ParkerDL , SaamT , et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. American Heart Journal2008;155(3):584.e1–584.e8. [DOI: 10.1016/j.ahj.2007.11.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00654394]">Underhill 2008</a>; <a href="./references#CD013573-bbs2-0030" title="C000000319. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. upload.umin.ac.jp (first received 01 February 2006). [UMIN-CTR CLINICAL TRIAL REGISTER:: C000000319]HoriM . The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. Circulation Journal2006;70(1):124-8. [DOI: 10.1253/circj.70.124]The J-ELAN Investigators. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. Circulation Journal2006;70:124-8. [DOI: 10.1253/circj.70.124]YamamotoK , OzakiH , TakayasuK , AkehiN , FukuiS , SakaiA , et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertension Research2011;34:325-30. [DOI: 10.1038/hr.2010.237] [UMIN CLINICAL TRIALS REGISTRY: C000000319]">Yamamoto 2011</a>). </p> <p>Full descriptions of the included studies are presented in the <a href="./references#CD013573-sec-0166" title="">Characteristics of included studies</a> table. </p> <section id="CD013573-sec-0049"> <h5 class="title">Population</h5> <p>The included studies involved a total of 11,571 outpatient participants with asymptomatic carotid stenosis. The 22 studies available for quantitative analysis had a total of 6887 participants. Two studies did not provide any demographic details of their participants (<a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>). The age of participants ranged from 18 to 100 years old (mean age of 61 years old), and the proportion of men was about 61% of included participants. We could not find smoking data in 11 of the 34 included studies. In the remaining 23 studies, nearly 23% of participants were smokers during the course of the trial. </p> </section> <section id="CD013573-sec-0050"> <h5 class="title">Sample size</h5> <p>The studies' sample size ranged from 14 to 2035. Twelve studies had fewer than 100 participants (<a href="./references#CD013573-bbs2-0003" title="Blanco-ColioLM , Martin-VenturaJL , SolJM , DiazC , HernandezG , EgidoJ . Decreased circulating fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology2004;43(7):1188-94. [DOI: 10.1016/j.jacc.2003.10.046]Gómez-GeriqueJA , RosE , OlivánJ , MostazaJM , VilardellM , PintóX , et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis2002;162(2):245–51. [DOI: 10.1016/s0021-9150(01)00708-0]">Blanco‐Colio 2004</a>; <a href="./references#CD013573-bbs2-0005" title="CortiR , FusterV , FayadZA , WorthleySG , HelftG , ChaplinWF , et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. Journal of the American College of Cardiology2005;46(1):106-12. [DOI: 10.1016/j.jacc.2005.03.054]">Corti 2005</a>; <a href="./references#CD013573-bbs2-0011" title="HuY , TongG , XuW , PanJ , RyanK , YangR , et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diabetes and Vascular Disease Research2009;6(4):262-8. [DOI: 10.1177/1479164109339966]">Hu 2009</a>; <a href="./references#CD013573-bbs2-0013" title="KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouA , GerasimidisT , LiapisCD . Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2010;51:114-21. [DOI: 10.1016/j.jvs.2009.07.119]KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouAT , FotiadisG , VittaI , et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2009;49(5 suppl 1):4S-5S. ">Kadoglou 2010</a>; <a href="./references#CD013573-bbs2-0014" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49:838-47. [DOI: 10.1177/0091270009337011]">Meaney 2009</a>; <a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>; <a href="./references#CD013573-bbs2-0018" title="ReidJA , WolsleyC , LauLL , HannonRJ , LeeB , YoungIS , et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. European Journal of Vascular and Endovascular Surgery2005;30:464-8. [DOI: 10.1016/j.ejvs.2005.05.007]">Reid 2005</a>; <a href="./references#CD013573-bbs2-0021" title="SempliciniA , MarescaA , SimonellaC , ChierichettiF , PaulettoP , MeneghettiG , et al. Cerebral perfusion in hypertensives with carotid artery stenosis: a comparative study of lacidipine and hydrochlorothiazide. Blood Pressure2000;9:34-9. [DOI: 10.1080/080370500439407 · S]SempliciniA , SimonellaC , MeneghettiG , ChierichettiF , SantipoloN , PaulettoP , et al. Lacidipine and cerebral perfusion in uncomplicated essential hypertensives with mild to moderate carotid artery stenosis. Journal of Hypertension1998;16 Suppl 2:S243. ">Semplicini 2000</a>; <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>; <a href="./references#CD013573-bbs2-0027" title="DuR , CaiJ , PingY , WangQ , LiuD , WuH . Effect of low dose rosuvastatin therapy on regression of carotid plaque and vasa vasorums in Chinese population: a prospective clinical trial by MRI. Journal of the American College of Cardiology2013;61(10 Suppl 1):E938. HatsukamiTS , ZhaoXQ , YuanC , TessierJJ , MillerE , PearsJS . Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis. Atherosclerosis. Supplements2001;2:47-8. [DOI: 10.1016/s1567-5688(01)80057-x]NCT00654394. Progression of carotid artery atheroma in moderately hypercholesterolemic subjects. clinicaltrials.gov/ct2/show/NCT00654394 (first received 3 April 2008). [CLINICAL TRIALS REGISTER: NCT00654394]UnderhillHR , YuanC , ZhaoXQ , KraissLW , ParkerDL , SaamT , et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. American Heart Journal2008;155(3):584.e1–584.e8. [DOI: 10.1016/j.ahj.2007.11.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00654394]">Underhill 2008</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0030" title="C000000319. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. upload.umin.ac.jp (first received 01 February 2006). [UMIN-CTR CLINICAL TRIAL REGISTER:: C000000319]HoriM . The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. Circulation Journal2006;70(1):124-8. [DOI: 10.1253/circj.70.124]The J-ELAN Investigators. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. Circulation Journal2006;70:124-8. [DOI: 10.1253/circj.70.124]YamamotoK , OzakiH , TakayasuK , AkehiN , FukuiS , SakaiA , et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertension Research2011;34:325-30. [DOI: 10.1038/hr.2010.237] [UMIN CLINICAL TRIALS REGISTRY: C000000319]">Yamamoto 2011</a>), and nine had at least 500 participants (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>; <a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>). </p> </section> <section id="CD013573-sec-0051"> <h5 class="title">Interventions and comparators</h5> <p>All but one type of intervention (glycaemic‐lowering agents) that we set out to investigate could be found in the included studies. Twenty‐two studies explored lipid‐lowering agents (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>; <a href="./references#CD013573-bbs2-0003" title="Blanco-ColioLM , Martin-VenturaJL , SolJM , DiazC , HernandezG , EgidoJ . Decreased circulating fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology2004;43(7):1188-94. [DOI: 10.1016/j.jacc.2003.10.046]Gómez-GeriqueJA , RosE , OlivánJ , MostazaJM , VilardellM , PintóX , et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis2002;162(2):245–51. [DOI: 10.1016/s0021-9150(01)00708-0]">Blanco‐Colio 2004</a>; <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>; <a href="./references#CD013573-bbs2-0005" title="CortiR , FusterV , FayadZA , WorthleySG , HelftG , ChaplinWF , et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. Journal of the American College of Cardiology2005;46(1):106-12. [DOI: 10.1016/j.jacc.2005.03.054]">Corti 2005</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0011" title="HuY , TongG , XuW , PanJ , RyanK , YangR , et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diabetes and Vascular Disease Research2009;6(4):262-8. [DOI: 10.1177/1479164109339966]">Hu 2009</a>; <a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>; <a href="./references#CD013573-bbs2-0013" title="KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouA , GerasimidisT , LiapisCD . Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2010;51:114-21. [DOI: 10.1016/j.jvs.2009.07.119]KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouAT , FotiadisG , VittaI , et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2009;49(5 suppl 1):4S-5S. ">Kadoglou 2010</a>; <a href="./references#CD013573-bbs2-0014" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49:838-47. [DOI: 10.1177/0091270009337011]">Meaney 2009</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0018" title="ReidJA , WolsleyC , LauLL , HannonRJ , LeeB , YoungIS , et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. European Journal of Vascular and Endovascular Surgery2005;30:464-8. [DOI: 10.1016/j.ejvs.2005.05.007]">Reid 2005</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>; <a href="./references#CD013573-bbs2-0027" title="DuR , CaiJ , PingY , WangQ , LiuD , WuH . Effect of low dose rosuvastatin therapy on regression of carotid plaque and vasa vasorums in Chinese population: a prospective clinical trial by MRI. Journal of the American College of Cardiology2013;61(10 Suppl 1):E938. HatsukamiTS , ZhaoXQ , YuanC , TessierJJ , MillerE , PearsJS . Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis. Atherosclerosis. Supplements2001;2:47-8. [DOI: 10.1016/s1567-5688(01)80057-x]NCT00654394. Progression of carotid artery atheroma in moderately hypercholesterolemic subjects. clinicaltrials.gov/ct2/show/NCT00654394 (first received 3 April 2008). [CLINICAL TRIALS REGISTER: NCT00654394]UnderhillHR , YuanC , ZhaoXQ , KraissLW , ParkerDL , SaamT , et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. American Heart Journal2008;155(3):584.e1–584.e8. [DOI: 10.1016/j.ahj.2007.11.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00654394]">Underhill 2008</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>; <a href="./references#CD013573-bbs2-0034" title="ZhuS , SuG , MengQH . Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clinical Chemistry2006;52(11):2036-42. [DOI: 10.1373/clinchem.2006.074724]">Zhu 2006</a>). Fourteen studies addressed other interventions, such as anticoagulants (<a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0022" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45(2):188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>), antiplatelet agents (<a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>), and antihypertensive drugs (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0028" title="MagnaniB , Dal PaluC , ZanchettiA . Preliminary clinical experience with calcium antagonists in atherosclerosis. Drugs1992;44 Suppl 1:128-33. RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA , VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension 1997 Nov;15(11):1337-44. [DOI: 10.1097/00004872-199715110-00019]ZanchettiA , MagnaniB , Dal PaluC , on behalf of the VHAS Investigators. Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonography evaluations. Journal of Hypertension1997;15 Suppl 4:S91. ZanchettiA , MagnaniB , Dal PaluC , on behalf of the Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. Atherosclerosis and calcium antagonists: the VHAS. Journal of Human Hypertension1992;6 Suppl 2:S45-8. ZanchettiA , RoseiEA , Dal PaluC , LeonettiG , MagnaniB , PessinaA , et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16:1667-76. ZanchettiA . VHAS: Verapamil in Hypertension and Atherosclerosis Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. ">VHAS 1998</a>; <a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>; <a href="./references#CD013573-bbs2-0021" title="SempliciniA , MarescaA , SimonellaC , ChierichettiF , PaulettoP , MeneghettiG , et al. Cerebral perfusion in hypertensives with carotid artery stenosis: a comparative study of lacidipine and hydrochlorothiazide. Blood Pressure2000;9:34-9. [DOI: 10.1080/080370500439407 · S]SempliciniA , SimonellaC , MeneghettiG , ChierichettiF , SantipoloN , PaulettoP , et al. Lacidipine and cerebral perfusion in uncomplicated essential hypertensives with mild to moderate carotid artery stenosis. Journal of Hypertension1998;16 Suppl 2:S243. ">Semplicini 2000</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>; <a href="./references#CD013573-bbs2-0030" title="C000000319. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. upload.umin.ac.jp (first received 01 February 2006). [UMIN-CTR CLINICAL TRIAL REGISTER:: C000000319]HoriM . The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. Circulation Journal2006;70(1):124-8. [DOI: 10.1253/circj.70.124]The J-ELAN Investigators. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. Circulation Journal2006;70:124-8. [DOI: 10.1253/circj.70.124]YamamotoK , OzakiH , TakayasuK , AkehiN , FukuiS , SakaiA , et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertension Research2011;34:325-30. [DOI: 10.1038/hr.2010.237] [UMIN CLINICAL TRIALS REGISTRY: C000000319]">Yamamoto 2011</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>). </p> <p>Fifteen included studies compared an intervention with placebo. Other studies used varied comparators, including: different doses of the same lipid‐lowering agent; one class of lipid‐lowering agent versus another class of lipid‐lowering agent; one class of antihypertensive agent versus another class of antihypertensive agent; anticoagulant agent versus antiplatelet agent, or no treatment. </p> <p>We performed quantitative analysis in 10 comparisons for which we could extract numerical data (<a href="./full#CD013573-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013573-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013573-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD013573-tbl-0004">summary of findings Table 4</a>; <a href="#CD013573-tbl-0007">Table 3</a>; <a href="#CD013573-tbl-0008">Table 4</a>; <a href="#CD013573-tbl-0009">Table 5</a>; <a href="#CD013573-tbl-0010">Table 6</a>; <a href="#CD013573-tbl-0011">Table 7</a>; <a href="#CD013573-tbl-0012">Table 8</a>). Additionally, we could conduct meta‐analysis for: three outcomes when comparing lipid‐lowering agents to placebo (<a href="./references#CD013573-fig-0018" title="">Analysis 5.1</a>; <a href="./references#CD013573-fig-0019" title="">Analysis 5.2</a>; <a href="./references#CD013573-fig-0020" title="">Analysis 5.3</a>); one outcome when comparing one class of lipid‐lowering agent to another class of lipid‐lowering agent (<a href="./references#CD013573-fig-0024" title="">Analysis 7.2</a>); and two outcomes when comparing one class of antihypertensive agent to another class of antihypertensive agent (<a href="./references#CD013573-fig-0027" title="">Analysis 9.1</a>; <a href="./references#CD013573-fig-0028" title="">Analysis 9.2</a>). </p> <div class="table" id="CD013573-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Additional SoF table: one antihypertensive agent plus lipid‐lowering agent compared to another antihypertensive agent plus lipid‐lowering agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>One antihypertensive agent plus lipid‐lowering agent compared to another antihypertensive agent plus lipid‐lowering agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> one antihypertensive agent plus lipid‐lowering agent </p> <p><b>Comparison:</b> another antihypertensive agent plus lipid‐lowering agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another antihypertensive agent plus lipid‐lowering agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with one antihypertensive agent plus lipid‐lowering agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke</p> <p>(not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34<br/>(0.01 to 8.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 fewer per 1000<br/>(8 fewer to 56 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>One study included in this comparison<br/><sup>b</sup>Hydrochlorthiazide + pravastatin versus fosinopril + pravastatin<br/><sup>c</sup>Downgraded two levels due to imprecision: few participants, few studies, and 95% CI consistent with possible benefit and possible harm </p> </div> </div> <div class="table" id="CD013573-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Additional SoF table: lipid‐lowering agent plus antihypertensive agent compared to antihypertensive agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Lipid‐lowering agent plus antihypertensive agent compared to antihypertensive agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> lipid‐lowering agent plus antihypertensive agent </p> <p><b>Comparison:</b> antihypertensive agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antihypertensive agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lipid‐lowering agent plus antihypertensive agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke (physical examination, CT scan)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64<br/>(0.27 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 fewer per 1000<br/>(80 fewer to 55 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 20.09<br/>(1.19 to 338.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(0 fewer to 0 fewer) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RR:</b> risk ratio; <b>SoF</b>: summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>One study in this comparison<br/><sup>b</sup>Fenofibrate + benazepril and/or amlodipine versus benazepril and/or amlodipine<br/><sup>c</sup>Downgraded one level due to high risk of bias for blinding of participants and personnel (open‐label study)<br/><sup>d</sup>Downgraded two levels due to imprecision: few participants, few studies, and 95% CI consistent with possible benefit and possible harm </p> </div> </div> <div class="table" id="CD013573-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Additional SoF table: one lipid‐lowering agent compared to another lipid‐lowering agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>One lipid‐lowering agent compared to another lipid‐lowering agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> one lipid‐lowering agent </p> <p><b>Comparison:</b> another lipid‐lowering agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> (measurement/time point) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another lipid‐lowering agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with one lipid‐lowering agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>332<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.96<br/>(0.12 to 72.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(0 fewer to 0 fewer) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (laboratory measurement/1, 2, 4, 6, 12, 18, and 24 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497<br/>(2 RCTs)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92<br/>(0.30 to 2.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 fewer per 1000<br/>(209 fewer to 555 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Two studies included in this comparison<br/><sup>b</sup>Rosuvastatin versus pravastatin<br/><sup>c</sup>Downgraded one level due to high risk of bias (blinding)<br/><sup>d</sup>Downgraded two levels due to imprecision: few events, few studies, and 95% CI consistent with possible benefit and possible harm<br/><sup>e</sup>Rosuvastatin versus pravastatin; probucol versus pravastatin </p> </div> </div> <div class="table" id="CD013573-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Additional SoF table: two lipid‐lowering agents compared to one lipid‐lowering agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Two lipid‐lowering agents compared to one lipid‐lowering agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> two lipid‐lowering agents </p> <p><b>Comparison:</b> one lipid‐lowering agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b>(measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with one lipid‐lowering agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with two lipid‐lowering agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>683<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.04<br/>(0.12 to 74.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(0 fewer to 0 fewer) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>683<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.25<br/>(0.61 to 2.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/>(15 fewer to 59 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>One study included in this comparison<br/><sup>b</sup>Torcetrapib plus atorvastatin versus atorvastatin alone<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, one study, and 95% CI consistent with possible benefit and possible harm </p> </div> </div> <div class="table" id="CD013573-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Additional SoF table: one antihypertensive agent compared to another antihypertensive agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>One antihypertensive agent compared to another antihypertensive agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> one antihypertensive agent </p> <p><b>Comparison:</b> another antihypertensive agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b>(measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another antihypertensive agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with one antihypertensive agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke (review meeting/semi‐annual<sup>b</sup>; review meeting/3 times<sup>c</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2918<br/>(2 RCTs)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/>(0.34 to 2.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(8 fewer to 22 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (only reported for two studies: one used review meeting/semi‐annual<sup>b</sup>; the other used review meeting/3 times<sup>c</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3239<br/>(4 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.82 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(24 fewer to 29 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Four studies included in this comparison<br/><sup>b</sup><a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a><br/><sup>c</sup><a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a><br/><sup>d</sup>Israpidin versus hydrochlorothiazide; lacidipine versus atenolol<br/><sup>e</sup>Downgraded two levels due to imprecision: few events, few studies, and 95% CI consistent with possible benefit and possible harm<br/><sup>f</sup>Israpidin versus hydrochlorothiazide; lacidipine versus atenolol; olmesartan versus atenolol; amlodipine versus lisinopril </p> </div> </div> <div class="table" id="CD013573-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Additional SoF table: higher dose of lipid‐lowering agent compared to lower dose of the same lipid‐lowering agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Higher dose of lipid‐lowering agent compared to lower dose of the same lipid‐lowering agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> higher dose of lipid‐lowering agent </p> <p><b>Comparison:</b> lower dose of the same lipid‐lowering agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b>(measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower dose of the same lipid‐lowering agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with higher dose of lipid‐lowering agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke</p> <p>(not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/>(0.01 to 7.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/>(50 fewer to 336 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (laboratory measurements/baseline and 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278<br/>(1 RCT)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.57<br/>(0.66 to 3.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 more per 1000<br/>(19 fewer to 153 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Two studies included in this comparison<br/><sup>b</sup>Pitavastatin<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, few studies, and 95% CI consistent with possible benefit and possible harm<br/><sup>d</sup>Atorvastatin<br/><sup>e</sup>Downgraded one level due to high risk of bias (blinding) </p> </div> </div> </section> <section id="CD013573-sec-0052"> <h5 class="title">Outcomes</h5> <p>Although we included 34 studies, as noted above, only 22 had the outcomes of interest prespecified in our protocol (<a href="./references#CD013573-bbs2-0130" title="ClezarCN , CassolaN , FlumignanCD , NakanoLC , TrevisaniVF , FlumignanRL . Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD013573. [DOI: 10.1002/14651858.CD013573]">Clezar 2020</a>). </p> <p>Of the primary outcomes, we found data on ipsilateral major or disabling stroke in 14 studies (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>; <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>; <a href="./references#CD013573-bbs2-0034" title="ZhuS , SuG , MengQH . Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clinical Chemistry2006;52(11):2036-42. [DOI: 10.1373/clinchem.2006.074724]">Zhu 2006</a>), but we could not extract information on neurological impairment from any of the included studies. </p> <p>Of the secondary outcomes, we found data for stroke‐related mortality in four studies (<a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>), major bleeding in two studies (<a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>), progression of carotid stenosis in two studies (<a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>), and adverse events in 16 studies (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>; <a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>; <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>; <a href="./references#CD013573-bbs2-0034" title="ZhuS , SuG , MengQH . Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clinical Chemistry2006;52(11):2036-42. [DOI: 10.1373/clinchem.2006.074724]">Zhu 2006</a>). We did not find information in the included studies about quality of life in people with asymptomatic carotid stenosis undergoing pharmacological treatment. </p> </section> </section> <section id="CD013573-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded 30 studies in total (<a href="./references#CD013573-bbs2-0035" title="AnandSS , BoschJ , EikelboomJW , ConnollySJ , DiazR , WidimskyP , et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet2018;391(10117):219-29. [DOI: 10.1016/ S0140-6736(17)32409-1]BhagirathVC , EikelboomJW , AnandSS . Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future Cardiology2018;14(6):443-53. [DOI: 10.2217/fca-2018-0059]BhattDL . Setting a new direction in CAD and PAD - the COMPASS trial. Cardiology2018;140 Suppl 1:200. BoschJ , EikelboomJW , ConnollySJ , BrunsNC , LaniusV , YuanF , et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Canadian Journal of Cardiology2017;33(8):1027-35. [DOI: 10.1016/j.cjca.2017.06.001]DarmonA , SorbetsE , DucrocqG , ElbezY , AbtanJ , PopovicB , et al. Identifying higher risk patients among the COMPASS-eligible population: an analysis from the REduction of Atherothrombosis for Continued Health (REACH) Registry. European Heart Journal2018;39 Suppl 1:1084. [DOI: 10.1016/j.acvdsp.2018.10.007]EikelboomJW , ConnollySJ , BoschJ , DagenaisGR , HartRG , ShestakovskaO , et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine2017;377(14):1319-30. [DOI: 10.1056/NEJMoa1709118]HussainMA , WheatcroftM , NaultP , LindsayTF , BhattDL , AnandSS , et al. COMPASS for vascular surgeons: practical considerations. Current Opinion in Cardiology2019;34(2):178-84. [DOI: DOI:10.1097/HCO.0000000000000597]LamyA , EikelboomJ , ConnollyS , BoschJ , FoxKA , TongW , et al. Costs impact rivaroxaban plus aspirin versus aspirin in the COMPASS trial. Circulation2017;136:e456-7. NCT01776424. Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery disease (COMPASS). clinicaltrials.gov/ct2/show/NCT01776424 (first received 24 January 2013). [CLINICAL TRIALS REGISTER: NCT01776424]SharmaM , HartRG , ConnollySJ , BoschJ , ShestakovskaO , NgKK , et al. Stroke outcomes in the COMPASS trial. Circulation2019;139(9):1134-45. [DOI: 10.1161/CIRCULATIONAHA.118.035864]">Anand 2018</a>; <a href="./references#CD013573-bbs2-0036" title="BondjersG , WiklundO , HultheJ , SchmidtC , OlofssonSO , WikstrandJ . The effect of metoprolol CR/XL on atherosclerosis. Atherosclerosis2000;151(1):92. [DOI: 10.1016/s0021-9150(00)80419-0]">Bondjers 2000</a>; <a href="./references#CD013573-bbs2-0037" title="DavidsonM , RosensonRS , MakiKC , NichollsSJ , BallantyneCM , SetzeC , et al. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovascular Drugs and Therapy2012;26:349-58. [CLINICALTRIALS.GOV: NCT00616772] [DOI: 10.1007/s10557-012-6395-z]">Davidson 2012</a>; <a href="./references#CD013573-bbs2-0038" title="DumanD , DemirtuncR , SahinS , EsertasK . The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study. Journal of Cardiovascular Medicine2007;8:1007-11. ">Duman 2007</a>; <a href="./references#CD013573-bbs2-0039" title="EspositoK , GiuglianoD , NappoF , MarfellaR , on behalf of the Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation2004;110:214-9. [DOI: 10.1161/01.CIR.0000134501.57864.66]">Esposito 2004</a>; <a href="./references#CD013573-bbs2-0040" title="CalcagnoC , RamachandranS , Izquierdo-GarciaD , ManiV , MillonA , RosenbaumD . The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. European Journal of Nuclear Medicine and Molecular Imaging2013;40(12):1884-93. [DOI: 10.1007/s00259-013-2518-4]DuivenvoordenR , ManiV , WoodwardM , KallendD , SuchankovaG , FusterV . Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. JACC: Cardiovascular Imaging2013;6(10):1087-94. [DOI: 10.1016/j.jcmg.2013.03.009]FayadZA , ManiV , WoodwardM , KallendD , BansilalS , PozzaJ , et al. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computer tomography. American Heart Journal2011;162:214-21. FayadZA , ManiV , WoodwardM , WoodwardM , KallendD , AbtM , BurgessT , et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet2011;378(9802):1547-59. [DOI: 10.1016/S0140-6736(11)61383-4]">Fayad 2011</a>; <a href="./references#CD013573-bbs2-0041" title="HosomiN , MizushigeK , OhyamaH , HatanakaY , MatsuoH , KoziolJA . ACE inhibition with enalapril slows progressive intima-media thickening of common carotid artery in NIDDM patients. Circulation2000;102(18 Suppl 2):II-869. HosomiN , MizushigeK , OhyamaH , TakahashiT , KitadaiM , HatanakaY , et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke2001;32:1539-45. [DOI: 10.1161/01.str.32.7.1539]">Hosomi 2001</a>; <a href="./references#CD013573-bbs2-0042" title="HuangZ , LeiMX , LiuL , TangQB . Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed Type 2 diabetic patients. Zhong Nan da Xue Xue Bao Yi Xue Ban (Journal of Central South University - Medical Sciences)2006;31(3):367-72. ">Huang 2006</a>; <a href="./references#CD013573-bbs2-0043" title="IchiharaA , KaneshiroY , SakodaM , TakemitsuT , ItohH . Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. Journal of Cardiovascular Pharmacology2007;49(3):161-6. [DOI: 10.1097/FJC.0b013e31803104e5]IchiharaA , KaneshiroY , TakemitsuT , SakodaM . Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. Journal of Human Hypertension2006;20:787-94. [DOI: https://doi.org/10.1038/sj.jhh.1002067]">Ichihara 2006</a>; <a href="./references#CD013573-bbs2-0044" title="IgaseM , KoharaK , TabaraY , NagaiT , OchiN , KidoT , et al. Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause2012;19(12):1294-9. [DOI: 10.1097/gme.0b013e318259c04e]">Igase 2012</a>; <a href="./references#CD013573-bbs2-0045" title="ItoY , KawasakiM , YokoyamaH , OkuboM , SanoK , AraiM , et al. Different effects of pravastatin and cerivastatin on the media of the carotid arteries as assessed by integrated backscatter ultrasound. Circulation Journal2004;68(8):784-90. [DOI: 10.1253/circj.68.784]">Ito 2004</a>; <a href="./references#CD013573-bbs2-0046" title="KoeijvoetsKC , RodenburgJ , HuttenBA , WiegmanA , KasteleinJJ , SijbrandsEJ . Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia. Substudy of an Intima-Media Thickness Trial. Circulation2005;112:3168-73. [DOI: 10.1161/CIRCULATIONAHA.105.565507]">Koeijvoets 2005</a>; <a href="./references#CD013573-bbs2-0047" title="LauroraG , CesaroneMR , BelcaroG , deSanctisMT , PomanteP , IncandelaL , et al. Control of arteriosclerosis progression in high risk subjects treated with mesoglycan. Evaluation of intima-media thickness. Minerva Cardioangiologica1998;46(3):41-8. ">Laurora 1998</a>; <a href="./references#CD013573-bbs2-0048" title="LudwigM , StapffM , RibeiroA , FritschkaE , ThollU , SmithRD , et al. Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. Clinical Therapeutics2002;24(7):1175-93. [DOI: 10.1016/s0149-2918(02)80028-5]">Ludwig 2002</a>; <a href="./references#CD013573-bbs2-0049" title="BetteridgeDJ . CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundamental &amp; Clinical Pharmacology2009;23(6):675-9. [DOI: 10.1111/j.1472-8206.2009.00741.x]DavidsonM , MeyerPM , HaffnerS , FeinsteinS , D'AgostinoR , KondosGT , et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with Type 2 Diabetes Mellitus. Circulation2008;117(16):2123-30. [DOI: 10.1161/CIRCULATIONAHA.107.746610]MazzoneT , MeyerPM , FeinsteinSB , DavidsonMH , KondosGT , D'AgostinoRB , et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA2006;296(21):2572-81. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00225264] [DOI: 10.1001/jama.296.21.joc60158]NCT00225264. Efficacy study of pioglitazone and glimepiride on the rate of progression of atherosclerotic disease (CHICAGO). www.clinicaltrials.gov/ct2/show/NCT00225264 (first received 23 September 2005). [CLINICALTRIALS.GOV: NCT00225264]">Mazzone 2006</a>; <a href="./references#CD013573-bbs2-0050" title="MeuweseMC , De GrootE , DuivenvoordenR , TripMD , OseL , MaritzFJ , et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA2009;301(11):1131-9. [DOI: 10.1001/jama.301.11.1131]NCT00151788. Efficacy and safety of the ACAT Inhibitor CS-505 (pactimibe) for reducing the progression of carotid artery disease. (CAPTIVATE study). www.clinicaltrials.gov/ct2/show/NCT00151788 (first received 7 September 2005). [CLINICALTRIALS.GOV IDENTIFIER: NCT00151788]">Meuwese 2009</a>; <a href="./references#CD013573-bbs2-0051" title="MizuguchiY , OishiY , MiyoshiH , IuchiA , NagaseN , OkiT . Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circulation Journal2008;72:538-44. [DOI: 10.1253/circj.72.538]">Mizuguchi 2008</a>; <a href="./references#CD013573-bbs2-0052" title="MokCC , LaiJ , WongCK , LamCS . Effect of rosuvastatin on homocysteine, hsCRP and endothelial markers in systemic lupus erythematosus (SLE): a randomized controlled trial. Lupus2010;19 Suppl 1:5. [DOI: 10.1177/09612033100190010101]">Mok 2010</a>; <a href="./references#CD013573-bbs2-0053" title="MortsellD , MalmqvistK , HeldC , KahanT . Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. Journal of Internal Medicine2007;261:472-9. [DOI: 10.1111/j.1365-2796.2007.01775.x]">Mortsell 2007</a>; <a href="./references#CD013573-bbs2-0054" title="OyamaT , SaikiA , EndohK , BanN , NagayamaD , OhhiraM , et al. Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. Journal of Atherosclerosis and Thrombosis2008;15(3):154-9. [DOI: 10.5551/jat.e549]">Oyama 2008</a>; <a href="./references#CD013573-bbs2-0055" title="PerssonJ , IsraelssonB , StavenowL , HolmstromE , BerglundG . Progression of atherosclerosis in middle-aged men: effects of multifactorial intervention. Journal of Internal Medicine1996;239(5):425-33. [DOI: 10.1046/j.1365-2796.1996.476814000.x]">Persson 1996</a>; <a href="./references#CD013573-bbs2-0056" title="PontremoliR , ViazziF , RaveraM , LeonciniG , BerrutiV , BezanteGP , et al. Long term effect of nifedipine GITS and lisinopril on subclinical organ damage in patients with essential hypertension. Journal of Nephrology2001;14(1):19-26. ">Pontremoli 2001</a>; <a href="./references#CD013573-bbs2-0057" title="SaremiA , SchwenkeDC , BuchananTA , HodisHN , MackWJ , BanerjiM , et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Atherosclerosis, Thrombosis and Vascular Biology2013;33:393-9. [DOI: 10.1161/ATVBAHA.112.300346]">Saremi 2013</a>; <a href="./references#CD013573-bbs2-0058" title="StantonAV , ChapmanJN , MayetJ , SeverPS , PoulterNR , HughesAD , et al. Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clinical Science2001;101(5):455-64. [DOI: https://doi.org/10.1042/cs1010455]StantonAV , ChapmanJN , SeverPS , PoulterNR , HughesAD , ThomSA . Greater regression of early atherosclerosis by calcium channel blockade than by angiotensin converting enzyme inhibition. Hypertension1998;32(4):795. ">Stanton 2001</a>; <a href="./references#CD013573-bbs2-0059" title="StumpeKO , LudwigM , HeagertyAM , KollochRE , ManciaG , SafarM , et al. Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT. American Journal of Cardiology1995;76:50E-4E. StumpeKO , LudwigM , HeagertyAM , KollochRE , ManciaG , SafarM . Effect of antihypertensive therapy on increased vascular wall thickness: objectives and design of the PROTECT Study. Journal of Hypertension1994;12 Suppl:149. ">Stumpe 1994</a>; <a href="./references#CD013573-bbs2-0060" title="TasićIS , MijalkovićD , DjordjevićD , LovićB , JankovićD , Miladinović-TasićN , et al. Effect of fosinopril on progression of the asymptomatic carotid atherosclerosis and left ventricular hypertrophy in hypertensive patients. Srpski Arhiv Za Celokupno Lekarstvo2006;134(3-4):106-13. [DOI: 10.2298/sarh0604106t]">Tasić 2006</a>; <a href="./references#CD013573-bbs2-0061" title="VukusichA , KunstmannS , VarelaC , GainzaD , BravoS , SepulvedaD , et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clinical Journal of the American Society of Nephrology2010;5(8):1380-7. [DOI: 10.2215/CJN.09421209]">Vukusich 2010</a>; <a href="./references#CD013573-bbs2-0062" title="YamasakiY , KatakamiN , FurukadoS , KitagawaK , NagatsukaK , KashiwagiA , et al. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Journal of Atherosclerosis and Thrombosis2010;17:1132-40. [DOI: 10.5551/jat.4663]">Yamasaki 2010</a>; <a href="./references#CD013573-bbs2-0063" title="YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32(8):903-12. [DOI: 10.3109/0886022X.2010.502276] [PMID: 20722555]YilmazR , AltunB , KahramanS , OzerN , AkinciD , TurganC . Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Failure2010;32:903-12. [DOI: 10.3109/0886022X.2010.502276]">Yilmaz 2004</a>; <a href="./references#CD013573-bbs2-0064" title="YokoyamaH , KawasakiM , ItoY , MinatoguchiS , FujiwaraH . Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity. Journal of the American College of Cardiology2005;46(11):2031-7. [DOI: 10.1016/j.jacc.2005.06.084]">Yokoyama 2005</a>). In every case, the general reason for exclusion was an ineligible study population. In 24 of the excluded studies, participants had an intima‐media thickness (IMT) test value of less than 1.3 mm, meaning they did not have carotid stenosis according to our definition. Three of the excluded studies included participants with an IMT test value of greater than 1.3 mm (<a href="./references#CD013573-bbs2-0045" title="ItoY , KawasakiM , YokoyamaH , OkuboM , SanoK , AraiM , et al. Different effects of pravastatin and cerivastatin on the media of the carotid arteries as assessed by integrated backscatter ultrasound. Circulation Journal2004;68(8):784-90. [DOI: 10.1253/circj.68.784]">Ito 2004</a>; <a href="./references#CD013573-bbs2-0054" title="OyamaT , SaikiA , EndohK , BanN , NagayamaD , OhhiraM , et al. Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. Journal of Atherosclerosis and Thrombosis2008;15(3):154-9. [DOI: 10.5551/jat.e549]">Oyama 2008</a>; <a href="./references#CD013573-bbs2-0061" title="VukusichA , KunstmannS , VarelaC , GainzaD , BravoS , SepulvedaD , et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clinical Journal of the American Society of Nephrology2010;5(8):1380-7. [DOI: 10.2215/CJN.09421209]">Vukusich 2010</a>). However, these studies did not subgroup participants by IMT test value, and we were unable to extract data specific to our population of interest. We excluded one study, <a href="./references#CD013573-bbs2-0035" title="AnandSS , BoschJ , EikelboomJW , ConnollySJ , DiazR , WidimskyP , et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet2018;391(10117):219-29. [DOI: 10.1016/ S0140-6736(17)32409-1]BhagirathVC , EikelboomJW , AnandSS . Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future Cardiology2018;14(6):443-53. [DOI: 10.2217/fca-2018-0059]BhattDL . Setting a new direction in CAD and PAD - the COMPASS trial. Cardiology2018;140 Suppl 1:200. BoschJ , EikelboomJW , ConnollySJ , BrunsNC , LaniusV , YuanF , et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Canadian Journal of Cardiology2017;33(8):1027-35. [DOI: 10.1016/j.cjca.2017.06.001]DarmonA , SorbetsE , DucrocqG , ElbezY , AbtanJ , PopovicB , et al. Identifying higher risk patients among the COMPASS-eligible population: an analysis from the REduction of Atherothrombosis for Continued Health (REACH) Registry. European Heart Journal2018;39 Suppl 1:1084. [DOI: 10.1016/j.acvdsp.2018.10.007]EikelboomJW , ConnollySJ , BoschJ , DagenaisGR , HartRG , ShestakovskaO , et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine2017;377(14):1319-30. [DOI: 10.1056/NEJMoa1709118]HussainMA , WheatcroftM , NaultP , LindsayTF , BhattDL , AnandSS , et al. COMPASS for vascular surgeons: practical considerations. Current Opinion in Cardiology2019;34(2):178-84. [DOI: DOI:10.1097/HCO.0000000000000597]LamyA , EikelboomJ , ConnollyS , BoschJ , FoxKA , TongW , et al. Costs impact rivaroxaban plus aspirin versus aspirin in the COMPASS trial. Circulation2017;136:e456-7. NCT01776424. Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery disease (COMPASS). clinicaltrials.gov/ct2/show/NCT01776424 (first received 24 January 2013). [CLINICAL TRIALS REGISTER: NCT01776424]SharmaM , HartRG , ConnollySJ , BoschJ , ShestakovskaO , NgKK , et al. Stroke outcomes in the COMPASS trial. Circulation2019;139(9):1134-45. [DOI: 10.1161/CIRCULATIONAHA.118.035864]">Anand 2018</a>, because less than 50% of the population was of interest and data on the subgroup of interest were unavailable. We excluded one study, <a href="./references#CD013573-bbs2-0040" title="CalcagnoC , RamachandranS , Izquierdo-GarciaD , ManiV , MillonA , RosenbaumD . The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. European Journal of Nuclear Medicine and Molecular Imaging2013;40(12):1884-93. [DOI: 10.1007/s00259-013-2518-4]DuivenvoordenR , ManiV , WoodwardM , KallendD , SuchankovaG , FusterV . Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. JACC: Cardiovascular Imaging2013;6(10):1087-94. [DOI: 10.1016/j.jcmg.2013.03.009]FayadZA , ManiV , WoodwardM , KallendD , BansilalS , PozzaJ , et al. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computer tomography. American Heart Journal2011;162:214-21. FayadZA , ManiV , WoodwardM , WoodwardM , KallendD , AbtM , BurgessT , et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet2011;378(9802):1547-59. [DOI: 10.1016/S0140-6736(11)61383-4]">Fayad 2011</a>, because it did not evaluate plaque but rather the decrease in blood flow by volume per time (mL/minute). We excluded the final study, <a href="./references#CD013573-bbs2-0059" title="StumpeKO , LudwigM , HeagertyAM , KollochRE , ManciaG , SafarM , et al. Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT. American Journal of Cardiology1995;76:50E-4E. StumpeKO , LudwigM , HeagertyAM , KollochRE , ManciaG , SafarM . Effect of antihypertensive therapy on increased vascular wall thickness: objectives and design of the PROTECT Study. Journal of Hypertension1994;12 Suppl:149. ">Stumpe 1994</a>, because its exclusion criteria effectively meant that it excluded people with carotid stenosis. </p> </section> </section> <section id="CD013573-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>We provide information on risk of bias in the included studies in the <a href="./references#CD013573-sec-0166" title="">Characteristics of included studies</a> table, and summarise this information in <a href="#CD013573-fig-0003">Figure 3</a> and <a href="#CD013573-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD013573-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013573-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013573-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013573-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013573-sec-0055"> <h4 class="title">Random sequence generation (selection bias)</h4> <p>The randomisation of participants was adequate in 20 studies, and we assessed these as having a low risk of bias (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>; <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0022" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45(2):188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>). However, the remaining 14 studies did not report the precise methodology of sequence generation, and we assessed these as having an unclear risk of bias in this domain. </p> </section> <section id="CD013573-sec-0056"> <h4 class="title">Allocation</h4> <p>We assessed 17 of the included RCTs as having a low risk of bias with adequate allocation and concealment (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>; <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>; <a href="./references#CD013573-bbs2-0014" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49:838-47. [DOI: 10.1177/0091270009337011]">Meaney 2009</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0022" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45(2):188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>). </p> <p>The remaining 17 studies provided insufficient details for determining adequacy of the allocation process or its concealment; thus, we assessed them as having an unclear risk of bias (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>; <a href="./references#CD013573-bbs2-0003" title="Blanco-ColioLM , Martin-VenturaJL , SolJM , DiazC , HernandezG , EgidoJ . Decreased circulating fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology2004;43(7):1188-94. [DOI: 10.1016/j.jacc.2003.10.046]Gómez-GeriqueJA , RosE , OlivánJ , MostazaJM , VilardellM , PintóX , et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis2002;162(2):245–51. [DOI: 10.1016/s0021-9150(01)00708-0]">Blanco‐Colio 2004</a>; <a href="./references#CD013573-bbs2-0005" title="CortiR , FusterV , FayadZA , WorthleySG , HelftG , ChaplinWF , et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. Journal of the American College of Cardiology2005;46(1):106-12. [DOI: 10.1016/j.jacc.2005.03.054]">Corti 2005</a>; <a href="./references#CD013573-bbs2-0011" title="HuY , TongG , XuW , PanJ , RyanK , YangR , et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diabetes and Vascular Disease Research2009;6(4):262-8. [DOI: 10.1177/1479164109339966]">Hu 2009</a>; <a href="./references#CD013573-bbs2-0013" title="KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouA , GerasimidisT , LiapisCD . Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2010;51:114-21. [DOI: 10.1016/j.jvs.2009.07.119]KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouAT , FotiadisG , VittaI , et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2009;49(5 suppl 1):4S-5S. ">Kadoglou 2010</a>; <a href="./references#CD013573-bbs2-0028" title="MagnaniB , Dal PaluC , ZanchettiA . Preliminary clinical experience with calcium antagonists in atherosclerosis. Drugs1992;44 Suppl 1:128-33. RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA , VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension 1997 Nov;15(11):1337-44. [DOI: 10.1097/00004872-199715110-00019]ZanchettiA , MagnaniB , Dal PaluC , on behalf of the VHAS Investigators. Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonography evaluations. Journal of Hypertension1997;15 Suppl 4:S91. ZanchettiA , MagnaniB , Dal PaluC , on behalf of the Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. Atherosclerosis and calcium antagonists: the VHAS. Journal of Human Hypertension1992;6 Suppl 2:S45-8. ZanchettiA , RoseiEA , Dal PaluC , LeonettiG , MagnaniB , PessinaA , et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16:1667-76. ZanchettiA . VHAS: Verapamil in Hypertension and Atherosclerosis Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. ">VHAS 1998</a>; <a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>; <a href="./references#CD013573-bbs2-0018" title="ReidJA , WolsleyC , LauLL , HannonRJ , LeeB , YoungIS , et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. European Journal of Vascular and Endovascular Surgery2005;30:464-8. [DOI: 10.1016/j.ejvs.2005.05.007]">Reid 2005</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0021" title="SempliciniA , MarescaA , SimonellaC , ChierichettiF , PaulettoP , MeneghettiG , et al. Cerebral perfusion in hypertensives with carotid artery stenosis: a comparative study of lacidipine and hydrochlorothiazide. Blood Pressure2000;9:34-9. [DOI: 10.1080/080370500439407 · S]SempliciniA , SimonellaC , MeneghettiG , ChierichettiF , SantipoloN , PaulettoP , et al. Lacidipine and cerebral perfusion in uncomplicated essential hypertensives with mild to moderate carotid artery stenosis. Journal of Hypertension1998;16 Suppl 2:S243. ">Semplicini 2000</a>; <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>; <a href="./references#CD013573-bbs2-0027" title="DuR , CaiJ , PingY , WangQ , LiuD , WuH . Effect of low dose rosuvastatin therapy on regression of carotid plaque and vasa vasorums in Chinese population: a prospective clinical trial by MRI. Journal of the American College of Cardiology2013;61(10 Suppl 1):E938. HatsukamiTS , ZhaoXQ , YuanC , TessierJJ , MillerE , PearsJS . Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis. Atherosclerosis. Supplements2001;2:47-8. [DOI: 10.1016/s1567-5688(01)80057-x]NCT00654394. Progression of carotid artery atheroma in moderately hypercholesterolemic subjects. clinicaltrials.gov/ct2/show/NCT00654394 (first received 3 April 2008). [CLINICAL TRIALS REGISTER: NCT00654394]UnderhillHR , YuanC , ZhaoXQ , KraissLW , ParkerDL , SaamT , et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. American Heart Journal2008;155(3):584.e1–584.e8. [DOI: 10.1016/j.ahj.2007.11.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00654394]">Underhill 2008</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0030" title="C000000319. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. upload.umin.ac.jp (first received 01 February 2006). [UMIN-CTR CLINICAL TRIAL REGISTER:: C000000319]HoriM . The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. Circulation Journal2006;70(1):124-8. [DOI: 10.1253/circj.70.124]The J-ELAN Investigators. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. Circulation Journal2006;70:124-8. [DOI: 10.1253/circj.70.124]YamamotoK , OzakiH , TakayasuK , AkehiN , FukuiS , SakaiA , et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertension Research2011;34:325-30. [DOI: 10.1038/hr.2010.237] [UMIN CLINICAL TRIALS REGISTRY: C000000319]">Yamamoto 2011</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>; <a href="./references#CD013573-bbs2-0034" title="ZhuS , SuG , MengQH . Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clinical Chemistry2006;52(11):2036-42. [DOI: 10.1373/clinchem.2006.074724]">Zhu 2006</a>). </p> </section> <section id="CD013573-sec-0057"> <h4 class="title">Blinding</h4> <section id="CD013573-sec-0058"> <h5 class="title">Participant blinding (performance bias)</h5> <p>In 20 studies, both the participants and personnel were double‐blinded, so we assessed these studies as having a low risk of bias (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0003" title="Blanco-ColioLM , Martin-VenturaJL , SolJM , DiazC , HernandezG , EgidoJ . Decreased circulating fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology2004;43(7):1188-94. [DOI: 10.1016/j.jacc.2003.10.046]Gómez-GeriqueJA , RosE , OlivánJ , MostazaJM , VilardellM , PintóX , et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis2002;162(2):245–51. [DOI: 10.1016/s0021-9150(01)00708-0]">Blanco‐Colio 2004</a>; <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>; <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>; <a href="./references#CD013573-bbs2-0018" title="ReidJA , WolsleyC , LauLL , HannonRJ , LeeB , YoungIS , et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. European Journal of Vascular and Endovascular Surgery2005;30:464-8. [DOI: 10.1016/j.ejvs.2005.05.007]">Reid 2005</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0021" title="SempliciniA , MarescaA , SimonellaC , ChierichettiF , PaulettoP , MeneghettiG , et al. Cerebral perfusion in hypertensives with carotid artery stenosis: a comparative study of lacidipine and hydrochlorothiazide. Blood Pressure2000;9:34-9. [DOI: 10.1080/080370500439407 · S]SempliciniA , SimonellaC , MeneghettiG , ChierichettiF , SantipoloN , PaulettoP , et al. Lacidipine and cerebral perfusion in uncomplicated essential hypertensives with mild to moderate carotid artery stenosis. Journal of Hypertension1998;16 Suppl 2:S243. ">Semplicini 2000</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>; <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>;<a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>; <a href="./references#CD013573-bbs2-0027" title="DuR , CaiJ , PingY , WangQ , LiuD , WuH . Effect of low dose rosuvastatin therapy on regression of carotid plaque and vasa vasorums in Chinese population: a prospective clinical trial by MRI. Journal of the American College of Cardiology2013;61(10 Suppl 1):E938. HatsukamiTS , ZhaoXQ , YuanC , TessierJJ , MillerE , PearsJS . Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis. Atherosclerosis. Supplements2001;2:47-8. [DOI: 10.1016/s1567-5688(01)80057-x]NCT00654394. Progression of carotid artery atheroma in moderately hypercholesterolemic subjects. clinicaltrials.gov/ct2/show/NCT00654394 (first received 3 April 2008). [CLINICAL TRIALS REGISTER: NCT00654394]UnderhillHR , YuanC , ZhaoXQ , KraissLW , ParkerDL , SaamT , et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. American Heart Journal2008;155(3):584.e1–584.e8. [DOI: 10.1016/j.ahj.2007.11.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00654394]">Underhill 2008</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>; <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>). Only one study was single‐blinded (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>), and we assessed it as having a high risk of bias. A further eight studies were open‐label and, consequently, we also judged these to have a high risk of bias in this domain (<a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>; <a href="./references#CD013573-bbs2-0013" title="KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouA , GerasimidisT , LiapisCD . Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2010;51:114-21. [DOI: 10.1016/j.jvs.2009.07.119]KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouAT , FotiadisG , VittaI , et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2009;49(5 suppl 1):4S-5S. ">Kadoglou 2010</a>; <a href="./references#CD013573-bbs2-0028" title="MagnaniB , Dal PaluC , ZanchettiA . Preliminary clinical experience with calcium antagonists in atherosclerosis. Drugs1992;44 Suppl 1:128-33. RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA , VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension 1997 Nov;15(11):1337-44. [DOI: 10.1097/00004872-199715110-00019]ZanchettiA , MagnaniB , Dal PaluC , on behalf of the VHAS Investigators. Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonography evaluations. Journal of Hypertension1997;15 Suppl 4:S91. ZanchettiA , MagnaniB , Dal PaluC , on behalf of the Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. Atherosclerosis and calcium antagonists: the VHAS. Journal of Human Hypertension1992;6 Suppl 2:S45-8. ZanchettiA , RoseiEA , Dal PaluC , LeonettiG , MagnaniB , PessinaA , et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16:1667-76. ZanchettiA . VHAS: Verapamil in Hypertension and Atherosclerosis Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. ">VHAS 1998</a>; <a href="./references#CD013573-bbs2-0014" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49:838-47. [DOI: 10.1177/0091270009337011]">Meaney 2009</a>; <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0030" title="C000000319. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. upload.umin.ac.jp (first received 01 February 2006). [UMIN-CTR CLINICAL TRIAL REGISTER:: C000000319]HoriM . The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. Circulation Journal2006;70(1):124-8. [DOI: 10.1253/circj.70.124]The J-ELAN Investigators. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. Circulation Journal2006;70:124-8. [DOI: 10.1253/circj.70.124]YamamotoK , OzakiH , TakayasuK , AkehiN , FukuiS , SakaiA , et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertension Research2011;34:325-30. [DOI: 10.1038/hr.2010.237] [UMIN CLINICAL TRIALS REGISTRY: C000000319]">Yamamoto 2011</a>; <a href="./references#CD013573-bbs2-0034" title="ZhuS , SuG , MengQH . Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clinical Chemistry2006;52(11):2036-42. [DOI: 10.1373/clinchem.2006.074724]">Zhu 2006</a>). </p> <p>We assessed five studies as having an unclear risk of performance bias because these studies did not report on blinding of participants and personnel (<a href="./references#CD013573-bbs2-0005" title="CortiR , FusterV , FayadZA , WorthleySG , HelftG , ChaplinWF , et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. Journal of the American College of Cardiology2005;46(1):106-12. [DOI: 10.1016/j.jacc.2005.03.054]">Corti 2005</a>; <a href="./references#CD013573-bbs2-0011" title="HuY , TongG , XuW , PanJ , RyanK , YangR , et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diabetes and Vascular Disease Research2009;6(4):262-8. [DOI: 10.1177/1479164109339966]">Hu 2009</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0022" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45(2):188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>). </p> </section> <section id="CD013573-sec-0059"> <h5 class="title">Investigator blinding (detection bias)</h5> <p>Thirty‐one of the 34 studies described blinded outcome assessment; we judged these studies to be at low risk of bias. Two studies did not report a blinded assessor (<a href="./references#CD013573-bbs2-0003" title="Blanco-ColioLM , Martin-VenturaJL , SolJM , DiazC , HernandezG , EgidoJ . Decreased circulating fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology2004;43(7):1188-94. [DOI: 10.1016/j.jacc.2003.10.046]Gómez-GeriqueJA , RosE , OlivánJ , MostazaJM , VilardellM , PintóX , et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis2002;162(2):245–51. [DOI: 10.1016/s0021-9150(01)00708-0]">Blanco‐Colio 2004</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>); we judged these to be at an unclear risk of bias. After six months of double‐blinding, participants in the <a href="./references#CD013573-bbs2-0028" title="MagnaniB , Dal PaluC , ZanchettiA . Preliminary clinical experience with calcium antagonists in atherosclerosis. Drugs1992;44 Suppl 1:128-33. RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA , VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension 1997 Nov;15(11):1337-44. [DOI: 10.1097/00004872-199715110-00019]ZanchettiA , MagnaniB , Dal PaluC , on behalf of the VHAS Investigators. Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonography evaluations. Journal of Hypertension1997;15 Suppl 4:S91. ZanchettiA , MagnaniB , Dal PaluC , on behalf of the Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. Atherosclerosis and calcium antagonists: the VHAS. Journal of Human Hypertension1992;6 Suppl 2:S45-8. ZanchettiA , RoseiEA , Dal PaluC , LeonettiG , MagnaniB , PessinaA , et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16:1667-76. ZanchettiA . VHAS: Verapamil in Hypertension and Atherosclerosis Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. ">VHAS 1998</a> study continued with treatment under an open‐label trial design; we thus assessed it as having a high risk of bias. </p> </section> </section> <section id="CD013573-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>For 27 of the included RCTs, there were no serious issues relating to attrition at the end of the intervention, and we assessed these as having a low risk of bias arising from incomplete outcome data. We assessed the remaining seven studies to be at an unclear risk of bias due to incomplete outcome data as they did not report follow‐up participant data (<a href="./references#CD013573-bbs2-0011" title="HuY , TongG , XuW , PanJ , RyanK , YangR , et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diabetes and Vascular Disease Research2009;6(4):262-8. [DOI: 10.1177/1479164109339966]">Hu 2009</a>; <a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>; <a href="./references#CD013573-bbs2-0018" title="ReidJA , WolsleyC , LauLL , HannonRJ , LeeB , YoungIS , et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. European Journal of Vascular and Endovascular Surgery2005;30:464-8. [DOI: 10.1016/j.ejvs.2005.05.007]">Reid 2005</a>; <a href="./references#CD013573-bbs2-0021" title="SempliciniA , MarescaA , SimonellaC , ChierichettiF , PaulettoP , MeneghettiG , et al. Cerebral perfusion in hypertensives with carotid artery stenosis: a comparative study of lacidipine and hydrochlorothiazide. Blood Pressure2000;9:34-9. [DOI: 10.1080/080370500439407 · S]SempliciniA , SimonellaC , MeneghettiG , ChierichettiF , SantipoloN , PaulettoP , et al. Lacidipine and cerebral perfusion in uncomplicated essential hypertensives with mild to moderate carotid artery stenosis. Journal of Hypertension1998;16 Suppl 2:S243. ">Semplicini 2000</a>; <a href="./references#CD013573-bbs2-0022" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45(2):188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>; <a href="./references#CD013573-bbs2-0034" title="ZhuS , SuG , MengQH . Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clinical Chemistry2006;52(11):2036-42. [DOI: 10.1373/clinchem.2006.074724]">Zhu 2006</a>). </p> </section> <section id="CD013573-sec-0061"> <h4 class="title">Selective reporting</h4> <p>For 30 of the 34 studies, there were no serious issues relating to reporting biases, and we judged these to be at low risk of bias. Three other studies did not report details about outcomes, and we assessed these as having an unclear risk of bias (<a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>; <a href="./references#CD013573-bbs2-0022" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45(2):188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>). We assessed the one remaining study, <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>, to be at a high risk of bias. A weakness of this study (also known as the SHEP trial) was that the duplex scans were not obtained earlier in the study, before treatment. Unfortunately, the SHEP trial ended before all participants had completed their follow‐up scans. </p> </section> <section id="CD013573-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>We judged 33 studies to be at low risk of other potential sources of bias. However, we assessed the <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a> study as having an unclear risk of bias, as the study method was not reported. </p> </section> </section> <section id="CD013573-sec-0063"> <h3 class="title" id="CD013573-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD013573-tbl-0001"><b>Summary of findings 1</b> Antiplatelet agent versus placebo for asymptomatic carotid stenosis</a>; <a href="./full#CD013573-tbl-0002"><b>Summary of findings 2</b> Antihypertensive agent versus placebo for asymptomatic carotid stenosis</a>; <a href="./full#CD013573-tbl-0003"><b>Summary of findings 3</b> Anticoagulant agent versus placebo for asymptomatic carotid stenosis</a>; <a href="./full#CD013573-tbl-0004"><b>Summary of findings 4</b> Lipid‐lowering agent compared to placebo or no treatment for asymptomatic carotid stenosis</a> </p> <p>From the 34 studies identified for this review, we included 22 in the quantitative analysis. In addition, we performed a sensitivity analysis comparing a fixed‐effect versus random‐effects model for the outcome of 'ipsilateral major or disabling stroke' for the following comparisons only: 'lipid‐lowering agent versus placebo or no treatment' and 'one antihypertensive agent compared to another antihypertensive agent'. </p> <section id="CD013573-sec-0064"> <h4 class="title">1. Antiplatelet agent versus placebo</h4> <p>We identified one study for this comparison: <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>, a Canadian trial from the early 1990s, compared the antiplatelet, acetylsalicylic acid (enteric‐coated aspirin), 325 mg per day, to placebo in 372 participants. It reported outcomes at six‐month intervals throughout the six‐year period. We assessed the overall risk of bias for <a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a> as low. This study did not measure two of our prespecified outcomes: the primary outcome of neurological impairment, and the secondary outcome of quality of life. See <a href="./full#CD013573-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013573-sec-0065"> <h5 class="title">Primary outcomes</h5> <section id="CD013573-sec-0066"> <h6 class="title">Ipsilateral major or disabling stroke</h6> <p>Acetylsalicylic acid may result in no difference in ipsilateral major or disabling stroke when compared to placebo (risk ratio (RR) 1.08, 95% confidence interval (CI) 0.47 to 2.47; P = 0.86; 372 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0007" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD013573-sec-0067"> <h5 class="title">Secondary outcomes</h5> <section id="CD013573-sec-0068"> <h6 class="title">Stroke‐related mortality</h6> <p>Acetylsalicylic acid may result in no difference in stroke‐related mortality when compared to placebo (RR 1.40, 95% CI 0.54 to 3.59; P = 0.49; 372 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0008" title="">Analysis 1.2</a>). </p> </section> <section id="CD013573-sec-0069"> <h6 class="title">Major bleeding</h6> <p>The effect of acetylsalicylic acid on major bleeding when compared to placebo is very uncertain (RR 0.98, 95% CI 0.06 to 15.53; P = 0.99; 372 participants; very low‐certainty evidence; <a href="./references#CD013573-fig-0009" title="">Analysis 1.3</a>). </p> </section> <section id="CD013573-sec-0070"> <h6 class="title">Progression of carotid stenosis</h6> <p>Acetylsalicylic acid may result in no difference in progression of carotid stenosis when compared to placebo (RR 1.16, 95% CI 0.79 to 1.71; P = 0.44; 372 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0010" title="">Analysis 1.4</a>). </p> </section> <section id="CD013573-sec-0071"> <h6 class="title">Adverse events</h6> <p>Acetylsalicylic acid may result in no difference in adverse events when compared to placebo (RR 0.81, 95% CI 0.41 to 1.59, P = 0.53; 372 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0011" title="">Analysis 1.5</a>). </p> </section> </section> </section> <section id="CD013573-sec-0072"> <h4 class="title">2. Antihypertensive agent versus placebo</h4> <p>We included two studies in this comparison (<a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>), both conducted in the 1990s. <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a> (129 participants) compared chlorthalidone 12.5 mg daily to placebo, and obtained two serial duplex scans of the carotid arteries separated by two years. We assessed the overall risk of bias for <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a> as low. The <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a> study randomised participants to placebo or 25 mg of metoprolol CR/XL (metoprolol succinate extended‐release tablets) once daily and measured changes in mean intima‐media thickness (IMT) in the common carotid artery. Also, <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a> monitored adverse events, laboratory findings, mortality, and incidence of myocardial infarction and stroke for three years. We assessed the overall risk of bias for <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a> as low. Neither included study measured four of our prespecified outcomes: the primary outcome of neurological impairment, and the secondary outcomes of major bleeding, adverse events, and quality of life. We were unable to perform a meta‐analysis or sensitivity analysis on this comparison because the studies reported different outcomes. See <a href="./full#CD013573-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013573-sec-0073"> <h5 class="title">Primary outcomes</h5> <section id="CD013573-sec-0074"> <h6 class="title">Ipsilateral major or disabling stroke</h6> <p>One study, <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>, found that metoprolol may result in no difference in ipsilateral major or disabling stroke when compared to placebo (RR 0.14, 95% CI 0.02 to 1.16; P = 0.07; 793 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0012" title="">Analysis 2.1</a>). </p> </section> </section> <section id="CD013573-sec-0075"> <h5 class="title">Secondary outcomes</h5> <section id="CD013573-sec-0076"> <h6 class="title">Stroke‐related mortality</h6> <p>One study, <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>, found that metoprolol may result in no difference in stroke‐related mortality when compared to placebo (RR 0.57, 95% CI 0.17 to 1.94; P = 0.37; 793 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0013" title="">Analysis 2.2</a>). </p> </section> <section id="CD013573-sec-0077"> <h6 class="title">Progression of carotid stenosis</h6> <p>One study, <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>, found that chlorthalidone may prevent progression of carotid stenosis when compared to placebo (RR 0.45, 95% CI 0.23 to 0.91; P = 0.02; 129 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0014" title="">Analysis 2.3</a>). </p> </section> </section> </section> <section id="CD013573-sec-0078"> <h4 class="title">3. One antihypertensive agent plus lipid‐lowering agent versus another antihypertensive agent plus lipid‐lowering agent </h4> <p>We found one study for this comparison: <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>, with 254 participants in Italy, compared hydrochlorothiazide 25 mg per day versus fosinopril 20 mg per day, plus pravastatin 40 mg per day, concomitantly with open‐label nifedipine GITS (gastrointestinal therapeutic system), 30 to 60 mg daily. A complete carotid ultrasound examination was performed every six months for three years to assess changes in mean maximum IMT. The study evaluated changes in the clinic and ambulatory blood pressure and changes in serum total, low‐density lipoprotein (LDL) and high‐density lipoprotein (HDL) cholesterol, and other laboratory variables. We assessed the overall risk of bias for <a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a> as low. This study did not measure six of our prespecified outcomes (namely, the primary outcome of neurological impairment, and the five secondary outcomes). See <a href="#CD013573-tbl-0007">Table 3</a>. </p> <section id="CD013573-sec-0079"> <h5 class="title">Primary outcomes</h5> <section id="CD013573-sec-0080"> <h6 class="title">Ipsilateral major or disabling stroke</h6> <p>One antihypertensive agent plus lipid‐lowering agent (hydrochlorothiazide plus pravastatin) may result in little to no difference in ipsilateral major or disabling stroke when compared to another antihypertensive agent plus lipid‐lowering agent (fosinopril plus pravastatin) (RR 0.34, 95% CI 0.01 to 8.23; P = 0.51; 254 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0015" title="">Analysis 3.1</a>). </p> </section> </section> </section> <section id="CD013573-sec-0081"> <h4 class="title">4. Anticoagulant agent versus placebo</h4> <p>We included one study for this comparison. <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a> compared warfarin, administered at a fixed 1 mg daily, to placebo in 919 participants from the USA in the 1990s with a mean follow‐up of three years. Regular clinic visits were scheduled every six weeks for the first 15 months and quarterly thereafter to permit safety monitoring. The study reported all outcomes at six‐month intervals throughout the six‐year period. Trialists conducted B‐mode ultrasonography semi‐annually and alanine aminotransferase (ALT) and urine tests at every visit. Drug adherence was assessed by pill count and participant report of usage. The annual visits involved a brief physical examination and dietary assessment. We assessed the overall risk of bias for <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a> as low. This study did not measure five of our prespecified outcomes: neither of the primary outcomes, and the secondary outcomes of stroke‐related mortality, progression of carotid stenosis, and quality of life. See <a href="./full#CD013573-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD013573-sec-0082"> <h5 class="title">Secondary outcomes</h5> <section id="CD013573-sec-0083"> <h6 class="title">Major bleeding</h6> <p>The effect of warfarin on major bleeding when compared to placebo is uncertain (RR 1.19, 95% CI 0.97 to 1.46; P = 0.10; 919 participants; very low‐certainty evidence; <a href="./references#CD013573-fig-0016" title="">Analysis 4.1</a>). </p> </section> <section id="CD013573-sec-0084"> <h6 class="title">Adverse events</h6> <p>Warfarin may reduce adverse events when compared to placebo (RR 0.89, 95% CI 0.81 to 0.99; P = 0.04; 919 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0017" title="">Analysis 4.2</a>). </p> </section> </section> </section> <section id="CD013573-sec-0085"> <h4 class="title">5. Lipid‐lowering agent versus placebo or no treatment</h4> <p>We identified nine studies for this comparison (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>). Six different lipid‐lowering agents were investigated by these studies: fluvastatin, rosuvastatin, lovastatin, atorvastatin, probucol, and pravastatin. They provided data for short‐ and long‐term outcomes (ranging from six months to six years after the beginning of the intervention) for 3916 participants from Japan, China, USA, and Europe (Norway, Italy, and Finland) in the 1990s, 2000s, and 2010s. The studies ranged in duration from two to six years. They assessed a wide range of physiological, biochemical, and clinical outcomes. We assessed seven studies as having a low overall risk of bias, one as having an unclear risk of bias (<a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>), and the remaining study as having an overall high risk of bias (<a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>). None of these included studies measured our prespecified primary outcome of neurological impairment, and three of our secondary outcomes (major bleeding, progression of carotid stenosis, and quality of life). See the <a href="./references#CD013573-sec-0166" title="">Characteristics of included studies</a> table for details of individual studies and <a href="./full#CD013573-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD013573-sec-0086"> <h5 class="title">Primary outcomes</h5> <section id="CD013573-sec-0087"> <h6 class="title">Ipsilateral major or disabling stroke</h6> <p>Five studies assessed this outcome (<a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>). Lipid‐lowering agents (lovastatin, pravastatin, atorvastatin, rosuvastatin) may result in no difference in ipsilateral major or disabling stroke when compared to placebo or no treatment (RR 0.36, 95% CI 0.09 to 1.53; P = 0.13, I<sup>2</sup> = 44%; 5 studies, 2235 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0018" title="">Analysis 5.1</a>). A sensitivity analysis using a fixed‐effect model changed the effect estimate substantially (RR 0.39, 95% CI 0.18 to 0.87; <a href="#CD013573-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD013573-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Sensitivity analysis (Ipsilateral major or disabling stroke): fixed effect." data-id="CD013573-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-05.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sensitivity analysis (Ipsilateral major or disabling stroke): fixed effect.</p> </div> </div> </div> </section> </section> <section id="CD013573-sec-0088"> <h5 class="title">Secondary outcomes</h5> <section id="CD013573-sec-0089"> <h6 class="title">Stroke‐related mortality</h6> <p>Two studies assessed this outcome (<a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>). Lipid‐lowering agents (lovastatin and pravastatin) may result in no difference in stroke‐related mortality when compared to placebo or no treatment (RR 0.25, 95% CI 0.03 to 2.29; P = 0.82; 2 studies, 1366 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0019" title="">Analysis 5.2</a>). </p> </section> <section id="CD013573-sec-0090"> <h6 class="title">Adverse events</h6> <p>Seven studies assess this outcome (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>). Lipid‐lowering agents (probucol, pravastatin, lovastatin, fluvastatin, rosuvastatin) may result in no difference in adverse events when compared to placebo or no treatment (RR 0.76, 95% CI 0.53 to 1.10; P = 0.04, I<sup>2</sup> = 54%; 7 studies, 3726 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0020" title="">Analysis 5.3</a>). </p> </section> </section> </section> <section id="CD013573-sec-0091"> <h4 class="title">6. Lipid‐lowering agent plus antihypertensive agent versus antihypertensive agent</h4> <p>We included one study in this comparison. <a href="./references#CD013573-bbs2-0034" title="ZhuS , SuG , MengQH . Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clinical Chemistry2006;52(11):2036-42. [DOI: 10.1373/clinchem.2006.074724]">Zhu 2006</a> compared 160 mg of micronised fenofibrate daily plus antihypertensive drug therapy (benazepril 10 to 20 mg/day and/or amlodipine 5 to 10 mg/day) to only antihypertensive drug therapy (benazepril 10 to 20 mg/day and/or amlodipine 5 to 10 mg/day). The study reported all outcomes at the end of the observation period (two years). This study did not measure five of our prespecified outcomes: the primary outcome of neurological impairment, and the secondary outcomes of stroke‐related mortality, major bleeding, progression of carotid stenosis, and quality of life. We assessed the overall risk of bias as high. See <a href="#CD013573-tbl-0008">Table 4</a>. </p> <section id="CD013573-sec-0092"> <h5 class="title">Primary outcomes</h5> <section id="CD013573-sec-0093"> <h6 class="title">Ipsilateral major or disabling stroke</h6> <p>It is uncertain whether fenofibrate plus benazepril and/or amlodipine prevent ipsilateral major or disabling stroke when compared to benazepril and/or amlodipine alone (RR 0.64, 95% CI 0.27 to 1.50; P = 0.30; 225 participants; very low‐certainty evidence; <a href="./references#CD013573-fig-0021" title="">Analysis 6.1</a>). </p> </section> </section> <section id="CD013573-sec-0094"> <h5 class="title">Secondary outcomes</h5> <section id="CD013573-sec-0095"> <h6 class="title">Adverse events</h6> <p>It is uncertain whether fenofibrate plus benazepril and/or amlodipine increase adverse events when compared to benazepril and/or amlodipine alone (RR 20.09, 95% CI 1.19 to 338.84; P = 0.04; 225 participants; very low‐certainty evidence; <a href="./references#CD013573-fig-0022" title="">Analysis 6.2</a>). </p> </section> </section> </section> <section id="CD013573-sec-0096"> <h4 class="title">7. One lipid‐lowering agent versus another lipid‐lowering agent</h4> <p>We included two studies in this comparison (<a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>). <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a> compared 5 mg rosuvastatin once daily to 10 mg pravastatin once daily. It was an open‐label study, with blinded end‐point evaluation, and we assessed it at high risk of bias. <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a> compared probucol 500 mg twice daily to pravastatin 10 mg/day, and we assessed the overall risk of bias as low. They provided data for long‐term outcomes in 650 participants from Japan and Mexico for one to two years, during the 1990s and 2000s. Both studies assessed a wide range of biochemical and clinical outcomes. Neither of the included studies for this comparison measured our primary outcome (i.e. neurological impairment) or four of our secondary outcomes (stroke‐related mortality, major bleeding, progression of carotid stenosis, or quality of life). We were unable to perform a meta‐analysis or sensitivity analysis on the primary outcome ipsilateral major or disabling stroke because only one of the two studies measured this outcome. See <a href="#CD013573-tbl-0009">Table 5</a>. </p> <section id="CD013573-sec-0097"> <h5 class="title">Primary outcomes</h5> <section id="CD013573-sec-0098"> <h6 class="title">Ipsilateral major or disabling stroke</h6> <p>One study, <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>, measured this outcome. It is uncertain whether rosuvastatin results in any difference in ipsilateral major or disabling stroke when compared to pravastatin (RR 2.96, 95% CI 0.12 to 72.24, P = 0.50; 332 participants; very low‐certainty evidence; <a href="./references#CD013573-fig-0023" title="">Analysis 7.1</a>). </p> </section> </section> <section id="CD013573-sec-0099"> <h5 class="title">Secondary outcomes</h5> <section id="CD013573-sec-0100"> <h6 class="title">Adverse events</h6> <p>It is uncertain whether rosuvastatin or probucol results in any difference in adverse events when compared to pravastatin (RR 0.92, 95% CI 0.30 to 2.86; P = 0.03, I<sup>2</sup> = 80%; 2 studies, 497 participants; very low‐certainty evidence; <a href="./references#CD013573-fig-0024" title="">Analysis 7.2</a>). </p> </section> </section> </section> <section id="CD013573-sec-0101"> <h4 class="title">8. Two lipid‐lowering agents compared to one lipid‐lowering agent</h4> <p>We found one study for this comparison. <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a> compared torcetrapib 60 mg plus atorvastatin 10, 20, 40, or 80 mg per day to atorvastatin 10, 20, 40, or 80 mg per day in 683 participants in 64 centres in North America and Europe (Canada, USA, Czech Republic, Finland, France and the Netherlands) in the 2000s. This study was prematurely terminated as all torcetrapib clinical trials were stopped. Therefore, 48 participants who were still receiving torcetrapib were contacted and instructed to discontinue treatment immediately and return for final evaluation that same month. This study did not measure five of our prespecified outcomes: the primary outcome of neurological impairment, and four of the secondary outcomes (stroke‐related mortality, major bleeding, progression of carotid stenosis, and quality of life). See <a href="#CD013573-tbl-0010">Table 6</a>. </p> <section id="CD013573-sec-0102"> <h5 class="title">Primary outcomes</h5> <section id="CD013573-sec-0103"> <h6 class="title">Ipsilateral major or disabling stroke</h6> <p>Two lipid‐lowering agents (torcetrapib plus atorvastatin) may result in no difference in ipsilateral major or disabling stroke when compared to one lipid‐lowering agent (atorvastatin) (RR 3.04, 95% CI 0.12 to 74.46; P = 0.49; 683 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0025" title="">Analysis 8.1</a>). </p> </section> </section> <section id="CD013573-sec-0104"> <h5 class="title">Secondary outcomes</h5> <section id="CD013573-sec-0105"> <h6 class="title">Adverse events</h6> <p>Two lipid‐lowering agents (torcetrapib plus atorvastatin) may result in no difference in adverse events when compared to one lipid‐lowering agent (atorvastatin) (RR 1.25, 95% CI 0.61 to 2.56; P = 0.54; 683 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0026" title="">Analysis 8.2</a>). </p> </section> </section> </section> <section id="CD013573-sec-0106"> <h4 class="title">9. One antihypertensive agent compared to another antihypertensive agent</h4> <p>We identified four studies for this comparison (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>). These studies ranged in duration from two to four years, and in participant numbers from 165 to 2035. <a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a> compared 2.5 mg or 5 mg isradipine twice daily to 12.5 mg or 25 mg hydrochlorothiazide twice daily. <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a> compared lacidipine 4 mg once daily to atenolol 50 mg once daily. <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a> compared olmesartan 20 mg once a day to atenolol 50 mg daily. <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a> compared amlodipine 5 mg to lisinopril 10 mg. We assessed the overall risk of bias for the four studies as low. These studies assessed a wide range of imaging and clinical outcomes. However, none measured five of our prespecified outcomes: the primary outcome of neurological impairment, and the secondary outcomes of stroke‐related mortality, major bleeding, progression of carotid stenosis, and quality of life. See <a href="#CD013573-tbl-0011">Table 7</a>. </p> <section id="CD013573-sec-0107"> <h5 class="title">Primary outcomes</h5> <section id="CD013573-sec-0108"> <h6 class="title">Ipsilateral major or disabling stroke</h6> <p>Two studies measured this outcome (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>). One antihypertensive agent (isradipine or lacidipine) may result in little to no difference in ipsilateral major or disabling stroke when compared to another antihypertensive agent (hydrochlorothiazide or atenolol) (RR 0.99, 95% CI 0.34 to 2.87; P = 0.17, I<sup>2</sup> = 46%; 2 studies, 2918 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0027" title="">Analysis 9.1</a>). A sensitivity analysis using a fixed‐effect model did not change the effect estimate substantially (RR 0.88, 95% CI 0.43 to 1.79; <a href="#CD013573-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD013573-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Sensitivity analysis (Ipsilateral major or disabling stroke): fixed effect." data-id="CD013573-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-06.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sensitivity analysis (Ipsilateral major or disabling stroke): fixed effect.</p> </div> </div> </div> </section> </section> <section id="CD013573-sec-0109"> <h5 class="title">Secondary outcomes</h5> <section id="CD013573-sec-0110"> <h6 class="title">Adverse events</h6> <p>One antihypertensive agent (isradipine, lacidipine, olmesartan, or amlodipine) may result in little to no difference in adverse events when compared to another antihypertensive agent (hydrochlorothiazide, atenolol, or lisinopril) (RR 1.00, 95% CI 0.82 to 1.21; P = 0.38, I<sup>2</sup> = 3%; 4 studies, 3239 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0028" title="">Analysis 9.2</a>). </p> </section> </section> </section> <section id="CD013573-sec-0111"> <h4 class="title">10. Higher dose of lipid‐lowering agent compared to low dose of the same lipid‐lowering agent </h4> <p>We found two studies for this comparison (<a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>;<a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>). <a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a> compared pitavastatin at different doses. Outcomes were measured after 12 months. This was an open‐label study, with a blinded end‐point evaluation, and we assessed the performance bias domain as high risk of bias. <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a> compared 80 mg atorvastatin once daily to 10 mg atorvastatin once daily. We assessed the overall risk of bias for as low. These studies evaluated 573 participants from the USA, Japan, Greece, and the UK in the 2000s with four months to two years of follow‐up. The two studies assessed a wide range of imaging and clinical outcomes. Neither included study measured five of our prespecified outcomes: the primary outcome of neurological impairment, and four of the secondary outcomes (stroke‐related mortality, major bleeding, progression of carotid stenosis, and quality of life). We were unable to perform a meta‐analysis or sensitivity analysis on this comparison because the studies reported different outcomes. See <a href="#CD013573-tbl-0012">Table 8</a>. </p> <section id="CD013573-sec-0112"> <h5 class="title">Primary outcomes</h5> <section id="CD013573-sec-0113"> <h6 class="title">Ipsilateral major or disabling stroke</h6> <p>One study measured this outcome (<a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>). A higher dose of a lipid‐lowering agent (atorvastatin 80 mg) may result in no difference in ipsilateral major or disabling stroke when compared to a lower dose of the same lipid‐lowering agent (atorvastatin 10 mg) (RR 0.33, 95% CI 0.01 to 7.72; P = 0.49; 40 participants; low‐certainty evidence; <a href="./references#CD013573-fig-0029" title="">Analysis 10.1</a>). </p> </section> </section> <section id="CD013573-sec-0114"> <h5 class="title">Secondary outcomes</h5> <section id="CD013573-sec-0115"> <h6 class="title">Adverse events</h6> <p>One study measured this outcome (<a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>). It is uncertain whether a higher dose of a lipid‐lowering agent (pitavastatin 3 (± 1.2) mg) results in any difference in adverse events when compared to a lower dose of the same lipid‐lowering agent (pitavastatin 1.9 (± 0.8) mg) (RR 1.57, 95% CI 0.66 to 3.71; P = 0.31; 278 participants; very low‐certainty evidence; <a href="./references#CD013573-fig-0030" title="">Analysis 10.2</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013573-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013573-sec-0116"></div> <p>This review aimed to assess the effects of pharmacological interventions on preventing neurological impairment, ipsilateral major or disabling stroke, death, major bleeding, and other outcomes in people with asymptomatic carotid stenosis. </p> <section id="CD013573-sec-0117"> <h3 class="title" id="CD013573-sec-0117">Summary of main results</h3> <p>We included 34 randomised controlled trials (RCTs) in total in the review; of these, we included 22 in the quantitative analysis. These studies compared different pharmacological interventions, such as antiplatelet agents, anticoagulant agents, lipid‐lowering agents, and antihypertensive agents. Three of the included studies were multi‐armed trials (<a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>). We identified one ongoing study (<a href="./references#CD013573-bbs2-0065" title="AranzullaTC , PiazzaS , RicottiA , MusumeciG , GaggianoA . Carotid plaque stabilization and regression with evolocumab: rationale and design of the CARUSO study. Catheter Cardiovascular Intervention2021;98(1):E115-21. [DOI: 10.1002/ccd.29743]">Aranzulla 2021</a>). </p> <p>Of the included studies, 12 did not assess any of our prespecified outcomes (<a href="./references#CD013573-bbs2-0130" title="ClezarCN , CassolaN , FlumignanCD , NakanoLC , TrevisaniVF , FlumignanRL . Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD013573. [DOI: 10.1002/14651858.CD013573]">Clezar 2020</a>). The other 22 studies provided data for 10 different comparisons. However, these studies did not assess all of our outcomes of interest, including neurological impairment and quality of life. </p> <p>A sensitivity analysis comparing fixed‐effect versus random‐effects models was only possible for the outcome of 'ipsilateral major or disabling stroke', in just two comparisons: 'lipid‐lowering agent versus placebo or no treatment' and 'one class of antihypertensive agent compared to another class of antihypertensive agent'. </p> <section id="CD013573-sec-0118"> <h4 class="title">Antiplatelets agents</h4> <p>One included Canadian study from the early 1990s (<a href="./references#CD013573-bbs2-0006" title="CôtéR , BattistaR , LangloisY . Asymptomatic cervical bruit study (ACBS). Stroke1995;26:349. CôtéR , BattistaRN , AbrahamowiczM , LangloisY , BourqueF , MackeyA . Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Annals of Internal Medicine1995;123(9):649‐55. [DOI: 10.7326/0003-4819-123-9-199511010-00002]CôtéR , the Asymptomatic Cervical Bruit Study Group. The Asymptomatic Cervical Bruit Study: progress report. Canadian Journal of Neurological Sciences1994;21 Suppl 2:S7. The Asymptomatic Cervical Bruit Study Group. Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group. Archives of Neurology1991;48(7):683-6. [DOI: 10.1001/archneur.1991.00530190029010]">Côté 1995</a>), which compared an antiplatelet agent versus placebo in people with asymptomatic carotid stenosis, provided data for our protocol‐proposed outcomes. This study showed that antiplatelet agents may result in no difference for ipsilateral major or disabling stroke, stroke‐related mortality, progression of carotid stenosis, and adverse events (all low‐certainty evidence). The effect of antiplatelet agents on major bleeding when compared to placebo was very uncertain and the certainty of the evidence was very low (<a href="./full#CD013573-tbl-0001">summary of findings Table 1</a>). There were no data regarding neurological impairment or quality of life. </p> </section> <section id="CD013573-sec-0119"> <h4 class="title">Lipid‐lowering agents</h4> <p>We found five different comparisons of lipid‐lowering agents, involving 23 studies, 15 of which measured outcomes predefined in our protocol (<a href="./references#CD013573-bbs2-0130" title="ClezarCN , CassolaN , FlumignanCD , NakanoLC , TrevisaniVF , FlumignanRL . Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD013573. [DOI: 10.1002/14651858.CD013573]">Clezar 2020</a>). </p> <p>The most common comparison in studies in lipid‐lowering agents was with placebo or no treatment (ranging from six weeks to five years after the beginning of the intervention) (<a href="./references#CD013573-bbs2-0001" title="AnderssenSA , HjelstuenAK , HjermannI , BjerkanK , HolmeI . Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis2005;178:387-97. [DOI: 10.1016/j.atherosclerosis.2004.08.033]">Anderssen 2005</a>; <a href="./references#CD013573-bbs2-0003" title="Blanco-ColioLM , Martin-VenturaJL , SolJM , DiazC , HernandezG , EgidoJ . Decreased circulating fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology2004;43(7):1188-94. [DOI: 10.1016/j.jacc.2003.10.046]Gómez-GeriqueJA , RosE , OlivánJ , MostazaJM , VilardellM , PintóX , et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis2002;162(2):245–51. [DOI: 10.1016/s0021-9150(01)00708-0]">Blanco‐Colio 2004</a>; <a href="./references#CD013573-bbs2-0007" title="BotsML , PalmerMK , DoganS , PlantingaY , RaichlenJS , EvansGW , et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine2009;265:698-707. [DOI: 10.1111/j.1365-2796.2009.02073.x]Crouse JR 3rd, GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR Study. Cardiovascular Drugs and Therapy2004;18(3):231-8. [DOI: 10.1023/B:CARD.0000033645.55138.3d]CrouseJR , BotsML , EvansGW , PalmerMK , O'LearyDH , GrobbeeDE , et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention and Rehabilitation2010;17:223-9. [DOI: 10.1097/HJR.0b013e3283359c38]CrouseJR , GrobbeeDE , O'LearyDH , BotsML , EvansGW , PalmerMK , et al. Rosuvastatin arrests progression of carotid intima media thickness in low-risk individuals: main results of the METEOR study. Journal of the American College of Cardiology2007;49(9):392A-3A. [DOI: 10.1016/j.jacc.2007.01.043]CrouseJR , GrobbeeDE , O'LearyDH , KasteleinJJ , BotsML , EvansGW , et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin - the METEOR Study. Atherosclerosis. Supplements2002;3(2):94. CrouseJR , RaichlenJS , RileyWA , EvansGW , PalmerMK , O'LearyDH , et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA2007;297(12):1344-53. [DOI: 10.1001/ jama.297.12.1344]KasteleinJJ , WiegmanA , deGrootE . Surrogate markers of atherosclerosis: impact of statins. Atherosclerosis. Supplements2003;4:31-6. [DOI: 10.1016/S1567-5688(03)00007-2]NCT00225589. A study measuring effects on intima media thickness: an evaluation of rosuvastatin 40 mg (METEOR). clinicaltrials.gov/ct2/show/NCT00225589 (first received 22 September 2005). [CLINICAL TRIAL: NCT00225589]ParaskevasKI , WierzbickiAS , MikhailidisDP . METEOR: aiming at the stars for asymptomatic carotid artery stenosis?International Journal of Clinical Practice2007;61(8):1239-50. [DOI: 10.1111/j.1742-1241.2007.01483.x]PetersSA , DoganS , MeijerR , PalmerMK , GrobbeeDE , Crouse JR 3rd, et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. Journal of Atherosclerosis and Thrombosis2011;18(9):784-95. [DOI: 10.5551/jat.8169]PetersSA , PalmerMK , GrobbeeDE , CrouseJR , O'LearyDH , RaichlenJS , et al. C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine2010;268:155-61. [DOI: 10.1111/j.1365-2796.2010.02230.x]">Crouse 2007</a>; <a href="./references#CD013573-bbs2-0011" title="HuY , TongG , XuW , PanJ , RyanK , YangR , et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diabetes and Vascular Disease Research2009;6(4):262-8. [DOI: 10.1177/1479164109339966]">Hu 2009</a>; <a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a>; <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0015" title="BaldassarreD , VegliaF , GobbiC , GallusG , VenturaA , CrepaldiG , et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis2000;151(2):575-83. [DOI: 10.1016/s0021-9150(99)00434-7]MercuriM , BondMG , SirtoriCR , VegliaF , CrepaldiG , FeruglioFS , et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine1996;101(6):627-34. [DOI: 10.1016/s0002-9343(96)00333-6]SirtoriCR , BianchiG , BondMG , D’Alo’G , GallusG , LiberatoreS , et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. International Journal of Cardiovascular Imaging1995;11(S2):119-24. [DOI: 10.1007/bf01419825]">Mercuri 1996</a>; <a href="./references#CD013573-bbs2-0018" title="ReidJA , WolsleyC , LauLL , HannonRJ , LeeB , YoungIS , et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. European Journal of Vascular and Endovascular Surgery2005;30:464-8. [DOI: 10.1016/j.ejvs.2005.05.007]">Reid 2005</a>; <a href="./references#CD013573-bbs2-0019" title="SalonenR , NyyssonenK , Porkkal-saratahoE , SalonenJT . The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology1995;76:34C-39C. [DOI: 10.1016/s0002-9149(99)80468-8]SalonenR , NyyssonenK , PorkkalaE , RummukainenJ , BelderR , Park J-S, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995;92(7):1758-64. [DOI: 10.1161/01.CIR.92.7.1758]SalonenR , NyyssonenK , PorkkataE , RummukainenJ , SalonenJT . KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation1994;90:I-127. ">Salonen 1995</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>; <a href="./references#CD013573-bbs2-0029" title="UMIN000001114. Effects of lipid lowering by atorvastatin on carotid atherosclerotic plaque (ACAP) study: a randomized trial for analysis of qualitative change in carotid atherosclerrotic plaque with IB echo and Black Blood MRI. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001347 (first received 01 June 2006). [UNIQUE ID ISSUED BY UMIN: UMIN000001114]YamadaK , YoshimuraS , KawasakiM , EnomotoY , AsanoT , MinatoguchiS , et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovascular Diseases2009;28:417-24. [DOI: 10.1159/000235746]">Yamada 2009</a>; <a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a>; <a href="./references#CD013573-bbs2-0032" title="ZengX , Zeng X Sr, LiY , Zeng YII . Effects of pravastatin on carotid plaques and preventing stroke in patients with hypercholesterolemia. Stroke2004;35(1):257. [DOI: https://doi.org/10.1161/str.35.1.253]">Zeng 2004</a>). Data from nine studies showed that lipid‐lowering agents may result in no difference in ipsilateral major or disabling stroke, stroke‐related mortality, and adverse events when compared to placebo or no treatment (all low‐certainty evidence; <a href="./full#CD013573-tbl-0004">summary of findings Table 4</a>). A sensitivity analysis using the fixed‐effect model changed the effect estimate substantially for ipsilateral major or disabling stroke (<a href="#CD013573-fig-0005">Figure 5</a>). Neurological impairment, major bleeding, progression of carotid stenosis, and quality of life were not reported. </p> <p>Another five studies compared two different doses of the same lipid‐lowering agent (<a href="./references#CD013573-bbs2-0005" title="CortiR , FusterV , FayadZA , WorthleySG , HelftG , ChaplinWF , et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. Journal of the American College of Cardiology2005;46(1):106-12. [DOI: 10.1016/j.jacc.2005.03.054]">Corti 2005</a>; <a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a>; <a href="./references#CD013573-bbs2-0013" title="KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouA , GerasimidisT , LiapisCD . Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2010;51:114-21. [DOI: 10.1016/j.jvs.2009.07.119]KadoglouNP , SailerN , MoumtzouoglouA , KapelouzouAT , FotiadisG , VittaI , et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Journal of Vascular Surgery2009;49(5 suppl 1):4S-5S. ">Kadoglou 2010</a>; <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a>; <a href="./references#CD013573-bbs2-0027" title="DuR , CaiJ , PingY , WangQ , LiuD , WuH . Effect of low dose rosuvastatin therapy on regression of carotid plaque and vasa vasorums in Chinese population: a prospective clinical trial by MRI. Journal of the American College of Cardiology2013;61(10 Suppl 1):E938. HatsukamiTS , ZhaoXQ , YuanC , TessierJJ , MillerE , PearsJS . Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis. Atherosclerosis. Supplements2001;2:47-8. [DOI: 10.1016/s1567-5688(01)80057-x]NCT00654394. Progression of carotid artery atheroma in moderately hypercholesterolemic subjects. clinicaltrials.gov/ct2/show/NCT00654394 (first received 3 April 2008). [CLINICAL TRIALS REGISTER: NCT00654394]UnderhillHR , YuanC , ZhaoXQ , KraissLW , ParkerDL , SaamT , et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. American Heart Journal2008;155(3):584.e1–584.e8. [DOI: 10.1016/j.ahj.2007.11.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00654394]">Underhill 2008</a>), of which only two assessed our outcomes of interest. <a href="./references#CD013573-bbs2-0025" title="ISRCTN64894118. A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI). www.isrctn.com/ISRCTN64894118 (first applied 3 March 2006). [DOI: 10.1186/ISRCTN64894118]Li Z-Y, TangT , GillardJ . Aggressive atorvastatin decreases wall shear stress in the carotid artery. Stroke2012;43 Suppl 1:A2790. LiZY , TangTY , JiangF , ZhangY , GillardJH . Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease. Circulation Journal2011;75(6):1486-92. [DOI: 10.1253/circj.cj-10-1210]NCT00368589. Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging. clinicaltrials.gov/ct2/show/NCT00368589 (first received 22 August 2006). [CLINICAL TRIALS REGISTER:: NCT00368589]SadatU , HowarthSP , UsmanA , TavianiV , TangTY , GravesMJ , et al. Effect of low- and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging - A post-hoc sub group analysis of ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Journal of Atherosclerosis and Thrombosis2013;20(1):46-56. [DOI: 10.5551/jat.12633]TangTY , HowarthSPS , MillerSR , GravesMJ , PattersonAJ , U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology2009;53(22):2039-50. [DOI: 10.1016/j.jacc.2009.03.018] [CLINICALTRIALS.GOV IDENTIFIER: NCT00368589]">Tang 2009</a> showed that a higher dose of a lipid‐lowering agent may result in no difference in ipsilateral major or disabling stroke when compared to a lower dose of a lipid‐lowering agent (low‐certainty evidence). <a href="./references#CD013573-bbs2-0012" title="KojiI , TomosaburoT , HiroyukiY , KiyoakiM , TakahisaS , TakashiM , et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). European Journal of Preventive Cardiology2013;20(6):1069-79. [CLINICALTRIALS.GOV IDENTIFIER:: NCT00711919] [DOI: 10.1177/2047487312451539] [UNIQUE ID ISSUED BY UMIN: UMIN000001229]NCT00711919. Pitavastatin on carotid intima-media thickness (PEACE). clinicaltrials.gov/ct2/show/record/NCT00711919 (first received 7 July 2008). [CLINICAL TRIALS REGISTER: NCT00711919]">Ikeda 2013</a> suggested that it is uncertain whether a higher dose of lipid‐lowering agents results in any difference in adverse events when compared to a lower dose of the same lipid‐lowering agent (very low‐certainty evidence; <a href="#CD013573-tbl-0012">Table 8</a>). Neurological impairment, stroke‐related mortality, major bleeding, progression of carotid stenosis, and quality of life outcomes were not reported in either trial. The three other studies did not assess any of the outcomes prespecified in our protocol. </p> <p>Three studies compared different lipid‐lowering agents (<a href="./references#CD013573-bbs2-0014" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49:838-47. [DOI: 10.1177/0091270009337011]">Meaney 2009</a>; <a href="./references#CD013573-bbs2-0016" title="KurabayashiM , SakumaI , KawamoriR , DaidaH , YamazakiT , YoshidaM , et al. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients?Journal of Atherosclerosis and Thrombosis2009;17(4):416-22. [DOI: 10.5551/jat.2899] [UMIN ID: UMIN000001174]NoharaR , DaidaH , HataM , KakuK , KawamoriR , KishimotoJ , et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients - Justification for Atherosclerosis Regression Treatment (JART) study. Circulation Journal2012;76:221-9. [DOI: 10.1253/circj.CJ-11-0887]YamazakiT , NoharaR , DaidaH , HataM , KakuK , KawamoriR , et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. International Heart Journal2013;54:33-9. [DOI: 10.1536/ihj.54.33]">Nohara 2012</a>; <a href="./references#CD013573-bbs2-0020" title="SawayamaY , HayashiJ , MaedaN , ShimizuC , TanakaY , KashiwagiS . The therapeutic effects of probucol and pravastatin on common carotid intima-media thickness in asymptomatic hypercholesterolemic Japanese patients. Atherosclerosis2000;151(1):130. SawayamaY , ShimizuC , MaedaN , TatsukawaM , KinukawaN , KoyanagiS , et al. Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST). Journal of the American College of Cardiology2002;39(4):610-6. [DOI: 10.1016/s0735-1097(01)01783-1]WadaN , SekiguchiM , YoshiokaN , ToyoshimaH , MatsumotoA , NomuraM , et al. Effect of probucol and pravastatin on common-carotid atherosclerosis in diabetic patients with hypercholesterolemia. Journal of the Japan Diabetes Society2005;48(1):53-6. ">Sawayama 2002</a>). All three studies administered pravastatin. However, <a href="./references#CD013573-bbs2-0014" title="MeaneyA , CeballosG , AsbunJ , SolacheG , MendozaE , VelaA , et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. Journal of Clinical Pharmacology2009;49:838-47. [DOI: 10.1177/0091270009337011]">Meaney 2009</a> did not assess any of our prespecified outcomes, and thus was not included in the quantitative analysis. It is uncertain whether one lipid‐lowering agent results in any difference in ipsilateral major or disabling stroke or an increase in adverse events when compared to another lipid‐lowering agent. In both cases, the certainty of the evidence was very low (<a href="#CD013573-tbl-0009">Table 5</a>). Neither study assessed neurological impairment, stroke‐related mortality, major bleeding, progression of carotid stenosis, and quality of life. </p> <p>One study compared two lipid‐lowering agents to one lipid‐lowering agent (<a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a>). The findings from this study indicated that two lipid‐lowering agent may result in no difference in ipsilateral major or disabling stroke and adverse events when compared to one lipid‐lowering agent (both low‐certainty evidence; <a href="#CD013573-tbl-0010">Table 6</a>). <a href="./references#CD013573-bbs2-0004" title="BotsML , VisserenFL , EvansGW , RileyWA , RevkinJH , TegelerCH , et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007;379(9582):153-60. [DOI: 10.1016/S0140-6736(07)61088-5]DoganS , DuivenvoordenR , GrobbeeDE , KasteleinJJ , ShearCL , EvansGW , et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. Journal of Atherosclerosis and Thrombosis2010;17(5):526-35. [DOI: 10.5551/jat.3269]KasteleinJJ , BotsML , RileyWA , EvansGW , MeijerR , RevkinJH , et al. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. Supplements2005;6(1):51-2. [DOI: 10.1016/S1567-5688(05)80205-3]KasteleinJJ , Van LeuvenSI , BurgessL , EvansGW , KuivenhovenJA , BarterPJ , et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine2007;356(16):1620-30. [DOI: 10.1056/NEJMoa071359]KasteleinJJ , Van LeuvenSI , EvansGW , RileyWA , RevkinJH , ShearCL , et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current Medical Research and Opinion2007;23(4):885-94. [DOI: 10.1185/030079907X182121]NCT00134238. Carotid B-mode Ultrasound Study to compare anti-atherosclerotic effect of torcetrapib/atorvastatin to atorvastatin (RADIANCE 2). clinicaltrials.gov/ct2/show/NCT00134264 (first received 22 August 2005). [CLINICAL TRIALS REGISTER: NCT00134238]">Bots 2007</a> did not assess neurological impairment, stroke‐related mortality, major bleeding, progression of carotid stenosis, and quality of life. </p> <p>The last comparison involving lipid‐lowering agents was in the <a href="./references#CD013573-bbs2-0034" title="ZhuS , SuG , MengQH . Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clinical Chemistry2006;52(11):2036-42. [DOI: 10.1373/clinchem.2006.074724]">Zhu 2006</a> study. Based on this study's results, it is uncertain whether a lipid‐lowering agent plus antihypertensive agent prevent ipsilateral major or disabling stroke or increase adverse events when compared to an antihypertensive agent alone; the certainty of the evidence was very low for both outcomes (<a href="#CD013573-tbl-0008">Table 4</a>). No other outcome of interest was reported in this comparison. </p> </section> <section id="CD013573-sec-0120"> <h4 class="title">Anticoagulant agents</h4> <p><a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a> compared warfarin to placebo. An anticoagulant agent may reduce adverse events (low‐certainty evidence), but the effect of anticoagulants on major bleeding when compared to placebo is uncertain and the certainty of the evidence was very low (<a href="./full#CD013573-tbl-0003">summary of findings Table 3</a>). This study did not assess neurological impairment, ipsilateral major or disabling stroke, stroke‐related mortality, progression of carotid stenosis, and quality of life. </p> <p>Another trial that compared anticoagulant agents was <a href="./references#CD013573-bbs2-0022" title="Shinoda-TagawaT , YamasakiY , YoshidaS , KajimotoY , TsujinoT , HakuiN , et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia2002;45(2):188-94. [DOI: 10.1007/s00125-001-0740-2]">Shinoda‐Tagawa 2002</a>. It compared cilostazol (100 to 200 mg daily) to no treatment in 89 Japanese participants for three years. This study did not report any of our prespecified outcomes. </p> </section> <section id="CD013573-sec-0121"> <h4 class="title">Antihypertensive agents</h4> <p>Eleven included trials studied an antihypertensive agent, accounting for four different comparisons outlined below: (1) antihypertensive agent versus placebo; (2) one antihypertensive agent versus another antihypertensive agent; (3) one antihypertensive agent plus a lipid‐lowering agent versus another antihypertensive agent; and (4) an antihypertensive agent (metoprolol) plus aspirin versus placebo. </p> <p>Two studies compared an antihypertensive agent to placebo (<a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a>; <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a>). <a href="./references#CD013573-bbs2-0010" title="BCAPS. BCAPS: Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. BerglundG , WikstrandJ , JanzonL , WedelH , HedbladB . Low dose metoprolol and fluvastatin slow progression of atherosclerosis: main results from BCAPS. Atherosclerosis2000;151(1):4. HedbladB , WikstrandJ , JanzonL , WedelH , BerglundG . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from a B-blocker Cholesterol-lowering Asymtomatic Plaque Study (BCAPS). Circulation2001;103:1721-6. [DOI: 10.1161/01.CIR.103.13.1721]OstlingG , GoncalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis Supplements2011;12(1):67. OstlingG , GonçalvesI , WikstrandJ , BerglundG , NilssonJ , HedbladB . Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Atherosclerosis2011;215(2):440-5. [DOI: 10.1016/j.atherosclerosis.2010.12.031]WikstrandJ , BerglundG , HedbladB , HultheJ . Antiatherosclerotic effects of beta-blockers. American Journal of Cardiology2003;91(12 Suppl 1):25H-9H. [DOI: 10.1016/S0002-9149(03)00431-4]">Hedblad 2001</a> assessed two of our prespecified outcomes (ipsilateral major or disabling stroke; stroke‐related mortality), and <a href="./references#CD013573-bbs2-0024" title="DavisBR , VogtT , FrostPH , BurlandoA , CohenJ , WilsonA , et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40. NCT00000514. Systolic Hypertension in the Elderly Program (SHEP). clinicaltrials.gov/ct2/show/NCT00000514 (first received 27 October 1999). [CLINICALTRIALS.GOV IDENTIFIER: ClinicalTNCT00000514]SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255-64. [DOI: 10.1001/jama.1991.03460240051027]Sutton-TyrrellK , AlcornHG , HerzogH , KelseySF , KullerLH . Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke1995;26:1319-24. [DOI: 10.1161/01.STR.26.8.1319]Sutton-TyrrellK , KullerLH , WolfsonSK . Blood pressure treatment slows the rate of progression of carotid stenosis in patients with isolated systolic hypertension. Journal of the American College of Cardiology1993;21:70A. Sutton-TyrrellK , WolfsonSK , KullerLW . Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke1994;25:44-50. [DOI: 10.1161/01.STR.25.1.44]The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197-208. [DOI: 10.1016/0895-4356(88)90024-8]">Sutton‐Tyrrell 1994</a> assessed only progression of carotid stenosis. Based on data from these studies, an antihypertensive agent may result in no difference in ipsilateral major or disabling stroke and stroke‐related mortality, but may prevent the progression of carotid stenosis when compared to placebo (all low‐certainty evidence; <a href="./full#CD013573-tbl-0002">summary of findings Table 2</a>). These studies did not assess neurological impairment, major bleeding, adverse events, and quality of life. </p> <p>Seven studies compared two different antihypertensive agents (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0021" title="SempliciniA , MarescaA , SimonellaC , ChierichettiF , PaulettoP , MeneghettiG , et al. Cerebral perfusion in hypertensives with carotid artery stenosis: a comparative study of lacidipine and hydrochlorothiazide. Blood Pressure2000;9:34-9. [DOI: 10.1080/080370500439407 · S]SempliciniA , SimonellaC , MeneghettiG , ChierichettiF , SantipoloN , PaulettoP , et al. Lacidipine and cerebral perfusion in uncomplicated essential hypertensives with mild to moderate carotid artery stenosis. Journal of Hypertension1998;16 Suppl 2:S243. ">Semplicini 2000</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>; <a href="./references#CD013573-bbs2-0028" title="MagnaniB , Dal PaluC , ZanchettiA . Preliminary clinical experience with calcium antagonists in atherosclerosis. Drugs1992;44 Suppl 1:128-33. RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA , VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension 1997 Nov;15(11):1337-44. [DOI: 10.1097/00004872-199715110-00019]ZanchettiA , MagnaniB , Dal PaluC , on behalf of the VHAS Investigators. Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of ultrasonography evaluations. Journal of Hypertension1997;15 Suppl 4:S91. ZanchettiA , MagnaniB , Dal PaluC , on behalf of the Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. Atherosclerosis and calcium antagonists: the VHAS. Journal of Human Hypertension1992;6 Suppl 2:S45-8. ZanchettiA , RoseiEA , Dal PaluC , LeonettiG , MagnaniB , PessinaA , et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16:1667-76. ZanchettiA . VHAS: Verapamil in Hypertension and Atherosclerosis Study. Cardio-Vascular Clinical Trials Forum: Registry of Recent and On-Going Clinical Trials (BioMedNet)1998. ">VHAS 1998</a>; <a href="./references#CD013573-bbs2-0030" title="C000000319. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. upload.umin.ac.jp (first received 01 February 2006). [UMIN-CTR CLINICAL TRIAL REGISTER:: C000000319]HoriM . The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension. Circulation Journal2006;70(1):124-8. [DOI: 10.1253/circj.70.124]The J-ELAN Investigators. The effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. Circulation Journal2006;70:124-8. [DOI: 10.1253/circj.70.124]YamamotoK , OzakiH , TakayasuK , AkehiN , FukuiS , SakaiA , et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertension Research2011;34:325-30. [DOI: 10.1038/hr.2010.237] [UMIN CLINICAL TRIALS REGISTRY: C000000319]">Yamamoto 2011</a>). However, only four of these assessed any of our prespecified outcomes (<a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a>; <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a>; <a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>). <a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a> and <a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a> reported data on ipsilateral major or disabling stroke; all four studies presented data on adverse events (<a href="./references#CD013573-bbs2-0023" title="LudwigM , StumpeKO , Agabiti-RoseiE , ScholzeJ , StumpeI , ZielinskiT . Quantification of antihypertensive treatment effects on carotid atherosclerosis by 3-dimensional ultrasound: first report from the MORE trial. Stroke2006;37(2):664. NCT00185185. Olmesartan Medoxomil in Atherosclerosis. clinicaltrials.gov/ct2/show/NCT00185185 (first received 12 September 2005). [CLINICALTRIALS.GOV IDENTIFIER:: NCT00185185]StumpeKO , Agabiti-RoseiE , ZielinskiT , SchremmerD , ScholzeJ , LaeisP , et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease2007;1(2):97-106. [DOI: 10.1177/ 1753944707085982]">Stumpe 2007</a>; <a href="./references#CD013573-bbs2-0026" title="TerpstraWF , MayJF , SmitAJ , De GraeffPA , Meyboom-de JongB , CrijnsHJ . Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension2004;22:1309-16. [DOI: 10.1097/01.hjh.0000125412.50839.b5]">Terpstra 2004</a>). We were thus able to perform meta‐analysis for two prespecified outcomes. Antihypertensive agents may result in no difference in ipsilateral major or disabling stroke and adverse events when compared to another antihypertensive agent (both low‐certainty evidence; <a href="#CD013573-tbl-0011">Table 7</a>). A sensitivity analysis using a fixed‐effect model did not change the effect estimate substantially for ipsilateral major or disabling stroke (<a href="#CD013573-fig-0006">Figure 6</a>). </p> <p>Only one included study, with 254 participants, compared an antihypertensive agent plus a lipid‐lowering agent to another antihypertensive agent plus a lipid‐lowering agent (<a href="./references#CD013573-bbs2-0031" title="The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. Journal of Hypertension1993;11 Suppl 5:S314-5. ZanchettiA , CrepaldiG , BondG , GallusG , VegliaF , ManciaG , et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke2004;35:2807-12. [DOI: 10.1161/01.STR.0000147041.00840.59]ZanchettiA , CrepaldiG , BondG , GallusG , VegliaM , ManciaG , et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid Lowering Italian Study (PHYLLIS). Journal of Hypertension2003;21 Suppl 4:S346. ZanchettiA , CrepaldiG , BondMG , GallusGV , VegliaF , VenturaA , et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. Journal of Hypertension2001;19(1):79-88. [DOI: 10.1097/00004872-200101000-00011]ZanchettiA . The hypertensive patient with multiple risk factors. Is treatment really so difficult?American Journal of Hypertension1997;10(10 Pt 2):223S-9S. [DOI: 10.1016/s0895-7061(97)00327-0]">Zanchetti 2004</a>); it reported one of our outcomes of interest. An antihypertensive agent plus a lipid‐lowering agent may result in little to no difference in ipsilateral major or disabling stroke when compared to another antihypertensive agent plus a lipid‐lowering agent (low‐certainty evidence; <a href="#CD013573-tbl-0007">Table 3</a>). </p> <p>The remaining study compared an antihypertensive agent (metoprolol) plus aspirin to placebo in 162 participants (<a href="./references#CD013573-bbs2-0017" title="Carotid Stenosis Study Group. Failure of metoprolol and aspirin to regress carotid stenosis. Stroke1990;21:169. [DOI: 10.1161/01.STR.21.1.156]NorrisJW , ZiliottoC , TaylorDW , ChambersBR , BornsteinNM , D'AltonJG , et al. Failure of metoprolol and aspirin to regress carotid stenosis. Neurology1990;40 Suppl 1:415. [DOI: 10.1212/WNL.40.4_Suppl_1.1]">Norris 1990</a>). We could not extract any usable data from this study and our attempt to obtain raw data directly from the trial authors was unsuccessful. </p> </section> </section> <section id="CD013573-sec-0122"> <h3 class="title" id="CD013573-sec-0122">Overall completeness and applicability of evidence</h3> <p>In this systematic review, we focused on people of any age with asymptomatic carotid stenosis, to provide information about the effects of different classes of drugs in cardiovascular outcomes, including the prevention of neurological impairment, stroke, adverse effects, major bleeding, and quality of life. We included only RCTs. </p> <section id="CD013573-sec-0123"> <h4 class="title">Study design</h4> <p>Our extensive search for RCTs investigating pharmacological interventions for asymptomatic carotid stenosis identified only 34 studies with our predefined interventions. </p> <p>Although all studies were RCTs, most did not provide complete and clear information about their methodology or data. As a result, it was difficult to perform quantitative analyses and assess the risk of bias for many outcomes in some studies. Furthermore, there were only one to nine studies in each comparison, and most comparisons had only one or two of the included studies. </p> </section> <section id="CD013573-sec-0124"> <h4 class="title">Population</h4> <p>The randomised population ranged between 18 and 100 years of age, with the mean age in the 60‐year age group. Most participants were men. Both of these features are consistent with the epidemiology of the disease. </p> <p>Most of our included studies had relatively low participant numbers: 25 studies had up to 500 participants, 12 of which had fewer than 100 participants; seven studies had between 500 and 1000 participants; and just two studies had more than 1000 participants. </p> </section> <section id="CD013573-sec-0125"> <h4 class="title">Intervention</h4> <p>In two of our five interventions of interest – namely, lipid‐lowering and antihypertensive agents – there was considerable variation in the use of the intervention (e.g. dosages, different agents, association with other agents). In two other interventions – antiplatelet agents and anticoagulant agents – there were fewer studies and the intervention was limited to the standard dosage of the agent or was associated with another agent. Notably, we did not include any studies with one of our interventions of interest: glycaemic‐lowering agents. </p> </section> <section id="CD013573-sec-0126"> <h4 class="title">Setting</h4> <p>The studies included in this review were carried out in 21 different countries, with most (90%) being high‐income countries. Three of the included studies were multicentric. </p> <p>It should be remembered that various factors, such as socioeconomic conditions, access to physical activity, type of food and cuisine, and culture of the population of each country, may interfere with the acceptability and effectiveness of pharmacological treatments of asymptomatic carotid stenosis. Hence, the external validity of the general evidence presented in this review should be considered with caution. </p> </section> <section id="CD013573-sec-0127"> <h4 class="title">Outcomes</h4> <p>None of the included studies reported our primary outcome of neurological impairment. Only 14 of 34 studies reported ipsilateral major or disabling stroke in the different comparisons. Of our secondary outcomes, four studies reported stroke‐related mortality, two other studies detailed major bleeding, two reported progression of carotid stenosis, and 16 reported adverse events. However, we found no studies that evaluated the impact of pharmacological interventions on quality of life. </p> </section> </section> <section id="CD013573-sec-0128"> <h3 class="title" id="CD013573-sec-0128">Certainty of the evidence</h3> <p>The evidence for this review came from RCTs, but some studies had methodological problems, poorly‐reported study designs, or both. Randomisation and allocation were adequately reported in almost half of the trials; we judged the remaining as having an unclear risk of bias in these domains. We judged nine open‐label studies as having a high risk of bias due to not blinding participants and personnel, and another five studies as unclear. However, 20 trials were blinded to participants and personnel, avoided performance bias as much as possible, and were adequately reported. Furthermore, only two RCTs did not report the blinding of outcome assessment; we assessed these as having an unclear risk of bias for this domain. Also, we considered seven studies as having an unclear risk of attrition bias with incomplete outcomes, and three as having an unclear risk of reporting bias. We assessed only one trial as having a high risk of selective reporting bias. </p> <p>The certainty of the evidence for our outcomes ranged from low to very low. We downgraded the certainty of the evidence due to the risk of bias in four RCTs, mainly regarding the blinding of participants and personnel, as these studies were open‐label. Also, we downgraded the certainty of the evidence for all outcomes for imprecision because of the small number of participants in the trials, the few studies in each comparison, and large confidence intervals. Moreover, two trials were imprecise in their definitions of bleeding, which led to downgrading the evidence certainty of the major bleeding outcome. </p> <p>There are numerous clinical guidelines on and RCTs investigating treatments for asymptomatic carotid stenosis. However, there is still no high‐certainty evidence about the best pharmacological treatment for people with asymptomatic carotid stenosis. </p> </section> <section id="CD013573-sec-0129"> <h3 class="title" id="CD013573-sec-0129">Potential biases in the review process</h3> <p>We performed an unrestricted literature search and followed guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> in our selection of studies (<a href="./references#CD013573-bbs2-0103" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Lefebvre 2022</a>). We believe that we identified all relevant studies meeting our inclusion criteria. However, there is the possibility that some studies may have been missed, especially in the grey literature. </p> <p>We designed and published our protocol for studying pharmacological interventions in asymptomatic carotid stenosis prior to data collection and analysis (<a href="./references#CD013573-bbs2-0130" title="ClezarCN , CassolaN , FlumignanCD , NakanoLC , TrevisaniVF , FlumignanRL . Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD013573. [DOI: 10.1002/14651858.CD013573]">Clezar 2020</a>), and we adhered to the prespecified inclusion and exclusion criteria in the protocol to limit subjectivity. We did not include non‐randomised studies due to their high vulnerability to error and bias. Also, we attempted to contact study authors in order to obtain additional relevant data but were unable to do so with the included studies. If we are able to collect supplemental data, we will consider it in future updates. </p> </section> <section id="CD013573-sec-0130"> <h3 class="title" id="CD013573-sec-0130">Agreements and disagreements with other studies or reviews</h3> <section id="CD013573-sec-0131"> <h4 class="title">Systematic reviews of interventions</h4> <p>To the best of our knowledge, there are no systematic reviews that compare pharmacological treatments with placebo, no treatment, or another pharmacological intervention for asymptomatic carotid stenosis. However, there are three systematic reviews comparing pharmacological treatments with surgical treatment in people with carotid artery stenosis (<a href="./references#CD013573-bbs2-0089" title="GasiorSA , O'DonnellJP , DaveyM , ClarkeJ , JalaliA , Ryan É, et al. Optimal management of asymptomatic carotid artery stenosis: a systematic review and network meta-analysis. European Journal of Vascular and Endovascular Surgery2023;65(5):660-9. [DOI: 10.1016/j.ejvs.2023.01.020]">Gasior 2023</a>; <a href="./references#CD013573-bbs2-0108" title="MüllerMD , BonatiLH . Carotid artery stenosis – Current evidence and treatment recommendations. Clinical and Translational Neuroscience2021;5(1):1-8. [DOI: 10.1177/2514183X211001654]">Müller 2021</a>; <a href="./references#CD013573-bbs2-0114" title="RamanG , MoorthyD , HadarN , DahabrehIJ , O'DonnellTF , ThalerDE , et al. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Annals of Internal Medicine 2013 May 7;158(9):676-85. [DOI: 10.7326/0003-4819-158-9-201305070-00007] [PMID: 23648949]">Raman 2013</a>). <a href="./references#CD013573-bbs2-0089" title="GasiorSA , O'DonnellJP , DaveyM , ClarkeJ , JalaliA , Ryan É, et al. Optimal management of asymptomatic carotid artery stenosis: a systematic review and network meta-analysis. European Journal of Vascular and Endovascular Surgery2023;65(5):660-9. [DOI: 10.1016/j.ejvs.2023.01.020]">Gasior 2023</a> compared the effects of pharmacological treatment with invasive carotid endarterectomy and carotid artery stenting in people with asymptomatic carotid artery stenosis. They found evidence that contemporary pharmacological treatment shows similar reductions in stroke and carotid endarterectomy mortality. Furthermore, pharmacological treatment has the potential to reduce the need for surgical intervention in people with asymptomatic carotid stenosis. <a href="./references#CD013573-bbs2-0108" title="MüllerMD , BonatiLH . Carotid artery stenosis – Current evidence and treatment recommendations. Clinical and Translational Neuroscience2021;5(1):1-8. [DOI: 10.1177/2514183X211001654]">Müller 2021</a> reviewed available evidence from randomised clinical trials comparing pharmacological treatment with surgical treatment (both carotid artery stenting and carotid endarterectomy) in people with symptomatic and asymptomatic carotid stenosis. They found that carotid artery stenting may slightly increase the risk of stroke or death up to 30 days after treatment compared with carotid endarterectomy in asymptomatic patients. <a href="./references#CD013573-bbs2-0114" title="RamanG , MoorthyD , HadarN , DahabrehIJ , O'DonnellTF , ThalerDE , et al. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Annals of Internal Medicine 2013 May 7;158(9):676-85. [DOI: 10.7326/0003-4819-158-9-201305070-00007] [PMID: 23648949]">Raman 2013</a> reviewed RCT and non‐randomised study evidence for three different treatment strategies for asymptomatic carotid stenosis: pharmacological therapy alone, carotid endarterectomy plus pharmacological therapy, and carotid artery stenting plus pharmacological therapy. They also examined single‐group prospective cohort studies of pharmacological therapy to measure stroke incidence. They found evidence from three studies that carotid endarterectomy reduces the risk of ipsilateral stroke when compared to pharmacological treatment, but cautioned that these results may no longer be applicable to current clinical practice as they are from older studies. No study in their review compared carotid artery stenting with pharmacological therapy. </p> </section> <section id="CD013573-sec-0132"> <h4 class="title">Clinical guidelines and systematic reviews of clinical guidelines</h4> <p>There are some systematic reviews of guidelines for the primary and secondary prevention of stroke, which encompass both surgical (carotid endarterectomy and carotid angioplasty/stenting) and pharmacological treatment. </p> <p><a href="./references#CD013573-bbs2-0067" title="AbbottAL , ParaskevasKI , KakkosSK , GolledgeJ , EcksteinHH , Diaz-SandovalLJ , et al. Systematic review of guidelines for the management of asymptomatic and symptomatic carotid stenosis. Stroke2015;46(11):3288-301. [DOI: 10.1161/STROKEAHA.115.003390] [PMID: 26451020]">Abbott 2015</a> systematically searched for guidelines with recommendations on carotid endarterectomy and carotid angioplasty/stenting between January 2008 and 2015, published in any language. This review highlighted limitations in terms of the clarity, accessibility, organisation, and consistency of the recommendations, and also in terms of the currency of the scientific evidence used in these guidelines and protocols. The literature was outdated, as the studied therapies have undergone several modifications over the last 30 years (<a href="./references#CD013573-bbs2-0067" title="AbbottAL , ParaskevasKI , KakkosSK , GolledgeJ , EcksteinHH , Diaz-SandovalLJ , et al. Systematic review of guidelines for the management of asymptomatic and symptomatic carotid stenosis. Stroke2015;46(11):3288-301. [DOI: 10.1161/STROKEAHA.115.003390] [PMID: 26451020]">Abbott 2015</a>). As we observed in our review, most of the studies that evaluated pharmacological treatment in asymptomatic carotid stenosis are from the 1990s and 2000s, with a lot of emphasis on lipid‐lowering agents and less emphasis on antihypertensive agents. We also found few studies that assessed anticoagulants and antiplatelet drugs and no studies on hypoglycaemic agents and how diabetes management can impact these patients. </p> <p>All protocols and guidelines regarding the treatment of asymptomatic carotid stenosis are informed by clinical trials on carotid endarterectomy, carotid angioplasty/stenting, and pharmacological treatment, most of which were conducted 20 to 40 years ago. Many of these studies, including the Veterans Affairs Cooperative Study Group, the Asymptomatic Carotid Atherosclerosis Study (ACAS) study, and the ACST‐1 (Asymptomatic Carotid Surgery Trial) study, were not supportive of pharmacological treatment because they were conducted at a time when a minority of participants were using lipid‐lowering agents and blood pressure targets were not as low as they are today. However, our review shows that antihypertensive drugs can reduce the risk of progression of carotid stenosis and lipid‐lowering drugs can reduce the risk of major or disabling stroke. </p> <p>Consequently, new RCTs are required to legitimise current guidelines. At present, there are a few ongoing studies for asymptomatic carotid stenosis involving the use of carotid endarterectomy/carotid artery stenting and pharmacological treatment, including the Carotid Revascularization Endarterectomy versus Stent Trial 2 (<a href="./references#CD013573-bbs2-0101" title="HowardVJ , MeschiaJF , LalBK , TuranTN , RoubinGS , Brown RD Jr, et al. Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials. Int J Stroke 2017 Oct;12(7):770-8. [DOI: 10.1177/1747493017706238] [CLINICALTRIALS.GOV: NCT02089217]">Howard 2017</a>). </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013573-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Longitudinal view of carotid bifurcation with methods of measuring carotid stenosis at angiographyA: narrowest ICA diameter B: normal distal cervical ICA diameter C: estimated original diameter at the site of the most stenosisCCA: common carotid artery ECA: external carotid artery ECST: European Carotid Surgery Trial ICA: internal carotid artery NASCET: North American Symptomatic Carotid Endarterectomy Trial" data-id="CD013573-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-01.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Longitudinal view of carotid bifurcation with methods of measuring carotid stenosis at angiography </p> <p>A: narrowest ICA diameter<br/>B: normal distal cervical ICA diameter<br/>C: estimated original diameter at the site of the most stenosis </p> <p>CCA: common carotid artery<br/>ECA: external carotid artery<br/>ECST: European Carotid Surgery Trial<br/>ICA: internal carotid artery<br/>NASCET: North American Symptomatic Carotid Endarterectomy Trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-01.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013573-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013573-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013573-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Sensitivity analysis (Ipsilateral major or disabling stroke): fixed effect." data-id="CD013573-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-05.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Sensitivity analysis (Ipsilateral major or disabling stroke): fixed effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-05.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Sensitivity analysis (Ipsilateral major or disabling stroke): fixed effect." data-id="CD013573-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-06.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Sensitivity analysis (Ipsilateral major or disabling stroke): fixed effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-FIG-06.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agent versus placebo, Outcome 1: Ipsilateral major or disabling stroke" data-id="CD013573-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agent versus placebo, Outcome 1: Ipsilateral major or disabling stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agent versus placebo, Outcome 2: Stroke‐related mortality" data-id="CD013573-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agent versus placebo, Outcome 2: Stroke‐related mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agent versus placebo, Outcome 3: Major bleeding" data-id="CD013573-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agent versus placebo, Outcome 3: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agent versus placebo, Outcome 4: Progression of carotid stenosis" data-id="CD013573-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agent versus placebo, Outcome 4: Progression of carotid stenosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agent versus placebo, Outcome 5: Adverse events" data-id="CD013573-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agent versus placebo, Outcome 5: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antihypertensive agent versus placebo, Outcome 1: Ipsilateral major or disabling stroke" data-id="CD013573-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Antihypertensive agent versus placebo, Outcome 1: Ipsilateral major or disabling stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antihypertensive agent versus placebo, Outcome 2: Stroke‐related mortality" data-id="CD013573-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Antihypertensive agent versus placebo, Outcome 2: Stroke‐related mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antihypertensive agent versus placebo, Outcome 3: Progression of carotid stenosis" data-id="CD013573-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Antihypertensive agent versus placebo, Outcome 3: Progression of carotid stenosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: One antihypertensive agent plus lipid‐lowering agent versus another antihypertensive agent plus lipid‐lowering agent, Outcome 1: Ipsilateral major or disabling stroke" data-id="CD013573-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: One antihypertensive agent plus lipid‐lowering agent versus another antihypertensive agent plus lipid‐lowering agent, Outcome 1: Ipsilateral major or disabling stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Anticoagulant agent versus placebo, Outcome 1: Major bleeding" data-id="CD013573-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Anticoagulant agent versus placebo, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Anticoagulant agent versus placebo, Outcome 2: Adverse events" data-id="CD013573-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Anticoagulant agent versus placebo, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lipid‐lowering agent versus placebo or no treatment, Outcome 1: Ipsilateral major or disabling stroke" data-id="CD013573-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Lipid‐lowering agent versus placebo or no treatment, Outcome 1: Ipsilateral major or disabling stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lipid‐lowering agent versus placebo or no treatment, Outcome 2: Stroke‐related mortality" data-id="CD013573-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Lipid‐lowering agent versus placebo or no treatment, Outcome 2: Stroke‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lipid‐lowering agent versus placebo or no treatment, Outcome 3: Adverse events" data-id="CD013573-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Lipid‐lowering agent versus placebo or no treatment, Outcome 3: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lipid‐lowering agent plus antihypertensive agent versus antihypertensive agent, Outcome 1: Ipsilateral major or disabling stroke" data-id="CD013573-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Lipid‐lowering agent plus antihypertensive agent versus antihypertensive agent, Outcome 1: Ipsilateral major or disabling stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Lipid‐lowering agent plus antihypertensive agent versus antihypertensive agent, Outcome 2: Adverse events" data-id="CD013573-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Lipid‐lowering agent plus antihypertensive agent versus antihypertensive agent, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: One lipid‐lowering agent versus another lipid‐lowering agent, Outcome 1: Ipsilateral major or disabling stroke" data-id="CD013573-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: One lipid‐lowering agent versus another lipid‐lowering agent, Outcome 1: Ipsilateral major or disabling stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: One lipid‐lowering agent versus another lipid‐lowering agent, Outcome 2: Adverse events" data-id="CD013573-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: One lipid‐lowering agent versus another lipid‐lowering agent, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Two lipid‐lowering agents versus one lipid‐lowering agent, Outcome 1: Ipsilateral major or disabling stroke" data-id="CD013573-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Two lipid‐lowering agents versus one lipid‐lowering agent, Outcome 1: Ipsilateral major or disabling stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Two lipid‐lowering agents versus one lipid‐lowering agent, Outcome 2: Adverse events" data-id="CD013573-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Two lipid‐lowering agents versus one lipid‐lowering agent, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: One antihypertensive agent versus another antihypertensive agent, Outcome 1: Ipsilateral major or disabling stroke" data-id="CD013573-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: One antihypertensive agent versus another antihypertensive agent, Outcome 1: Ipsilateral major or disabling stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: One antihypertensive agent versus another antihypertensive agent, Outcome 2: Adverse events" data-id="CD013573-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: One antihypertensive agent versus another antihypertensive agent, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Higher dose of lipid‐lowering agent versus lower dose of the same lipid‐lowering agent, Outcome 1: Ipsilateral major or disabling stroke" data-id="CD013573-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Higher dose of lipid‐lowering agent versus lower dose of the same lipid‐lowering agent, Outcome 1: Ipsilateral major or disabling stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013573-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/urn:x-wiley:14651858:media:CD013573:CD013573-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Higher dose of lipid‐lowering agent versus lower dose of the same lipid‐lowering agent, Outcome 2: Adverse events" data-id="CD013573-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_t/tCD013573-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Higher dose of lipid‐lowering agent versus lower dose of the same lipid‐lowering agent, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/media/CDSR/CD013573/image_n/nCD013573-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013573-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet agent versus placebo for asymptomatic carotid stenosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antiplatelet agent compared to placebo<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> antiplatelet agent<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№</b> of participants<br/>(studies) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with antiplatelet agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ipsilateral major or disabling stroke (CT scan or MRI)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.47 to 2.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(29 fewer to 80 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke‐related mortality (CT scan or MRI)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(0.54 to 3.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 more per 1000<br/>(17 fewer to 99 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding (not reported)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.06 to 15.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(5 fewer to 79 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression of carotid stenosis (DUS/every 6 months)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/>(0.79 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 more per 1000<br/>(42 fewer to 143 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (not reported)</p> <p>Follow‐up: 2.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>372<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/>(0.41 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 fewer per 1000<br/>(52 fewer to 47 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CT scan</b> : computerised tomography scan; <b>DUS</b> : duplex ultrasonography; <b>MRI</b> : magnetic resonance imaging; <b>№:</b> number; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>One study included in this comparison<br/><sup>b</sup>Acetylsalicylic acid<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, one study, and 95% CI consistent with possible benefit and possible harm<br/><sup>d</sup>Downgraded one level due to indirectness: unexplained major bleeding definition </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet agent versus placebo for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013573-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antihypertensive agent versus placebo for asymptomatic carotid stenosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antihypertensive agent compared to placebo<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> antihypertensive agent<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement/time point)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№</b> of participants<br/>(studies) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with antihypertensive agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ipsilateral major or disabling stroke (not reported)</p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>793<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.14<br/>(0.02 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1000<br/>(17 fewer to 3 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke‐related mortality (not reported)</p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>793<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/>(0.17 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/>(15 fewer to 17 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression of carotid stenosis (DUS/at beginning and end)</p> <p>Follow‐up: 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>129<br/>(1 RCT)<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.45<br/>(0.23 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 fewer per 1000<br/>(239 fewer to 28 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CT scan</b> : computerised tomography scan; <b>DUS</b> : duplex ultrasonography; <b>MRI</b> : magnetic resonance imaging; <b>№:</b> number; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Two studies included in this comparison<br/><sup>b</sup>Metoprolol<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, few studies, and 95% CI consistent with possible benefit and possible harm<br/><sup>d</sup>Chlorthalidone </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antihypertensive agent versus placebo for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013573-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anticoagulant agent versus placebo for asymptomatic carotid stenosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Anticoagulant agent compared to placebo<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> anticoagulant agent<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement/time point)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of</b> participants<br/>(studies) </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with anticoagulant agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding (hospital records/every 6 weeks)</p> <p>Follow‐up: 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>919<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/>(0.97 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 more per 1000<br/>(8 fewer to 120 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (hospital records/every 6 weeks)</p> <p>Follow‐up: 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>919<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.81 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>644 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 fewer per 1000<br/>(122 fewer to 6 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>One study included in this comparison<br/><sup>b</sup> Warfarin<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, one study, and 95% CI consistent with possible benefit and possible harm<br/><sup>c</sup>Downgraded one level due to indirectness: unexplained major bleeding definition </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anticoagulant agent versus placebo for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013573-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Lipid‐lowering agent compared to placebo or no treatment for asymptomatic carotid stenosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Lipid‐lowering agent compared to placebo<sup>a</sup> or no treatment for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> lipid‐lowering agent<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p>Outcomes <b>(measurement/time point)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lipid‐lowering agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ipsilateral major or disabling stroke (only reported for two studies: one used CT scan, MRI and hospital records/every 6 weeks<sup>b</sup>; the other used physical examination/at beginning and 10 days after the end<sup>c</sup>) </p> <p>Follow‐up: 3.1 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2235<br/>(5 RCTs)<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.36<br/>(0.09 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 fewer per 1000<br/>(16 fewer to 10 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke‐related mortality (only reported for one study: CT scan, MRI and hospital records/every 6 weeks<sup>b</sup>) </p> <p>Follow‐up: 4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1366<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.25<br/>(0.03 to 2.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/>(4 fewer to 6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (only reported for two studies: one study used CT scan, MRI and hospital records/every 6 weeks<sup>b</sup>; the other used physical examination/at beginning and 10 days after the end<sup>c</sup>) </p> <p>Follow‐up: 3.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3726<br/>(7 RCTs)<sup>g</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76<br/>(0.53 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 fewer per 1000<br/>(41 fewer to 9 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CT scan</b> : computerised tomography scan; <b>MRI</b> : magnetic resonance imaging; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Nine studies included in this comparison<br/><sup>b</sup><a href="./references#CD013573-bbs2-0009" title="AdamsHP , ByingtonRP , HoenH , DempseyR , FurbergCD . Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovascular Diseases1995;5:171-7. [DOI: 10.1159/000107847]Anonymous. Lovastatin reverses carotid atherosclerosis. Primary Cardiology1994;20(8):10. ByingtonRP , EvansGW , EspelandMA , ApplegateWB , HunninghakeDB , ProbstfieldJ , et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation1999;100(3):e14-17. [DOI: https://doi.org/10.1161/01.CIR.100.3.e14]DolecekTA , BradhamKH , EspelandMA , MargiticSE , ByingtonRP , HoenH , et al. Maximising recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials1996;17:33-45. EspelandMA , CravenTE , RileyWA , CorsonJ , RomontA , FurbergCD . Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke1996;27(3):480-5. [DOI: 10.1161/01.str.27.3.480]FurbergCD , AdamsHP , ApplegateWB , ByingtonRP , EspelandMA , HartwellT , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994;90(4):1679-87. [DOI: 10.1161/01.cir.90.4.1679]FurbergCD , ByingtonRP , on behalf of the ACAPS Group. ACAPS: effects of lovastatin on progression of carotid atherosclerosis and clinical events. Circulation1993;88:I-386. FurbergCD , HoenHM , EspelandMA , ApplegateWB , BendixenBH . Effect of lovastatin on early carotid atherosclerosis in women. Atherosclerosis1994;109 (1-2):158. FurbergCD , on behalf of the ACAPS Research Group. Lovastatin, early carotid atherosclerosis and cardiovascular events: the results of ACAPS. Atherosclerosis1994;109(1-2):259. HoenH , EspelandM , RileyW , FurbergC , on behalf of the ACAPS Investigators. Summarizing carotid intimal-medial thickness in the asymptomatic carotid artery plaque study. Controlled Clinical Trials1993;14(5):433. MargiticSE . Logistics of closeout in the asymptomatic carotid artery plaque study (ACAPS). Controlled Clinical Trials1993;14(5):415. MargitićSE , ByingtonRP , EspelandMA , FurbergCD , HunninghakeDB , ProbstfieldJL . Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Controlled Clinical Trials1992;13(4):293-314. NCT00000469. Asymptomatic Carotid Artery Plaque Study (ACAPS). clinicaltrials.gov/ct2/show/study/NCT00000469 (first received 27 October 1999). [CLINICAL TRIAL: NCT00000469]ProbstfieldJL , MargiticSE , ByingtonRP , EspelandMA , FurbergCD . Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. American Journal of Cardiology1995;76:47c-53c. ">Furberg 1994</a><br/><sup>c</sup><a href="./references#CD013573-bbs2-0033" title="WangY , WangA , LiH , LiZ , HuB , LiX , et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis - design, rationale, and methodology of the METEOR-China study. Trials2020;21(1):921. [DOI: 10.1186/s13063-020-04741-0]ZhengH , LiH , WangY , LiZ , HuB , LiX , et al. Rosuvastatin slows progression of carotid intima-media thickness: the METEOR-China randomized controlled study. Stroke2022;53(10):3004-13. [DOI: 10.1161/STROKEAHA.120.031877]">Zheng 2022</a><br/><sup>d</sup>Lovastatin, pravastatin, rosuvastatin, and atorvastatin<br/><sup>e</sup>Downgraded two levels due to imprecision: few events, one study, and 95% CI consistent with possible benefit and possible harm<br/><sup>f</sup>Lovastatin and pravastatin<br/><sup>g</sup>Fluvastatin, rosuvastatin, lovastatin, pravastatin, and probucol </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Lipid‐lowering agent compared to placebo or no treatment for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013573-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amaurosis fugax</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient monocular visual loss associated with vascular thromboembolic events arising from the internal carotid arterial system </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticoagulants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drugs that suppress, delay, or prevent blood clots</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antiplatelet agents</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drugs which prevent blood clots by inhibiting platelet function</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atherosclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A disease characterised by a build‐up of abnormal fat, cholesterol and platelet deposits on the inner wall of the arteries </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atheromatous plaques</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A fatty deposit in the inner lining (intima) of an artery, resulting from atherosclerosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atherosclerotic debris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pieces of atheromatous plaque that can break off and be carried by the bloodstream</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body mass index (BMI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body mass divided by the square of the body height, universally expressed in units of kg/m<sup>2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computed tomography angiography (CTA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computed tomography scanning that uses an injection of contrast material into the blood vessels to help diagnose and evaluate blood vessel disease or related conditions </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digital subtraction angiography (DSA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoroscopy technique used in interventional radiology to clearly visualise blood vessels in a bony or dense soft tissue environment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Direct thrombin inhibitors</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug that acts as an anticoagulant by directly inhibiting the enzyme thrombin (factor IIa) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive evaluation of blood flow through the arteries and veins by ultrasound devices </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyslipidaemia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal concentration of fats (lipids or lipoproteins) in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Embolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obstruction of an artery or vein, typically by a clot of blood or an air bubble</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fator Xa inhibitors</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of anticoagulant that works by selectively and reversibly blocking the activity of clotting factor Xa, preventing clot formation </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug which is used to prevent blood clotting (anticoagulant, blood thinner)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ipsilateral encephalic territories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The same side of the brain</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low molecular weight heparin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A drug which is used to prevent blood clotting (anticoagulant)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnetic resonance angiography (MRA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A group of techniques based on magnetic resonance imaging (MRI) to image blood vessels</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obesity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A condition where the amount of body fat is beyond healthy conditions (BMI greater than 30 kg/m<sup>2</sup>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oedema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excess watery fluid which collects in tissues of the body, causing swelling when fluid leaks out of the body's vessels </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overweight</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where body fat is over that of the average population, but less than unhealthy conditions (BMI between 25 kg/m<sup>2</sup> and 30 kg/m<sup>2</sup>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substance or treatment with no active effect, like a sugar pill</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised controlled trial (RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A study in which the participants are divided randomly into separate groups to compare different treatments </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological deficit attributed to an acute focal injury of the central nervous system by a vascular cause, persisting ≥ 24 hours or until death </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local coagulation of blood (clot) in a part of the circulatory system</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient ischaemic attack (TIA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A transient episode (less than 24 hours) of neurological dysfunction caused by focal brain, spinal cord, or retinal ischaemia without acute infarction </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfractionated heparin (UFH)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A mixture of heparins obtained from animals which is used to prevent blood coagulation. Used to prevent and treat clotting disorders </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vascular</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relating to blood vessels (arteries and veins)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K antagonists (VKAs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substances that reduce blood clotting by reducing the action of vitamin K</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013573-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">DUS criteria for internal carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Consensus panel based on <a href="./references#CD013573-bbs2-0093" title="GrantEG , BensonCB , MonetaGL , AlexandrovAV , BakerJD , BluthEI , et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis - Society of Radiologists in Ultrasound Consensus Conference. Radiology2003;229(2):340-6. [PMID: 14500855]">Grant 2003</a> </p> </td> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Degree of stenosis (%)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Primary parameters</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Additional parameters</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ICA PSV (cm/sec)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Plaque estimate (%)*</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ICA/CCA PSV ratio</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ICA EDV (cm/sec)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% to 69%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125 to 230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0 to 4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 to 100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 70% but less than near occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Near occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High, low or undetectable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Undetectable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Visible, no detectable lumen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*Plaque estimate (diameter reduction) based on DUS B‐mode and on additional colour mode ultrasound. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CCA: common carotid artery<br/>DUS: duplex ultrasound<br/>EDV: end diastolic velocity<br/>ICA: internal carotid artery<br/>PSV: peak systolic velocity </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">DUS criteria for internal carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013573-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Additional SoF table: one antihypertensive agent plus lipid‐lowering agent compared to another antihypertensive agent plus lipid‐lowering agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>One antihypertensive agent plus lipid‐lowering agent compared to another antihypertensive agent plus lipid‐lowering agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> one antihypertensive agent plus lipid‐lowering agent </p> <p><b>Comparison:</b> another antihypertensive agent plus lipid‐lowering agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another antihypertensive agent plus lipid‐lowering agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with one antihypertensive agent plus lipid‐lowering agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke</p> <p>(not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34<br/>(0.01 to 8.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 fewer per 1000<br/>(8 fewer to 56 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>One study included in this comparison<br/><sup>b</sup>Hydrochlorthiazide + pravastatin versus fosinopril + pravastatin<br/><sup>c</sup>Downgraded two levels due to imprecision: few participants, few studies, and 95% CI consistent with possible benefit and possible harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Additional SoF table: one antihypertensive agent plus lipid‐lowering agent compared to another antihypertensive agent plus lipid‐lowering agent for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013573-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Additional SoF table: lipid‐lowering agent plus antihypertensive agent compared to antihypertensive agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Lipid‐lowering agent plus antihypertensive agent compared to antihypertensive agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> lipid‐lowering agent plus antihypertensive agent </p> <p><b>Comparison:</b> antihypertensive agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes (measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antihypertensive agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with lipid‐lowering agent plus antihypertensive agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke (physical examination, CT scan)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64<br/>(0.27 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 fewer per 1000<br/>(80 fewer to 55 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 20.09<br/>(1.19 to 338.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(0 fewer to 0 fewer) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RR:</b> risk ratio; <b>SoF</b>: summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>One study in this comparison<br/><sup>b</sup>Fenofibrate + benazepril and/or amlodipine versus benazepril and/or amlodipine<br/><sup>c</sup>Downgraded one level due to high risk of bias for blinding of participants and personnel (open‐label study)<br/><sup>d</sup>Downgraded two levels due to imprecision: few participants, few studies, and 95% CI consistent with possible benefit and possible harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Additional SoF table: lipid‐lowering agent plus antihypertensive agent compared to antihypertensive agent for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013573-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Additional SoF table: one lipid‐lowering agent compared to another lipid‐lowering agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>One lipid‐lowering agent compared to another lipid‐lowering agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> one lipid‐lowering agent </p> <p><b>Comparison:</b> another lipid‐lowering agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> (measurement/time point) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another lipid‐lowering agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with one lipid‐lowering agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>332<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.96<br/>(0.12 to 72.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(0 fewer to 0 fewer) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (laboratory measurement/1, 2, 4, 6, 12, 18, and 24 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497<br/>(2 RCTs)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92<br/>(0.30 to 2.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 fewer per 1000<br/>(209 fewer to 555 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Two studies included in this comparison<br/><sup>b</sup>Rosuvastatin versus pravastatin<br/><sup>c</sup>Downgraded one level due to high risk of bias (blinding)<br/><sup>d</sup>Downgraded two levels due to imprecision: few events, few studies, and 95% CI consistent with possible benefit and possible harm<br/><sup>e</sup>Rosuvastatin versus pravastatin; probucol versus pravastatin </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Additional SoF table: one lipid‐lowering agent compared to another lipid‐lowering agent for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013573-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Additional SoF table: two lipid‐lowering agents compared to one lipid‐lowering agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Two lipid‐lowering agents compared to one lipid‐lowering agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> two lipid‐lowering agents </p> <p><b>Comparison:</b> one lipid‐lowering agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b>(measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with one lipid‐lowering agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with two lipid‐lowering agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>683<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.04<br/>(0.12 to 74.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(0 fewer to 0 fewer) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>683<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.25<br/>(0.61 to 2.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/>(15 fewer to 59 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included study did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>One study included in this comparison<br/><sup>b</sup>Torcetrapib plus atorvastatin versus atorvastatin alone<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, one study, and 95% CI consistent with possible benefit and possible harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Additional SoF table: two lipid‐lowering agents compared to one lipid‐lowering agent for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013573-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Additional SoF table: one antihypertensive agent compared to another antihypertensive agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>One antihypertensive agent compared to another antihypertensive agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> one antihypertensive agent </p> <p><b>Comparison:</b> another antihypertensive agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b>(measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another antihypertensive agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with one antihypertensive agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke (review meeting/semi‐annual<sup>b</sup>; review meeting/3 times<sup>c</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2918<br/>(2 RCTs)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/>(0.34 to 2.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(8 fewer to 22 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (only reported for two studies: one used review meeting/semi‐annual<sup>b</sup>; the other used review meeting/3 times<sup>c</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3239<br/>(4 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.82 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(24 fewer to 29 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The included studies did not measure this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Four studies included in this comparison<br/><sup>b</sup><a href="./references#CD013573-bbs2-0002" title="ApplegateWB , ByingtonRP , on behalf of the MIDAS Research Group. MIDAS, the multicenter isradipine/diuretic atherosclerosis study. Design features and baseline data. American Journal of Hypertension1991;4(2):114S-7S. [DOI: 10.1093/ajh/4.2.114s]BondMG , MercuriM , BorhaniNO . The multicenter isradipine/diuretic atherosclerosis study (MIDAS): effect of a calcium antagonist on carotid arteries. Atherosclerosis1994;109(1-2):294. BorhaniNO , BondMG , SowersJR , Canossa-TerrisM , BuckalewV , GibbonsME , et al. The multicenter isradipine/diuretic atherosclerosis study: a study of the antiatherogenic properties of isradipine in hypertensive patients. Journal of Cardiovascular Pharmacology1991;18 Suppl 3:S15-9. BorhaniNO , BruggerSB , ByingtonRP , on behalf of the US MIDAS Research Group. Multicenter study with isradipine and diuretics against atherosclerosis. Journal of Cardiovascular Pharmacology1990;15 Suppl 1:S23-9. BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-terrisM , CarrAA , et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA1996;276(10):785-91. [DOI: 10.1001/jama.1996.03540100029024]ByingtonRP , CravenTE , FurbergCD , PahorM . Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet1997;350:1075-6. [DOI: 10.1016/S0140-6736(05)70455-4]FurbergCD , BorhaniNO , ByingtonRP , GibbonsME , SowersJR . Calcium antagonists and atherosclerosis. The multicenter isradipine/diuretic atherosclerosis study. American Journal of Hypertension1993;6:24S-9S. FurbergCD , ByingtonRP , Borhani NO The MIDAS Research Group. Multicenter isradipine diuretic atherosclerosis study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. GrimmRH , FlackJM , ByingtonR , BondG , BruggerS , The MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs1990;40 Suppl 2:38-43. PrisantLM , ZemelPC , NicholsFT , ZemelMB , SowersJR , CarrAA , et al. Carotid plaque associations among hypertensive patients. Archives of Internal Medicine1993;153(4):501-6. SchnaperHW , ApplegateWB , BuckalewVM , Canossa-TerrisM , LeeM , BorhaniN , the MIDAS Investigator Group. The Multiple Isradipine/Diuretic Atherosclerosis Study: adverse events over 3 years of antihypertensive therapy with isradipine vs hydrochlorothiazide. Atherosclerosis1994;109(1-2):157. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) Research Group. Effect of isradipine and diurectics on early carotid atherosclerosis in hypertension. Journal of Hypertension1994;12 Suppl 3:S67. ">Applegate 1991</a><br/><sup>c</sup><a href="./references#CD013573-bbs2-0008" title="BondG , Dal PalyC , HanssonL , MagnaniB , ManciaG , NeissA , et al. The ELSA trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. Journal of Cardiovascular Pharmacology1994;23 Suppl 5:S85-7. BondMG , MercuriM , the ELSA Research Group. Potential modification of plaque behavior through the European Lacidipine Study on Atherosclerosis. Journal of Cardiovascular Pharmacology1995;25 Suppl 3:S11-6. GiannattasioC , FaillaM , HennigM , HollweckR , LaurentS , MallionJM , et al. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension2005;23(3):557-62. [DOI: 10.1097/01.hjh.0000160212.33232.3e]LeonettiG . Preliminary clinical results of the ELSA study. Annali Italiani di Medicina Interna1995;10 Suppl:74S-7S. RahnKH , on behalf of the ELSA International Steering Committee and Investigators. The European Lacidipine Study on Atherosclerosis (ELSA): study design and results. Deutsche Medizinische Wochenschrift2001;126 Suppl 3:S15. RahnKH , on behalf of the ELSA Investigators. The European Lacipidine Study on Atherosclerosis (ELSA): prevalence of baseline carotid lesions and correlations with risk factors. Journal of Hypertension1998;16 Suppl 9:S31-3. ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PaluCD , et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106:2422-7. [DOI: 10.1161/01.cir.0000039288.86470.dd]ZanchettiA , BondMG , HennigM , NeissA , ManciaG , PalùCD , et al. Risk factors associated with alterations in carotid intima—media thickness in hypertension. Journal of Hypertension1998;16(7):949-61. [DOI: 10.1097/00004872-199816070-00008]ZanchettiA , BondMG , HennigM , TangR , HollweckR , ManciaG , et al. Absolute and relative changes in carotid intima media thickness and atherosclerotic plaques during long-term antihypertensive treatment. Journal of Hypertension2004;22(6):1201-12. [DOI: 10.1097/00004872-200406000-00022]ZanchettiA , HennigM , BaurechtH , TangR , CuspidiC , CarugoS , et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. Journal of Hypertension2007;25(12):2463-70. [DOI: 10.1097/hjh.0b013e3282f063d5]ZanchettiA . Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. Supplement1995;13 Suppl 4:S35-9. [DOI: 10.1097/00004872-199512002-00006]">ELSA 2002</a><br/><sup>d</sup>Israpidin versus hydrochlorothiazide; lacidipine versus atenolol<br/><sup>e</sup>Downgraded two levels due to imprecision: few events, few studies, and 95% CI consistent with possible benefit and possible harm<br/><sup>f</sup>Israpidin versus hydrochlorothiazide; lacidipine versus atenolol; olmesartan versus atenolol; amlodipine versus lisinopril </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Additional SoF table: one antihypertensive agent compared to another antihypertensive agent for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013573-tbl-0012"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Additional SoF table: higher dose of lipid‐lowering agent compared to lower dose of the same lipid‐lowering agent for asymptomatic carotid stenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Higher dose of lipid‐lowering agent compared to lower dose of the same lipid‐lowering agent<sup>a</sup> for asymptomatic carotid stenosis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> asymptomatic carotid stenosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> higher dose of lipid‐lowering agent </p> <p><b>Comparison:</b> lower dose of the same lipid‐lowering agent </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b>(measurement/time point)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower dose of the same lipid‐lowering agent</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with higher dose of lipid‐lowering agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ipsilateral major or disabling stroke</p> <p>(not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁⨁◯◯<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/>(0.01 to 7.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/>(50 fewer to 336 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression of carotid stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (laboratory measurements/baseline and 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278<br/>(1 RCT)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⨁◯◯◯<br/>Very low<sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.57<br/>(0.66 to 3.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 more per 1000<br/>(19 fewer to 153 more) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Neither included study measured this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>№:</b> number; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SoF:</b> summary of findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Two studies included in this comparison<br/><sup>b</sup>Pitavastatin<br/><sup>c</sup>Downgraded two levels due to imprecision: few events, few studies, and 95% CI consistent with possible benefit and possible harm<br/><sup>d</sup>Atorvastatin<br/><sup>e</sup>Downgraded one level due to high risk of bias (blinding) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Additional SoF table: higher dose of lipid‐lowering agent compared to lower dose of the same lipid‐lowering agent for asymptomatic carotid stenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/full#CD013573-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antiplatelet agent versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Ipsilateral major or disabling stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Stroke‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Progression of carotid stenosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antiplatelet agent versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antihypertensive agent versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Ipsilateral major or disabling stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Stroke‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Progression of carotid stenosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antihypertensive agent versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">One antihypertensive agent plus lipid‐lowering agent versus another antihypertensive agent plus lipid‐lowering agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Ipsilateral major or disabling stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">One antihypertensive agent plus lipid‐lowering agent versus another antihypertensive agent plus lipid‐lowering agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Anticoagulant agent versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>919</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Anticoagulant agent versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lipid‐lowering agent versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Ipsilateral major or disabling stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.09, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Stroke‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.53, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lipid‐lowering agent versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lipid‐lowering agent plus antihypertensive agent versus antihypertensive agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Ipsilateral major or disabling stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Lipid‐lowering agent plus antihypertensive agent versus antihypertensive agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">One lipid‐lowering agent versus another lipid‐lowering agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Ipsilateral major or disabling stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.30, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">One lipid‐lowering agent versus another lipid‐lowering agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Two lipid‐lowering agents versus one lipid‐lowering agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Ipsilateral major or disabling stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Two lipid‐lowering agents versus one lipid‐lowering agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">One antihypertensive agent versus another antihypertensive agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Ipsilateral major or disabling stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.34, 2.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">One antihypertensive agent versus another antihypertensive agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013573-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Higher dose of lipid‐lowering agent versus lower dose of the same lipid‐lowering agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Ipsilateral major or disabling stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Higher dose of lipid‐lowering agent versus lower dose of the same lipid‐lowering agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013573.pub2/references#CD013573-tbl-0022">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013573.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013573-note-0015">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013573-note-0024">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013573-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013573-note-0021">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013573-note-0018">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD013573-note-0022">Magyar</a> </li> <li class="section-language"> <a class="" href="ms#CD013573-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013573-note-0020">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD013573-note-0023">Română</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013573-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013573-note-0016">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013573\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013573\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013573\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013573\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013573\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013573.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013573.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013573.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013573.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013573.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715299080"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013573.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715299083"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013573.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d83b058e7f446',t:'MTc0MDcxNTI5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 